BlackRock Enhanced Equity Dividend Trust Form N-CSRS September 05, 2017

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM N-CSR

CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT INVESTMENT COMPANIES

Investment Company Act file number: 811-21784

Name of Fund: BlackRock Enhanced Equity Dividend Trust (BDJ)

Fund Address: 100 Bellevue Parkway, Wilmington, DE 19809

Name and address of agent for service: John M. Perlowski, Chief Executive Officer, BlackRock Enhanced Equity

Dividend Trust, 55 East 52nd Street, New York, NY 10055

Registrant s telephone number, including area code: (800) 882-0052, Option 4

Date of fiscal year end: 12/31/2017

Date of reporting period: 06/30/2017

Item 1 Report to Stockholders

JUNE 30, 2017

SEMI-ANNUAL REPORT (UNAUDITED)

BlackRock Energy and Resources Trust (BGR)

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

BlackRock Enhanced Equity Dividend Trust (BDJ)

BlackRock Enhanced Global Dividend Trust (BOE)

BlackRock Enhanced International Dividend Trust (BGY)

BlackRock Health Sciences Trust (BME)

BlackRock Resources & Commodities Strategy Trust (BCX)

BlackRock Science and Technology Trust (BST)

BlackRock Utility and Infrastructure Trust (BUI)

Not FDIC Insured May Lose Value No Bank Guarantee

The Markets in Review

Dear Shareholder,

In the 12 months ended June 30, 2017, risk assets, such as stocks and high-yield bonds, delivered strong performance. These markets showed great resilience during a period with big surprises, including the aftermath of the U.K. s vote to leave the European Union and the outcome of the U.S. presidential election, which brought only brief spikes in equity market volatility. However, interest rates rose, which worked against high-quality assets with more interest rate sensitivity. Aside from the shortest-term Treasury bills, most U.S. Treasuries posted negative returns, as rising energy prices, modest wage increases and steady job growth led to expectations of higher inflation and anticipation of interest rate increases by the U.S. Federal Reserve (the Fed).

The global reflationary theme—rising nominal growth, wages and inflation—was the dominant driver of asset returns during the period, outweighing significant political upheavals and economic uncertainty. Reflationary expectations accelerated after the U.S. election in November 2016 and continued into the beginning of 2017, stoked by expectations that the new administration—s policies would provide an extra boost to U.S. growth.

The Fed has responded to these positive developments by increasing interest rates three times in the last six months, setting expectations for additional interest rate increases and moving toward normalizing monetary policy. For its part, the European Central Bank also began to signal its intent to wind down asset purchases and begin the long move toward policy normalization, contingent upon further improvement in economic growth.

In recent months, growing skepticism about the near-term likelihood of significant U.S. tax reform and infrastructure spending has tempered enthusiasm around the reflation trade. Similarly, renewed concern about oversupply has weighed on energy prices. Nonetheless, financial markets and to an extent the Fed have adopted a wait-and-see approach to the economic data and potential fiscal stimulus. Although uncertainty has persisted, benign credit conditions, modest inflation and the outlook for economic growth have kept markets relatively tranquil.

In the fifth edition of our Global Investor Pulse Survey, we heard from 28,000 individuals across 18 countries, including more than 4,000 respondents from the United States. While retirement remains the single most important issue for American investors, only a third of respondents feel confident that they will have enough retirement income, and nearly 40% of respondents have yet to begin saving for retirement. We encourage you to talk with your financial advisor and visit blackrock.com for further insight about investing in today s markets.

Sincerely,

Rob Kapito

President, BlackRock Advisors, LLC

Rob Kapito

President, BlackRock Advisors, LLC

Total Returns as of June 30, 2017

Total Returns as of June 30, 2017		
	6-month	12-month
U.S. large cap equities	9.34%	17.90%
(S&P 500® Index)		
U.S. small cap equities	4.99	24.60
(Russell 2000® Index)		
International equities	13.81	20.27
(MSCI Europe, Australasia,		
Far East Index)		

Emerging market equities	18.43	23.75
(MSCI Emerging Markets Index)		
3-month Treasury bills	0.31	0.49
(BofA Merrill Lynch 3-Month		
U.S. Treasury Bill Index)		
U.S. Treasury securities	2.08	(5.58)
(BofA Merrill Lynch		
10-Year U.S. Treasury		
Index)		
U.S. investment grade bonds	2.27	(0.31)
(Bloomberg Barclays U.S.		
Aggregate Bond Index)		
Tax-exempt municipal	3.26	(0.28)
bonds (S&P Municipal		
Bond Index)		
U.S. high yield bonds	4.92	12.69
(Bloomberg Barclays U.S. Corporate High Yield 2% Issuer		
Cannad Inday)		

2

Capped Index)
Past performance is no guarantee of future results. Index performance is shown for illustrative purposes only. You cannot invest directly in an

THIS PAGE NOT PART OF YOUR FUND REPORT

Section 19(a) Notices

BlackRock Energy and Resources Trust s (BGR), BlackRock Enhanced Capital and Income Fund, Inc. s (CII), BlackRock Enhanced Equity Dividend Trust s (BDJ), BlackRock Enhanced Global Dividend Trust s (BOE), BlackRock Enhanced International Dividend Trust s (BGY), BlackRock Health Sciences Trust s (BME), BlackRock Resources & Commodities Strategy Trust s (BCX), BlackRock Science and Technology Trust s (BST) and BlackRock Utility and Infrastructure Trust s (BUI) (each, a Trust and collectively, the Trusts), amounts and sources of distributions reported are estimates and are being provided to you pursuant to regulatory requirements and are not being provided for tax reporting purposes. The actual amounts and sources for tax reporting purposes will depend upon each Trust s investment experience during the fiscal year and may be subject to changes based on tax regulations. Each Trust will provide a Form 1099-DIV each calendar year that will tell you how to report these distributions for U.S. federal income tax purposes.

June 30, 2017

Total Cumulative Distributions % Breakdown of the Total Cumulative for the Fiscal Period Distributions for the Fiscal Period Net Realized Net Realized Net Realized **Total Per** Net Realized Capital Gains Capital Gains Capital Gain@apital Gains **Total Per Net Investment** Return of CommonNet Investment Return of Common Income **Short-Term** Long-Term Capital Share Income Short-Term Long-Term Capital Share BGR* \$ 0.129255 \$ 0.465600 \$ 0.336345 28% 0% 100% 0% 72% CII* \$ 0.070837 \$ 0.425963 \$ 0.496800 14% 0% 0% 86% 100% BDJ \$ 0.079221 \$ 0.018831 \$ 0.182147 \$ 0.280200 28% 7% 65% 0% 100% BOE \$ 0.046257 0.421743 \$ 0.468000 10% 90% 0% 0% 100% 79% BGY* \$ 0.047393 \$ 0.180607 \$ 0.228000 21% 0% 0% 100% 0% 98% **BME** \$ 0.022815 \$ 1.177185 \$ 1.200000 2% 0% 100% \$ 0.219505 \$ 0.295600 26% 0% 74% 100% BCX* \$ 0.076095 0% BST* \$ 0.600000 \$ 0.600000 0% 0% 0% 100% 100% \$ 0.290489 \$ 0.284039 39% BUI* \$ 0.151472 \$ 0.726000 40% 0% 21% 100%

Section 19(a) notices for the Trusts, as applicable, are available on the BlackRock website http://www.blackrock.com.

Section 19(b) Disclosure

The Trusts, acting pursuant to a U.S. Securities and Exchange Commission (SEC) exemptive order and with the approval of each Trust s Board of Trustees/Directors (the Board), each have adopted a plan, consistent with its investment objectives and policies to support a level distribution of income, capital gains and/or return of capital (the Plan). In accordance with the Plans, the Trusts distribute the following fixed amounts per share on a monthly basis as of June 30, 2017:

	Amount Per
Exchange Symbol	Common Share
BGR	\$ 0.0776
CII	\$ 0.0828
BDJ	\$ 0.0467
BOE	\$ 0.0780
BGY	\$ 0.0380
BME	\$ 0.2000
BCX	\$ 0.0516
BST	\$ 0.1000

Extrain Trusts estimate that they have distributed more than the amount of earned income and net realized gains; therefore, a portion of the distribution may be a return of capital. A return of capital may occur, for example, when some or all of the shareholder s investment in a Trust is returned to the shareholder. A return of capital does not necessarily reflect a Trust s investment performance and should not be confused with yield or income. When distributions exceed total return performance, the difference will reduce the Trust s net asset value per share.

BUI \$ 0.1210

The fixed amounts distributed per share are subject to change at the discretion of each Trust s Board. Under its Plan, each Trust will distribute all available investment income to its shareholders, consistent with its primary investment objectives and as required by the Internal Revenue Code of 1986, as amended (the Code). If sufficient investment income is not available on a monthly basis, the Trusts will distribute long-term capital gains and/or return of capital to shareholders in order to maintain a level distribution. Each monthly distribution to shareholders is expected to be at the fixed amount established by the Board, except for extraordinary distributions and potential distribution rate increases or decreases to enable the Trusts to comply with the distribution requirements imposed by the Code.

Shareholders should not draw any conclusions about each Trust s investment performance from the amount of these distributions or from the terms of the Plan. Each Trust s total return performance on net asset value is presented in its financial highlights table.

The Board may amend, suspend or terminate a Trust s Plan at any time without prior notice to the Trust s shareholders if it deems such actions to be in the best interests of the Trust or its shareholders. The suspension or termination of the Plan could have the effect of creating a trading discount (if the Trust s stock is trading at or above net asset value) or widening an existing trading discount. The Trusts are subject to risks that could have an adverse impact on their ability to maintain level distributions. Examples of potential risks include, but are not limited to, economic downturns impacting the markets, decreased market volatility, companies suspending or decreasing corporate dividend distributions and changes in the Code. Please refer to each Trust s prospectus for a more complete description of its risks.

Table of Contents

	Page
The Markets in Review	2
Section 19(a) Notices	3
Section 19(b) Disclosure	3
Semi-Annual Report:	
The Benefits and Risks of Option Over-Writing	5
<u>Trust Summaries</u>	6
<u>Derivative Financial Instruments</u>	24
Financial Statements:	
Schedules of Investments	25
Statements of Assets and Liabilities	87
Statements of Operations	89
Statements of Changes in Net Assets	91
Statements of Cash Flows	100
Financial Highlights	102
Notes to Financial Statements	111
Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements	123
Officers and Trustees	130
Additional Information	131

The Benefits and Risks of Option Over-Writing

In general, the goal of each of the Trusts is to provide total return through a combination of current income and realized and unrealized gains (capital appreciation). The Trusts seek to pursue this goal primarily by investing in a portfolio of equity securities and utilizing an option over-writing strategy in an effort to enhance the Trusts distribution rate and total return performance. However, these objectives cannot be achieved in all market conditions.

The Trusts primarily write single stock covered call options, and may also from time to time write single stock put options. When writing (selling) a covered call option, the Trust holds an underlying equity security and enters into an option transaction which allows the counterparty to purchase the equity security at an agreed-upon price (strike price) within an agreed-upon time period. The Trusts receive cash premiums from the counterparties upon writing (selling) the option, which along with net investment income and net realized gains, if any, are generally available to support current or future distributions paid by the Trusts. During the option term, the counterparty may elect to exercise the option if the market value of the equity security rises above the strike price, and the Trust is obligated to sell the equity security to the counterparty at the strike price, realizing a gain or loss. Premiums received increase gains or reduce losses realized on the sale of the equity security. If the option remains unexercised upon its expiration, the Trusts realize gains equal to the premiums received. Alternatively, an option may be closed out by an offsetting purchase or sale of an option prior to expiration. The Trust realizes a capital gain from a closing purchase or sale transaction if the premium paid is less than the premium received from writing the option. The Trust realizes a capital loss from a closing purchase or sale transaction if the premium received is less than the premium paid to purchase the option.

Writing covered call options entails certain risks, which include, but are not limited to, the following: an increase in the value of the underlying equity security above the strike price can result in the exercise of a written option (sale by the Trust to the counterparty) when the Trust might not otherwise have sold the security; exercise of the option by the counterparty may result in a sale below the current market value and a gain or loss being realized by the Trust; and limiting the potential appreciation that could be realized on the underlying equity security to the extent of the strike price of the option. As such, an option over-writing strategy may outperform the general equity market in flat or falling markets but underperform in rising markets.

Each Trust employs a plan to support a level distribution of income, capital gains and/or return of capital. The goal of the plan is to provide shareholders with consistent and predictable cash flows by setting distribution rates based on expected long-term returns of the Trusts. Such distributions, under certain circumstances, may exceed a Trust s total return performance. When total distributions exceed total return performance for the period, the difference reduces the Trust s total assets and net asset value per share (NAV) and, therefore, could have the effect of increasing the Trust s expense ratio and reducing the amount of assets,

the Trust has available for long term investment. In order to make these distributions, a Trust may have to sell portfolio securities at less than opportune times.

The final tax characterization of distributions is determined after the fiscal year and is reported in the Trust s annual report to shareholders. Distributions can be characterized as ordinary income, capital gains and/or return of capital. The Trust s taxable net investment income or net realized capital gains (taxable income) may not be sufficient to support the level of distributions paid. To the extent that distributions exceed the Trust s current and accumulated earnings and profits, the excess may be treated as a non-taxable return of capital. Distributions that exceed a Trust s taxable income but do not exceed the Trust s current and accumulated earnings and profits, may be classified as ordinary income which are taxable to shareholders. Such distributions are reported as distributions in excess of net investment income.

A return of capital distribution does not necessarily reflect a Trust s investment performance and should not be confused with yield or income. A return of capital is a return of a portion of an investor s original investment. A return of capital is not taxable, but it reduces a shareholder s tax basis in his or her shares, thus reducing any loss or increasing any gain on a subsequent disposition by the shareholder of his or her shares. It is possible that a substantial portion of the distributions paid during a calendar year may ultimately be classified as return of capital or as distributions in excess of net investment income for U.S. federal income tax purposes when the final determination of the source and character of the distributions is made.

To illustrate these concepts, assume the following: (1) a common stock purchased at and currently trading at \$37.15 per share; (2) a three-month call option is written by a Trust with a strike price of \$40 (i.e., 7.7% higher than the current market price); and (3) the Trust receives \$2.45, or 6.6% of the common stock s value, as a premium. If the stock price remains unchanged, the option expires and there would be a 6.6% return for the three-month period. If the stock were to decline in price by 6.6% (i.e., decline to \$34.70 per share), the option strategy would break-even from an economic perspective resulting in neither a gain nor a loss. If the stock were to climb to a price of \$40 or above, the option would be exercised and the stock would return 7.7% coupled with the option premium received of 6.6% for a total return of 14.3%. Under this scenario, the Trust loses the benefit of any appreciation of the stock above \$40, and thus is limited to a 14.3% total return. The premium from writing the call option serves to offset some of the unrealized loss on the stock in the event that the price of the stock declines, but if the stock were to

decline more than 6.6% under this scenario, the Trust s downside protection is eliminated and the stock could eventually become worthless.

Each Trust intends to write covered call options to varying degrees depending upon market conditions. Please refer to each Trust s Schedule of Investments and the Notes to Financial Statements for details of written options.

SEMI-ANNUAL REPORT

JUNE 30, 2017

5

Trust Summary as of June 30, 2017

BlackRock Energy and Resources Trust

Trust Overview

BlackRock Energy and Resources Trust s (BGR) (the Trust) investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry. The Trust may invest directly in such securities or synthetically through the use of derivatives. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and utilizing an option over-writing strategy in an effort to seek total return performance and enhance distributions.

No assurance can be given that the Trust s investment objective will be achieved.

Trust Information

Symbol on New York Stock Exchange (NYSE)

Initial Offering Date

Current Distribution Rate on Closing Market Price as of June 30, 2017 (\$13.00)¹

Current Monthly Distribution per Common Share²

Current Annualized Distribution per Common Share²

\$0.0776

- 1 Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.
- The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2017 were as follows:

	Returns Based On		
	Market Price	Net Asset Value	
BGR ^{1,2}	(6.87)%	(10.55)%	
Lipper Natural Resources Funds ³	(2.89)%	(7.32)%	

- ¹ All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
- The Trust s discount to NAV narrowed during the period, which accounts for the difference between performance based on price and performance based on NAV.
- ³ Average return. Returns reflect reinvestment of dividends and/or distributions at NAV on the ex-dividend date as calculated by Lipper. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

The following discussion relates to the Trust s absolute performance based on NAV:

What factors influenced performance?

Despite gains for the broader world equity markets, natural resources stocks generally lost ground in the first half of 2017. The downturn largely stemmed from the weakness in energy stocks, which lagged as an unfavorable balance of supply and demand put significant downward pressure on oil prices. In this environment, the Trust produced a negative absolute return at net asset value in the six-month period.

The investment adviser positioned the portfolio based on its expectation for rising oil prices. Given that oil in fact fell in the first half of the year, this aspect of the Trust s positioning was a headwind to performance. Specifically, the Trust s significant exposure to the exploration and production (E&P) sub-sector weighed on results.

The Trust s position in the pressure pumping and service provider Superior Energy Services, Inc. detracted from absolute performance. The oil services companies Schlumberger Ltd. and Weatherford International Ltd. announced a joint venture focused on pressure pumping, which could potentially increase competition in this area.

Anadarko Petroleum Corp., which fell due to the company s possible link to two operational incidents that involved fatalities, also detracted from absolute performance.

Tesoro Corp. contributed to absolute performance, as refiners outperformed on the strength of solid demand for petroleum products and weakening oil prices (their major input cost). The company also benefited from its recent acquisition of Western Refining Corp., as the market sees the potential for synergies from the deal.

A position in Cabot Oil and Gas Corp. made a positive contribution, as well. Natural gas prices held up better than oil, and the market responded positively to increased visibility regarding the expansion of pipelines near the areas in which the company operates. The major North American energy company TransCanada Corp., which rallied following the approval for the Keystone XL pipeline, also added value.

The Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The option overlay strategy had a positive impact on results at a time of weakness in the overall sector.

Describe recent portfolio activity.

The investment adviser increased the Trust s exposure to U.S. onshore energy services companies and funded the purchases by taking profits in certain E&P holdings. The investment edviser also used the pullback in the broader energy sector to increase the portfolio s beta somewhat, reflecting its belief that the fundamentals of the oil market could improve in the coming months. The investment adviser focused on companies that can be expected to generate earnings even with oil at \$50 per barrel.

BlackRock Energy and Resources Trust

Performance and Portfolio Management Commentary (concluded)

Describe portfolio positioning at period end.

The E&P sector represented the Trust s largest allocation, followed by the integrated, oil services, distribution and refining & marketing industries,

respectively. The investment adviser positioned the Trust with a higher-quality bias, focusing on companies with robust balance sheets, below-average costs and higher-quality management teams.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

Market Price and Net Asset Value Per Share Summary

	6/30/17	12/31/16	Change	High	Low
Market Price	\$ 13.00	\$ 14.44	(9.97)%	\$ 14.87	\$ 12.60
Net Asset Value	\$ 14.12	\$ 16.33	(13.53)%	\$ 16.57	\$ 13.83

Market Price and Net Asset Value History For the Past Five Years

Overview of the Trust s Total Investments*

Ten Largest Holdings	6/30/17
Exxon Mobil Corp.	10%
Royal Dutch Shell PLC-ADR, Class A	9
BP PLC	7
Chevron Corp.	6
EOG Resources, Inc.	5
ConocoPhillips	5
TransCanada Corp.	4
Pioneer Natural Resources Co.	4
Anadarko Petroleum Corp.	3
Baker Hughes, Inc.	3

*	Excludes	option p	positions	and r	noney	market funds.	
Indi	ustry Allo	cation					

Industry Allocation	6/30/17	12/31/16
Oil, Gas & Consumable Fuels	89%	91%
Energy Equipment & Services	11%	9%

For Trust compliance purposes, the Trust sindustry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

SEMI-ANNUAL REPORT

JUNE 30, 2017

7

Trust Summary as of June 30, 2017

BlackRock Enhanced Capital and Income Fund, Inc.

Trust Overview

BlackRock Enhanced Capital and Income Fund, Inc. s (CII) (the Trust) investment objective is to provide investors with a combination of current income and capital appreciation. The Trust seeks to achieve its investment objective by investing in a portfolio of equity securities of U.S. and foreign issuers. The Trust may invest directly in such securities or synthetically through the use of derivatives. The Trust also seeks to achieve its investment policy by employing a strategy of writing (selling) call and put options.

No assurance can be given that the Trust s investment objective will be achieved.

Trust Information

Symbol on NYSE

Initial Offering Date

Current Distribution Rate on Closing Market Price as of June 30, 2017 (\$14.89)¹

Current Monthly Distribution per Common Share²

Current Annualized Distribution per Common Share²

\$0.0828

- 1 Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.
- ² The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2017 were as follows:

Returns Based On

	Market Price	Net Asset Value
CII ^{1,2}	12.36%	9.01%
S&P 500 [®] Index	N/A	9.34%

- ¹ All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
- The Trust s discount to NAV narrowed during the period, which accounts for the difference between performance based on price and performance based on NAV.

N/A Not applicable as the index does not have a market price.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

The following discussion relates to the Trust s relative performance based on the index cited above:

What factors influenced performance?

In sector terms, information technology (IT) was the prime contributor to relative performance due to strength among semiconductor and software holdings. Consumer discretionary also aided results, in particular household durables and hotels, restaurants & leisure. Selection in materials and underweight exposure to telecommunication services benefited as well. The main detractor from performance was health care due to weakness in biotechnology and pharmaceuticals. Financials and consumer staples were also a drag, namely capital markets and food & staples retailing.

On a stock-specific basis, IT holdings Lam Research Corp. and Activision Blizzard Inc. were the top individual contributors. Lam performed very well on the back of strong execution and growing demand for its products, driven by the build-out of 3D NAND capacity, for which the company is a key supplier. The valuation remained reasonable, reflecting ongoing concerns that this may be the peak of the cycle, resulting in strong stock performance while the fundamentals continued to improve. Activision

outperformed amid consistently strong earnings results, allaying investor worries earlier in the period about weak *Call of Duty* sales. Investor excitement continued to grow around the company s new content like *Overwatch* and *Destiny 2*, and the secular shifts in the industry such as the movement to digital monetization and eSports.

Cruise operator Carnival Corp. also added value. Carnival outperformed early in the period after a report from competitor Royal Caribbean confirmed strengthening demand in both the Caribbean and Mediterranean markets. Later, the company delivered strong earnings results, which indicated ongoing favorable supply/demand dynamics in all of the developed cruise markets, leading to continued improvement in pricing power.

Conversely, underweights to Facebook Inc. and Amazon.com Inc., two of the so-called FANG stocks, detracted from relative results as both posted gains of more than 25% during the six months.

The position in Goldman Sachs Group Inc. also weighed. The stock underperformed after the company reported an uncharacteristically weak quarter reflecting poor performance in its core FICC (fixed income, currencies and commodities) trading business.

The Trust made use of options, principally written call options on individual stocks, in order to seek enhanced returns while continuing to participate in the performance of the underlying equities. The Trust s option writing strategy had a negative impact on performance during the reporting period.

Describe recent portfolio activity.

Due to a combination of portfolio trading activity and market movement during the six-month period, the Trust s exposure to the health care sector considerably increased, particularly within equipment & supplies and pharmaceuticals. Exposure to IT, industrials and materials increased as well. The largest reduction was in consumer staples, largely with respect to beverages and tobacco. Energy exposure also declined.

BlackRock Enhanced Capital and Income Fund, Inc.

Performance and Portfolio Management Commentary (concluded)

Describe portfolio positioning at period end.

Relative to the S&P 500° Index, the Trust ended the period with its largest overweights in the IT and consumer discretionary sectors. The Trust s largest relative underweights were in industrials, consumer staples and real estate.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

Market Price and Net Asset Value Per Share Summary

	6/30/17	12/31/16	Change	High	Low
Market Price	\$ 14.89	\$ 13.71	8.61%	\$ 15.02	\$ 13.63
Net Asset Value	\$ 15.89	\$ 15.08	5.37%	\$ 15.98	\$ 15.08

Market Price and Net Asset Value History For the Past Five Years

Overview of the Trust s Total Investments*

Ten Largest Holdings	6/30/17
Apple, Inc.	5%
Alphabet, Inc., Class A	4
JPMorgan Chase & Co.	4
Microsoft Corp.	4
Comcast Corp., Class A	3
Bank of America Corp.	3
Pfizer, Inc.	3
Carnival Corp.	3
Dow Chemical Co.	2
Home Depot, Inc.	2

* Excludes option positions and money market funds.

Excludes option positions and money market rands.		
Sector Allocation	6/30/17	12/31/16
Information Technology	26%	26%
Health Care	16	14
Financials	16	17
Consumer Discretionary	16	15

Industrials	7	6
Energy	6	8
Consumer Staples	6	9
Materials	5	4
Utilities	2	1

For Trust compliance purposes, the Trust sector classifications refer to any one or more of the sector sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such sector sub-classifications for reporting ease.

Trust Summary as of June 30, 2017

BlackRock Enhanced Equity Dividend Trust

Trust Overview

BlackRock Enhanced Equity Dividend Trust s (BDJ) (the Trust) primary investment objective is to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing in common stocks that pay dividends and have the potential for capital appreciation and by utilizing an option writing (selling) strategy to seek total return performance and enhance distributions. The Trust invests, under normal market conditions, at least 80% of its total assets in dividend paying equities. The Trust may invest directly in such securities or synthetically through the use of derivatives.

No assurance can be given that the Trust s investment objectives will be achieved.

Trust Information

Symbol on NYSE
Initial Offering Date
August 31, 2005
Current Distribution Rate on Closing Market Price as of June 30, 2017 (\$8.80)¹
Current Monthly Distribution per Common Share²
Current Annualized Distribution per Common Share²
\$0.0467

- 1 Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.
- ² The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2017 were as follows:

Returns Based On

	Market Price	Net Asset Value
$\mathrm{BDJ}^{1,2}$	11.53%	6.32%
Russell 1000® Value Index	N/A	4.66%

- ¹ All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
- The Trust s discount to NAV narrowed during the period, which accounts for the difference between performance based on price and performance based on NAV.

N/A Not applicable as the index does not have a market price.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

The following discussion relates to the Trust s relative performance based on the index cited above:

What factors influenced performance?

The largest contribution to performance for the six-month period came from an overweight to the health care sector. Most notably, an overweight to the health care providers & services industry provided strong relative returns. Within information technology, an overweight to software and stock selection in technology hardware, storage, & peripherals added to relative performance. Lastly, an underweight to telecommunication services (telecom) as well as stock selection within the sector contributed to performance, as did stock selection within financials, consumer discretionary and materials.

The largest detractor from relative return came from stock selection in the consumer staples sector. In particular, selection within the food & staples retailing industry detracted, as non-benchmark holding Kroger Co. sold off on concerns over increasing competition in the wake of the acquisition of Whole Foods by Amazon. Additionally, stock selection in utilities weighed on performance, mainly within the multi-utilities industry. Stock selection in the industrials sector detracted from returns as well, as a significant underweight to the machinery industry proved unfavorable.

The Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The Trust s option writing strategy had a negative effect on performance.

Describe recent portfolio activity.

During the six-month period, the Trust s exposure to the industrials, information technology (IT), health care, utilities and telecom sectors was increased. Conversely, exposure to consumer staples, consumer discretionary, energy, financials and real estate was decreased.

Describe portfolio positioning at period end.

The Trust s largest allocations were in the financials, health care and industrials sectors. Relative to the benchmark, the Trust s largest overweight positions were in the industrials, financials, IT, health care, materials and energy sectors. The Trust s largest underweights were in the real estate, consumer staples, consumer discretionary, telecom and utilities segments.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

BlackRock Enhanced Equity Dividend Trust

Market Price and Net Asset Value Per Share Summary

	6/30/17	12/31/16	Change	High	Low
Market Price	\$ 8.80	\$ 8.15	7.98%	\$ 8.84	\$ 8.13
Net Asset Value	\$ 9.49	\$ 9.22	2.93%	\$ 9.54	\$ 9.16

Market Price and Net Asset Value History For the Past Five Years

Overview of the Trust s Total Investments*

Ten Largest Holdings	6/30/17
JPMorgan Chase & Co.	4%
Citigroup, Inc.	4
Bank of America Corp.	4
Pfizer, Inc.	3
Oracle Corp.	3
Dow Chemical Co.	3
Wells Fargo & Co.	3
Anthem, Inc.	2
General Electric Co.	2
Merck & Co., Inc.	2

* Excludes option positions and money market funds.

Sector Allocation	6/30/17	12/31/16
Financials	28%	30%
Health Care	16	14
Industrials	12	12
Energy	11	12
Information Technology	11	9
Consumer Staples	6	7
Utilities	5	5
Consumer Discretionary	5	6
Materials	4	3
Telecommunication Services	2	2

For Trust compliance purposes, the Trust sector classifications refer to any one or more of the sector sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such sector sub-classifications for reporting ease.

Trust Summary as of June 30, 2017

BlackRock Enhanced Global Dividend Trust

Trust Overview

BlackRock Enhanced Global Dividend Trust s (BOE) (the Trust) primary investment objective is to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing primarily in equity securities issued by companies located in countries throughout the world and utilizing an option writing (selling) strategy to seek total return performance and enhance distributions. Under normal circumstances, the Trust invests at least 80% of its net assets in dividend-paying equity securities and at least 40% of its assets outside of the U.S. (unless market conditions are not deemed favorable by Trust management, in which case the Trust would invest at least 30% of its assets outside of the U.S.). The Trust may invest in securities of companies of any market capitalization, but intends to invest primarily in securities of large capitalization companies.

On March 22, 2017, the Trust s Board approved a change to the Trust s name from BlackRock Global Opportunities Equity Trust to BlackRock Enhanced Global Dividend Trust. The Board also approved changes to certain of the Trust s non-fundamental investment policies. Please refer to the Additional Information section. These changes became effective on June 12, 2017.

No assurance can be given that the Trust s investment objectives will be achieved.

Trust Information

Symbol on NYSE
Initial Offering Date
Current Distribution Rate on Closing Market Price as of June 30, 2017 (\$13.25)¹
Current Monthly Distribution per Common Share²
Current Annualized Distribution per Common Share²
\$0.0780

- Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.
- The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2017 were as follows:

	Market Price	Net Asset Value
$BOE^{1,2}$	18.78%	12.24%
MSCI All Country World Index	N/A	11.48%

All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

² The Trust s discount to NAV narrowed during the period, which accounts for the difference between performance based on price and performance based on NAV.

N/A Not applicable as the index does not have a market price.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

The following discussion relates to the Trust s relative performance based on the index cited above:

What factors influenced performance?

Positive stock selection within the financials sector led contributors for the period, in particular the Trust s position in Federal Bank Ltd., an Indian retail bank, which benefited from an earnings report that exceeded analysts forecasts. Performance was also helped by the Trust s positioning and security selection within the information technology (IT) sector, the top-performing segment during the period. Within IT, holdings in Skyworks Solutions, Inc., a mobile communications semiconductor company that reported favorable earnings, was a notable contributor.

Conversely, stock selection within the industrials and consumer discretionary sectors detracted from performance. Within industrials, the Trust s

position in Acuity Brands, Inc., a manufacturer of energy efficient lighting solutions, led detractors due to a weak earnings report. The company s management has continued to cite the negative impact of macroeconomic uncertainty on its business, particularly with the recent U.S. election result. Unfavorable stock selection in the consumer discretionary sector was driven by the Trust s position in Jasper Infotech Private Ltd., a private Indian e-commerce company, which saw its valuation negatively impacted by a more competitive business environment and challenged funding terms.

Also, during the period, the Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The Trust s options writing strategy detracted from performance.

Describe recent portfolio activity.

The Trust increased exposure to the consumer staples and health care sectors, funded by reductions to holdings in information technology and consumer discretionary. Regionally, these changes resulted in added exposure to Europe and reduced exposure within the emerging markets, the Pacific Basin and North America.

Describe portfolio positioning at period end.

The Trust s largest sector overweights were in the consumer staples, health care and telecommunication services sectors, funded by underweights to financials and IT. Regionally, the Trust was significantly overweight in Europe funded by underweight exposures to Emerging Markets and the Pacific Basin.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

BlackRock Enhanced Global Dividend Trust

Market Price and Net Asset Value Per Share Summary

	6/30/17	12/31/16	Change	High	Low
Market Price	\$ 13.25	\$ 11.57	14.52%	\$ 13.48	\$ 11.57
Net Asset Value	\$ 14.48	\$ 13.38	8.22%	\$ 14.61	\$ 13.38

Market Price and Net Asset Value History For the Past Five Years

Overview of the Trust s Total Investments*

Ten Largest Holdings	6/30/17
Altria Group, Inc.	4%
British American Tobacco PLC	4
AstraZeneca PLC	4
Imperial Brands PLC	3
Johnson & Johnson	3
Novartis AG, Registered Shares	3
Pfizer, Inc.	3
Rogers Communications, Inc., Class B	3
TELUS Corp.	3
Philip Morris International, Inc.	3

* Excludes option positions and money market funds.

Geographic Allocation	6/30/17	12/31/16
United States	46%	59%
United Kingdom	17	6
Switzerland	10	2
Canada	6	1
Taiwan	3	
France	3	2
Germany	3	2
Australia	2	
Finland	2	
Belgium	2	2
Japan	1	6
China	1	3
India		3
Italy		2
Spain		1
Other	4 1	11 2

¹ Other includes a 1% holding or less in each of the following countries: Denmark, Hong Kong, Netherlands and Sweden.

Other includes a 1% holding or less in each of the following countries: Australia, Denmark, Hong Kong, Indonesia, Ireland, Israel, Mexico, Netherlands, New Zealand, Norway, Peru, Philippines, Portugal, South Africa, South Korea, Sweden, Taiwan and Thailand.

Trust Summary as of June 30, 2017

BlackRock Enhanced International Dividend Trust

Trust Overview

BlackRock Enhanced International Dividend Trust s (BGY) (the Trust) primary investment objective is to provide current income and current gains, with a secondary objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing primarily in equity securities issued by companies of any market capitalization located in countries throughout the world and utilizing an option writing (selling) strategy to seek total return performance and enhance distributions. The Trust invests, under normal circumstances, at least 80% of its net assets in dividend-paying equity securities issued by non-U.S. companies of any market capitalization, but intends to invest primarily in securities of large capitalization companies.

On March 22, 2017, the Trust s Board approved a change to the Trust s name from BlackRock International Growth & Income Trust to BlackRock Enhanced International Dividend Trust. The Board also approved changes to certain of the Trust s non-fundamental investment policies. Please refer to the Additional Information section. These changes became effective on June 12, 2017.

No assurance can be given that the Trust s investment objectives will be achieved.

Trust Information

Symbol on NYSE
Initial Offering Date
Current Distribution Rate on Closing Market Price as of June 30, 2017 (\$6.28)¹
Current Monthly Distribution per Common Share²
Current Annualized Distribution per Common Share²
\$0.0380

- 1 Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.
- ² The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2017 were as follows:

Returns Based On

- All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
- 2 The Trust s discount to NAV narrowed during the period, which accounts for the difference between performance based on price and performance based on NAV.
- N/A Not applicable as the index does not have a market price.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

The following discussion relates to the Trust s relative performance based on the index cited above:

What factors influenced performance?

Unfavorable stock selection within the internet & direct marketing retail sub-industry of the consumer discretionary sector detracted from performance during the period. This was led by the Trust s position in Jasper Infotech Private Ltd., a private Indian e-commerce company, which saw its valuation negatively impacted by a more competitive business environment and challenged funding terms. In addition, the Trust s overweight position in Shire PLC, a global biotechnology company, detracted after the FDA approved a generic equivalent for one of Shire s popular brand-name therapies.

For the period, favorable stock selection within the diversified banks sub-industry of the financials sector led relative gains. This was driven by

the Trust s position in HDFC Bank Ltd., India s second largest private bank, after HDFC s shares rallied following a strong earnings report. The next largest contribution came from stock selection in the technology hardware & equipment sub-industry group, most notably holdings of Catcher Technology Co., Ltd., an important supplier of parts for Apple s iPhone. The stock has performed well year to date on news of strong demand from additional smartphone providers, including Google and Samsung.

Also, during the period, the Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The Trust s options writing strategy detracted from relative returns.

Describe recent portfolio activity.

Over the six-month period, the Trust added to positions in the health care and consumer staples sectors, funded by reductions in the Trust s financials and consumer discretionary holdings. Regionally, these changes resulted in increased exposure to North America and Europe, and reduced exposure to the emerging markets and the Pacific Basin.

Describe portfolio positioning at period end.

Relative to the MSCI All Country World Index ex-US, the Trust s largest sector overweights were in health care and consumer staples, while the largest underweight positions were in financials and consumer discretionary. Regionally, the Trust s largest overweights were in Europe and North America, while the largest regional underweights were in the Pacific Basin and the emerging markets.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

BlackRock Enhanced International Dividend Trust

Market Price and Net Asset Value Per Share Summary

	6/30/17	12/31/16	Change	High	Low
Market Price	\$ 6.28	\$ 5.51	13.97%	\$ 6.45	\$ 5.45
Net Asset Value	\$ 6.79	\$ 6.28	8.12%	\$ 6.89	\$ 6.28

Market Price and Net Asset Value History For the Past Five Years

Overview of the Trust s Total Investments*

Ten Largest Holdings	6/30/17
British American Tobacco PLC	5%
Imperial Brands PLC	4
AstraZeneca PLC	4
Novartis AG, Registered Shares	4
Rogers Communications, Inc., Class B	4
TELUS Corp.	4
Nestle SA, Registered Shares	3
Deutsche Post AG, Registered Shares	3
Sanofi	3
WisdomTree Japan Hedged Equity Fund	3

* Excludes option positions and money market funds.

Excludes option positions and money market funds.		
Geographic Allocation	6/30/17	12/31/16
United Kingdom	23%	16%
Switzerland	13	5
United States	8	8
Canada	7	5
France	5	9
Netherlands	5	6
Germany	5	6
China	5	5
Japan	4	8
Taiwan	3	
Sweden	3	1
Australia	3	
Finland	3	
Hong Kong	2	2
South Korea	2	3
Belgium	2	2
India	2	4
Ireland	1	2
Italy	1	6
Spain		1

Mexico		1
Other	3 1	10 ²

- ¹ Other includes a 1% holding or less in each of the following countries: Denmark, Norway, Portugal and South Africa.
- Other includes a 1% holding or less in each of the following countries: Australia, Denmark, Indonesia, Israel, New Zealand, Norway, Peru, Philippines, Portugal, South Africa, Taiwan and Thailand.

Trust Summary as of June 30, 2017

BlackRock Health Sciences Trust

Trust Overview

BlackRock Health Sciences Trust s (BME) (the Trust) investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives with exposure to the health sciences industry. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and utilizing an option over-writing strategy in an effort to seek total return performance and enhance distributions.

No assurance can be given that the Trust s investment objective will be achieved.

Trust Information

Symbol on NYSE
Initial Offering Date
Initial Offering Date
Current Distribution Rate on Closing Market Price as of June 30, 2017 (\$36.65)¹
Current Monthly Distribution per Common Share²
Current Annualized Distribution per Common Share²
\$0.2000
Current Annualized Distribution per Common Share²
\$2.4000

- 1 Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.
- ² The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2017 were as follows:

	Market Price	Net Asset Value
$BME^{1,2}$	19.59%	16.71%
Russell 3000® Healthcare Index	N/A	16.82%

- ¹ All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
- The Trust s premium to NAV widened during the period, which accounts for the difference between performance based on price and performance based on NAV.

N/A Not applicable as the index does not have a market price.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

The following discussion relates to the Trust s relative performance based on the index cited above:

What factors influenced performance?

Underweight positions in the outperforming pharmaceutical stocks Johnson & Johnson and Eli Lilly & Co. detracted from Trust results during the period. Out-of-benchmark positions in the European companies Roche Holding AG and Sanofi SA, which lagged the overall pharmaceutical industry, were additional detractors. In addition, several small- to medium-capitalization holdings in the biotechnology sector hurt performance for the full period despite their strong showing in June.

On the positive side, the Trust s positioning in all four health care sub-sectors contributed to relative performance, led by the health care providers & services, biotechnology and pharmaceuticals sub-sectors.

In healthcare providers & services, the Trust benefited from stock selection in the managed care and healthcare services industries. In the latter group, Amedisys, Inc. and Quest Diagnostics, Inc. reported strong financial results and were leading contributors to performance. In biotechnology, the Trust benefited from the outperformance of Vertex Pharmaceuticals, Inc. and AveXis, Inc., both of which reported positive clinical developments. An underweight in Gilead Sciences, Inc., which was hampered by mixed financial results, and the lack of a position in Alexion Pharmaceuticals, Inc., which was pressured by an investigation into its sales practices, also aided performance.

Jazz Pharmaceuticals PLC which was boosted by positive clinical results was a top contributor in the pharmaceuticals industry. A position in AstraZeneca PLC and an underweight in Pfizer, Inc. also aided the Trust s return in this sub-sector.

The health care equipment industry was the key source of outperformance in the medical devices area. Several holdings generated positive returns thanks to their solid earnings, including C.R. Bard, Inc. (which was bid for by Becton Dickinson & Co.), Baxter International, Inc., Intuitive Surgical, Inc., Masimo Corp. and Boston Scientific Corp.

The Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. This strategy detracted from performance given the double-digit absolute return for health care stocks during the six-month period. The Trust also owned private securities during the time period, although this is not a principal strategy.

Describe recent portfolio activity.

The Trust increased its allocation in the medical devices & supplies sub-sector, while slightly reducing its weightings in the health care providers & services and pharmaceutical sub-sectors.

Describe portfolio positioning at period end.

The Trust continued to employ a bottom-up, fundamental investment process in an effort to construct a balanced, diversified portfolio of health care stocks.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

BlackRock Health Sciences Trust

Market Price and Net Asset Value Per Share Summary

	6/30/17	12/31/16	Change	High	Low
Market Price	\$ 36.65	\$ 31.75	15.43%	\$ 36.73	\$ 31.75
Net Asset Value	\$ 35.26	\$ 31.30	12.65%	\$ 35.72	\$ 31.30

Market Price and Net Asset Value History For the Past Five Years

Overview of the Trust s Total Investments*

Ten Largest Holdings	6/30/17
UnitedHealth Group, Inc.	8%
Medtronic PLC	5
Celgene Corp	4
Amgen, Inc.	3
Boston Scientific Corp.	3
Stryker Corp.	3
Anthem, Inc.	3
Humana, Inc.	3
Allergan PLC	3
Johnson & Johnson	3

^{*} Excludes option positions and money market funds.

=		
Industry Allocation	6/30/17	12/31/16
Health Care Providers & Services	28%	30%
Health Care Equipment & Supplies	25	21
Biotechnology	24	24
Pharmaceuticals	21	23
Life Sciences Tools & Services	2	1
Diversified Consumer Services		1

For Trust compliance purposes, the Trust sindustry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Trust Summary as of June 30, 2017

BlackRock Resources & Commodities Strategy Trust

Trust Overview

BlackRock Resources & Commodities Strategy Trust s (BCX) (the Trust) primary investment objective is to seek high current income and current gains, with a secondary objective of capital appreciation. The Trust will seek to achieve its investment objectives, under normal market conditions, by investing at least 80% of its total assets in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies or investments in securities and derivatives linked to the underlying price movement of commodities or natural resources. While permitted, the Trust does not currently expect to invest in securities and derivatives linked to the underlying price movement of commodities or natural resources. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and utilizing an option overwriting strategy in an effort to seek total return performance and enhance distributions.

No assurance can be given that the Trust s investment objectives will be achieved.

Trust Information

Symbol on NYSEBCXInitial Offering DateMarch 30, 2011Current Distribution Rate on Closing Market Price as of June 30, 2017 (\$8.01)17.73%Current Monthly Distribution per Common Share2\$0.0516Current Annualized Distribution per Common Share2\$0.6192

- 1 Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.
- ² The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2017 were as follows:

Returns	Based	On
---------	-------	----

	Market Price	Net Asset Value
$BCX^{1,2}$	0.28%	(3.19)%
Lipper Natural Resources Funds ³	(2.89)%	(7.32)%

- ¹ All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
- The Trust s discount to NAV narrowed during the period, which accounts for the difference between performance based on price and performance based on NAV.
- ³ Average return. Returns reflect reinvestment of dividends and/or distributions at NAV on the ex-dividend date as calculated by Lipper. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

The following discussion relates to the Trust s absolute performance based on NAV:

What factors influenced performance?

Despite gains for the broader world equity markets, natural resources stocks generally lost ground in the first half of 2017. The downturn largely stemmed from the weakness in energy stocks, which lagged as an unfavorable balance of supply and demand put significant downward pressure on oil prices. In this environment, the Trust produced a negative absolute return at net asset value in the six-month period.

At a time of weak returns for the broader natural resources sector, only certain stocks contributed positively to the Trust s absolute performance. A position in Packaging Corp of America, which was boosted by an improving demand outlook for U.S. packaging as demonstrated by increasing utilization rates across the industry made the largest contribution at the individual stock level. The Trust s position in the agriculture science company Monsanto Co. also performed well. Monsanto was bid for in 2016 by the German pharmaceutical company Bayer AG, and its share price subsequently increased toward the bid price as the market grew more confident the deal would receive regulatory approval.

The Trust s position in energy stocks was the most significant drag on absolute performance. The oil & gas exploration & production companies Anadarko Petroleum Corp., Cimarex Energy Co. and Devon Energy Corp. were the largest detractors. Anadarko s stock price was also hurt by the company s possible link to two operational incidents that involved fatalities.

The Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The option overlay strategy had a positive impact on results at a time of weakness in the overall sector.

Describe recent portfolio activity.

The investment adviser sought to capitalize on the downturn in the energy sector by modestly increasing the Trust s exposure to higher-quality exploration & production companies. The Trust also initiated a position in the diversified mining company BHP Billiton Ltd. on the belief that the company can generate cash and de-lever its balance sheet with iron ore prices in their current range.

Describe portfolio positioning at period end.

The energy sector represented the Trust's largest allocation, followed by mining and agriculture, respectively.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

BlackRock Resources & Commodities Strategy Trust

Market Price and Net Asset Value Per Share Summary

	6/30/17	12/31/16	Change	High	Low
Market Price	\$ 8.01	\$ 8.27	(3.14)%	\$ 8.99	\$ 7.76
Net Asset Value	\$ 9.22	\$ 9.86	(6.49)%	\$ 10.50	\$ 9.00

Market Price and Net Asset Value History For Past Five Years

Overview of the Trust s Total Investments*

Ten Largest Holdings	6/30/17
Royal Dutch Shell PLC, A Shares ADR	6%
BP PLC ADR	5
Monsanto Co.	5
Glencore PLC	5
Rio Tinto PLC ADR	4
BHP Billiton PLC	3
Exxon Mobil Corp.	3
Newcrest Mining Ltd.	3
Packaging Corp. of America	3
Chevron Corp.	3

* Excludes option positions and money market funds.

Industry Allocation	6/30/17	12/31/16
Oil, Gas & Consumable Fuels	36%	34%
Metals & Mining	34	30
Chemicals	14	18
Food Products	5	5
Energy Equipment & Services	4	3
Containers & Packaging	3	6
Real Estate Investment Trusts (REITs)	2	
Paper & Forest Products	1	1
Machinery	1	
Food & Staples Retailing		2
Other		1 1

Other includes less than 1% in each of the following industries: Building Products, Electric Utilities, Electrical Equipment, Electronic Equipment, Independent Power and Renewable Electricity Producers, Instruments & Components, Machinery, Multi-Utilities, Real Estate Investment Trusts (REITs), Semiconductors & Semiconductor Equipment and Water Utilities.

For Trust compliance purposes, the Trust s industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Trust Summary as of June 30, 2017

BlackRock Science and Technology Trust

Trust Overview

BlackRock Science and Technology Trust s (BST) (the Trust) investment objective is to provide income and total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of science and technology companies. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and utilizing an option over-writing strategy in an effort to seek total return performance and enhance distributions.

No assurance can be given that the Trust s investment objective will be achieved.

Trust Information

Symbol on NYSEBSTInitial Offering DateOctober 30, 2014Current Distribution Rate on Closing Market Price as of June 30, 2017 (\$22.21)15.40%Current Monthly Distribution per Common Share2\$0.1000Current Annualized Distribution per Common Share2\$1.2000

- 1 Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.
- The monthly distribution per Common Share, declared on July 3, 2017, was increased to \$0.1100 per share. The current distribution rate on closing market price, current monthly distribution per Common Share and current annualized distribution per Common Share do not reflect the new distribution rate. The new distribution rate is not constant and is subject to change in the future. A portion of the distribution may be deemed a return of capital or net realized gain.

Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2017 were as follows:

Returns Based On

	Market Price	Net Asset Value
BST ^{1,2}	27.34%	22.88%
MSCI World Information Technology Index	N/A	17.71%

- 1 All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
- 2 The Trust s discount to NAV narrowed during the period, which accounts for the difference between performance based on price and performance based on NAV.

N/A Not applicable as the index does not have a market price.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

The following discussion relates to the Trust s relative performance based on the index cited above:

What factors influenced performance?

Within software & services, the Trust s positions in the internet software companies Alibaba Group Holding Ltd. and Tencent Holdings Ltd. led contributors for the period. Both operate as e-commerce companies in China, and benefited from strong earnings reports.

Conversely, the Trust s position in Jasper Infotech Private Ltd., a private Indian e-commerce company, led detractors for the period, as the company s valuation was negatively impacted by a more competitive business environment and challenged funding terms. Within the internet & direct marketing retail sub-industry, shares of NetShoes, a

Brazilian online retailer of sporting goods, also meaningfully detracted following the company s initial public stock offering amid heightened political turmoil in the region.

During the period, the Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The Trust s options writing strategy detracted from returns.

Describe recent portfolio activity.

The Trust added to positions in the technology hardware & equipment sub-sector, and reduced its holdings in the real estate and consumer durables & apparel sub-sectors. Regionally, the Trust added to positions in the emerging markets, funded by reductions within Europe, the Pacific Basin and North America.

Describe portfolio positioning at period end.

The Trust held its largest allocation within the software & services industry group, particularly idiosyncratic opportunities within the internet software & services and application software sub-industries. The Trust also held large allocations in more stable cash flow businesses within the semiconductor & semiconductor equipment and technology hardware & equipment industries segments. Regionally, the Trust maintained most of its exposure in North America, followed by notable weights to the emerging markets and Europe.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

BlackRock Science and Technology Trust

Market Price and Net Asset Value Per Share Summary

	6/30/17	12/31/16	Change	High	Low
Market Price	\$ 22.21	\$ 17.94	23.80%	\$ 23.67	\$ 17.94
Net Asset Value	\$ 24.01	\$ 20.10	19.45%	\$ 25.01	\$ 20.10

Market Price and Net Asset Value History Since Inception

Overview of the Trust s Total Investments*

Ten Largest Holdings	6/30/17
Alphabet, Inc., Class A	6%
Apple, Inc.	6
Microsoft Corp.	5
Tencent Holdings Ltd.	5
Amazon.com, Inc.	5
Facebook, Inc., Class A	4
Alibaba Group Holding Ltd. ADR	4
Broadcom Ltd.	3
Visa, Inc., A Shares	2
Mastercard, Inc., Class A	2

* Excludes option positions and money market funds.

Industry Allocation	6/30/17	12/31/16
Internet Software & Services	23%	23%
Software	21	21
Semiconductors & Semiconductor Equipment	20	19
Internet & Direct Marketing Retail	11	7
Technology Hardware, Storage & Peripherals	9	7
IT Services	8	11
Real Estate Investment Trusts (REITs)	3	
Electronic Equipment, Instruments & Components	2	2
Media	2	2
Communications Equipment	1	
Equity Real Estate Investment Trusts (REITs)		4
Diversified Telecommunication Services		1
Other		3 1

Other includes a 1% holding or less in each of the following industries; Communications Equipment, Hotels, Restaurants & Leisure, Professional Services, Household Durables and Wireless Telecommunication Services.

For Trust compliance purposes, the Trust sindustry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

¹ Commencement of operations.

Trust Summary as of June 30, 2017

BlackRock Utility and Infrastructure Trust

Trust Overview

BlackRock Utility and Infrastructure Trust s (BUI) (the Trust) investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing primarily in equity securities issued by companies that are engaged in the Utilities and Infrastructure business segments anywhere in the world and by utilizing an option writing (selling) strategy in an effort to seek total return performance and enhance distributions. The Trust considers the Utilities business segment to include products, technologies and services connected to the management, ownership, operation, construction, development or financing of facilities used to generate, transmit or distribute electricity, water, natural resources or telecommunications and the Infrastructure business segment to include companies that own or operate infrastructure assets or that are involved in the development, construction, distribution or financing of infrastructure assets. Under normal circumstances, the Trust invests a substantial amount of its total assets in foreign issuers, issuers that primarily trade in a market located outside the United States or issuers that do a substantial amount of business outside the United States. The Trust may invest directly in such securities or synthetically through the use of derivatives.

No assurance can be given that the Trust s investment objective will be achieved.

Trust Information

Symbol on NYSE

Initial Offering Date

Current Distribution Rate on Closing Market Price as of June 30, 2017 (\$20.55)¹

Current Monthly Distribution per Common Share²

Current Annualized Distribution per Common Share²

\$0.1210

- 1 Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.
- The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2017 were as follows:

Returns Based On

	Market Price	Net Asset Value
BUI ^{1,2}	15.67%	10.51%
Lipper Utility Funds ³	17.89%	10.24%

All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

The Trust s discount to NAV narrowed during the period, which accounts for the difference between performance based on price and performance based on NAV.

³ Average return. Returns reflect reinvestment of dividends and/or distributions at NAV on the ex-dividend date as calculated by Lipper. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

The following discussion relates to the Trust s absolute performance based on NAV:

What factors influenced performance?

The largest contributor to absolute return was the Trust stock selection in utilities. Utilities performed strongly during the period, as investors continued to seek higher-yielding equities. From an industry standpoint, stock selection in electric utilities and independent power & renewable electricity producers were the most noteworthy contributors to performance. Within the electric utilities industry, the Trust s performance benefitted from its lack of exposure to Southern Co., as well as from overweight positions in NextEra Energy, Inc. and Italian utility operator Enel SpA.

The largest detractor from absolute returns was the Trust s overweight position in the energy sector, which has been negatively impacted by weak crude oil prices. The Trust s stock selection in the oil, gas, & consumable fuels industry detracted from performance, especially among midstream master limited partnerships Plains All American Pipeline, L.P., Energy Transfer Partners, L.P., and Dominion Energy Midstream Partners, L.P. Also detracting from the Trust s return was an underweight position in the industrials sector, particularly among transportation infrastructure industry stocks including airport services providers Aena, S.A. in Spain and Grupo Aeroportuario del Sureste, S.A.B. de C.V. in Mexico.

Also, during the period, the Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The Trust s option writing strategy detracted from performance during the period.

Describe recent portfolio activity.

During the period, the Trust made few changes to its sector and industry allocations. In terms of individual positions, notable changes included adding to existing positions in Enel SpA and FirstEnergy Corp., while exiting the Trust s position in Spanish renewable electricity company EDP Renovaveis S.A. and trimming exposure to multi-utility provider CMS Energy Corp.

Describe portfolio positioning at period end.

The utilities sector accounted for approximately 63% of the Trust s assets, with holdings concentrated in U.S. electric and multi-utilities. Against a backdrop of historically low interest rates, the demand for equity yield has led to valuations for U.S. utilities that are high relative to their historical

BlackRock Utility and Infrastructure Trust

Performance and Portfolio Management Commentary (concluded)

levels, placing even greater importance on stock selection. As such, the Trust was focused on owning companies with strong management teams that offer the potential for above-sector growth in earnings and dividends.

The Trust had a preference for regulated utilities over their non-regulated counterparts given their existing barriers to entry, strong balance sheets, and lower sensitivity to commodity prices.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

Market Price and Net Asset Value Per Share Summary

	6/30/17	12/31/16	Change	High	Low
Market Price	\$ 20.55	\$ 18.41	11.62%	\$ 21.40	\$ 18.36
Net Asset Value	\$ 20.71	\$ 19.42	6.64%	\$ 21.24	\$ 19.42

Market Price and Net Asset Value History For the Past Five Years

Overview of the Trust s Total Investments*

Ten Largest Holdings	6/30/17
NextEra Energy, Inc.	9%
Dominion Resources, Inc.	5
Enel SpA	5
Atlantia SpA	4
NextEra Energy Partners LP	4
National Grid PLC	4
Duke Energy Corp.	3
Exelon Corp.	3
Public Service Enterprise Group, Inc.	3
Transurban Group	3

* Excludes option positions and money market funds.

Exercises option positions and money market rands.		
Industry Allocation	6/30/17	12/31/16
Electric Utilities	32%	28%
Multi-Utilities	22	22
Transportation Infrastructure	16	14
Oil, Gas & Consumable Fuels	15	20
Independent Power and Renewable Electricity Producers	6	4
Construction & Engineering	3	3

Gas Utilities	2	1
Water Utilities	2	2
Real Estate Investment Trusts (REITs)	2	3
Diversified Telecommunication Services		2
Other		1 1

¹ Other includes a 1% holding or less in each of the following industries: Road & Rail and Wireless Telecommunication Services. For Trust compliance purposes, the Trust—s industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Derivative Financial Instruments

The Trusts may invest in various derivative financial instruments. These instruments are used to obtain exposure to a security, commodity, index, market, and/or other asset without owning or taking physical custody of securities, commodities and/or other referenced assets or to manage market, equity, credit, interest rate, foreign currency exchange rate, commodity and/or other risks. Derivative financial instruments may give rise to a form of economic leverage and involve risks, including the imperfect correlation between the value of a derivative financial instrument and the underlying asset, possible default of the counterparty to the

transaction or illiquidity of the instrument. The Trusts successful use of a derivative financial instrument depends on the investment adviser s ability to predict pertinent market movements accurately, which cannot be assured. The use of these instruments may result in losses greater than if they had not been used, may limit the amount of appreciation a Trust can realize on an investment and/or may result in lower distributions paid to shareholders. The Trusts investments in these instruments, if any, are discussed in detail in the Notes to Financial Statements.

Schedule of Investments June 30, 2017 (Unaudited)

BlackRock Energy and Resources Trust (BGR)

(Percentages shown are based on Net Assets)

Common Stocks	Shares		Value
Energy Equipment & Services 11.3%	252 400	¢	12 012 024
Baker Hughes, Inc. (a) Halliburton Co. (a)	253,400 312,600	\$	13,812,834 13,351,146
Precision Drilling Corp. (b)	849,830		2,903,105
Schlumberger Ltd. (a)	187,224		12,326,828
Superior Energy Services, Inc. (a)(b)	517,100		5,393,353
Superior Energy Services, Inc. (a)(b)	317,100		3,373,333
Oil. Gas & Consumable Fuels 87.9%			47,787,266
Oil, Gas & Consumable Fuels 87.9% Anadarko Petroleum Corp. (a)	308,783		14,000,221
BP PLC	4,732,250		27,315,359
Cabot Oil & Gas Corp. (a)	283,900		7,120,212
Cairn Energy PLC (b)	1,810,176		4,064,182
Canadian Natural Resources Ltd.	428,484		12,364,182
Chevron Corp. (a)(c)	229,800		23,975,034
Cimarex Energy Co.	118,900		11,177,789
ConocoPhillips (a)	493,050		21,674,478
Devon Energy Corp. (a)	311,050		9,944,268
Enbridge, Inc.	206,450		8,224,250
Encana Corp.	1,141,000		10,039,181
Eni SpA	533,450		8,016,613
EOG Resources, Inc. (a)	247,900		22,439,908
EQT Corp. (a)	115,900		6,790,581
Exxon Mobil Corp. (a)	531,800		42,932,214
Hess Corp. (a)	205,150		8,999,931
International Petroleum Corp. (b)	48,925		145,183
Kosmos Energy Ltd. (b)	721,207		4,622,937
Marathon Oil Corp. (a)	706,300		8,369,655
Noble Energy, Inc. (a)(c)	287,292		8,130,364
Oil Search Ltd.	1,085,763		5,685,688
Phillips 66 (a)	56,700		4,688,523
Pioneer Natural Resources Co. (a) Common Stocks	94,550 Shares		15,088,289 Value
Oil, Gas & Consumable Fuels (continued)	Shares		value
Royal Dutch Shell PLC ADR, Class A (a)	698,200	\$	37,137,258
Royal Dutch Shell PLC, Class A	511,048	Ψ	13,577,881
Tesoro Corp. (a)	82,050		7,679,880
TransCanada Corp.	324,450		15,466,918
Valero Energy Corp. (a)	156,200		10,537,252
			370,208,231
Total Long-Term Investments			
(Cost \$437,491,469) 99.2%			417,995,497
Short-Term Securities			
BlackRock Liquidity Funds, T-Fund, Institutional Class, 0.84% (d)(e) Total Short-Term Securities	6,214,460		6,214,460
(Cost \$6,214,460) 1.5% Total Investments Before Options Written			6,214,460
(Cost \$443,705,929) 100.7%			424,209,957
Options Written (Premiums Received \$3,341,898) (0.5)% Total Investments, Net of Options Written			(2,193,235) 422,016,722

(Cost \$440,364,031) 100.2%

Liabilities in Excess of Other Assets (0.2)% (872,218)

Net Assets 100.0% \$ 421,144,504

Notes to Schedule of Investments

- (a) All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.
- (b) Non-income producing security.
- (c) All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.
- (d) Current yield as of period end.
- (e) During the period ended June 30, 2017, investments in issuers considered to be affiliates of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

	Shares Held at	Net	Shares Held at	Value at June 30,		Change in Unrealized Net Realized ppreciation
Affiliate	December 31, 2016	Activity	June 30, 2017	2017	Income	Gain (Depreciation)
BlackRock Liquidity Funds, T-Fund,						
Institutional Class	3,936,617	2,277,843	6,214,460	\$ 6,214,460	\$ 16,781	
SL Liquidity Series, LLC, Money Market						
Series					22,6411	
Total				\$ 6,214,460	\$ 39,422	

¹ Represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

For Trust compliance purposes, the Trust s industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Portfolio Abbreviations

ADR	American Depositary Receipts
AUD	Australian Dollar
CAD	Canadian Dollar
CHF	Swiss Franc
EUR	Euro
GBP	British Pound
GDR	Global Depositary Receipt
HKD	Hong Kong Dollar
JPY	Japanese Yen
KRW	Korean Won
NOK	Norwegian Krone
NZD	New Zealand Dollar
OTC	Over-the-Counter
SEK	Swedish Krona
TWD	Taiwan Dollar

USD U.S. Dollar ZAR South African Rand

See Notes to Financial Statements.

BlackRock Energy and Resources Trust (BGR)

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written						
	Put/	Expiration		rike		
Description	Call	Date		rice	Contracts	Value
Marathon Oil Corp.	Call	7/06/17	USD	15.50	58	\$
Anadarko Petroleum Corp.	Call	7/07/17	USD	53.50	176	(704)
Baker Hughes, Inc.	Call	7/07/17	USD	56.00	102	(6,630)
Cabot Oil & Gas Corp.	Call	7/07/17	USD	23.00	548	(117,820)
Chevron Corp.	Call	7/07/17	USD	107.00	218	(981)
ConocoPhillips	Call	7/07/17	USD	46.00	159	(477)
Devon Energy Corp.	Call	7/07/17	USD	37.50	21	(84)
EOG Resources, Inc.	Call	7/07/17	USD	94.00	43	(430)
Exxon Mobil Corp.	Call	7/07/17	USD	82.00	129	(1,290)
Marathon Oil Corp.	Call	7/07/17	USD	14.00	244	(488)
Pioneer Natural Resources Co.	Call	7/07/17	USD	172.50	45	(3,600)
Royal Dutch Shell PLC ADR, Class A	Call	7/07/17	USD	55.95	514	(240)
Schlumberger Ltd.	Call	7/07/17	USD	70.00	86	(172)
Valero Energy Corp.	Call	7/07/17	USD	67.00	32	(2,816)
Chevron Corp.	Call	7/13/17	USD	107.50	218	(4,121)
Anadarko Petroleum Corp.	Call	7/14/17	USD	52.50	208	(832)
Baker Hughes, Inc.	Call	7/14/17	USD	56.00	198	(7,920)
Devon Energy Corp.	Call	7/14/17	USD	35.00	52	(416)
EOG Resources, Inc.	Call	7/14/17	USD	91.50	103	(10,867)
Exxon Mobil Corp.	Call	7/14/17	USD	81.00	378	(24,570)
Hess Corp.	Call	7/14/17	USD	46.00	203	(6,800)
Pioneer Natural Resources Co.	Call	7/14/17	USD	170.00	177	(7,522)
Valero Energy Corp.	Call	7/14/17	USD	66.00	130	(25,220)
Baker Hughes, Inc.	Call	7/21/17	USD	56.25	102	(6,736)
Canadian Natural Resources Ltd.	Call	7/21/17	CAD	38.00	367	(16,414)
ConocoPhillips	Call	7/21/17	USD	46.00	290	(7,830)
Devon Energy Corp.	Call	7/21/17	USD	33.00	86	(4,988)
Encana Corp.	Call	7/21/17	CAD	13.00	994	(6,132)
Encana Corp.	Call	7/21/17	CAD	15.00	290	(1,118)
EOG Resources, Inc.	Call	7/21/17	USD	97.50	21	(357)
EQT Corp.	Call	7/21/17	USD	55.00	202	(86,860)
Exxon Mobil Corp.	Call	7/21/17	USD	80.00	342	(50,445)
Exxon Mobil Corp.	Call	7/21/17	USD	85.00	216	(1,188)
Halliburton Co.	Call	7/21/17	USD	43.50	142	(9,727)
Halliburton Co.	Call	7/21/17	USD	48.00	245	(857)
Hess Corp.	Call	7/21/17	USD	52.50	288	(576)
Noble Energy, Inc.	Call	7/21/17	USD	30.00	580	(11,600)
Precision Drilling Corp.	Call	7/21/17	CAD	6.00	520	(2,005)
Royal Dutch Shell PLC ADR, Class A	Call	7/21/17	USD	55.95	514	(4,210)
Schlumberger Ltd.	Call	7/21/17	USD	72.50	135	(877)
Tesoro Corp.	Call	7/21/17	USD	90.00	87	(38,715)
TransCanada Corp.	Call	7/21/17	CAD	64.00	240	(1,758)
Valero Energy Corp.	Call	7/21/17	USD	65.00	197	(58,411)
Valero Energy Corp.	Call	7/21/17	USD	67.50	33	(4,026)
Exxon Mobil Corp.	Call	7/25/17	USD	83.25	192	(4,596)
Baker Hughes, Inc.	Call	7/28/17	USD	57.00	101	(22,422)
Cabot Oil & Gas Corp.	Call	7/28/17	USD	23.00	220	(53,350)
Canadian Natural Resources Ltd.	Call	7/28/17	CAD	38.00	765	(44,244)
Chevron Corp.	Call	7/28/17	USD	108.00	185	(11,008)
Devon Energy Corp.	Call	7/28/17	USD	33.00	265	(20,008)
EOG Resources, Inc.	Call	7/28/17	USD	92.00	178	(27,590)
Exxon Mobil Corp.	Call	7/28/17	USD	82.50	200	(12,000)
Halliburton Co.	Call	7/28/17	USD	44.00	143	(11,583)
Marathon Oil Corp.	Call	7/28/17	USD	13.00	502	(7,028)
<u>.</u>						

Pioneer Natural Resources Co.	Call	7/28/17	USD	167.50	47	(8,812)
Schlumberger Ltd.	Call	7/28/17	USD	70.00	189	(6,048)
Valero Energy Corp.	Call	7/28/17	USD	65.50	65	(18,850)
Royal Dutch Shell PLC ADR, Class A	Call	8/01/17	USD	55.50	1,415	(31,683)
Anadarko Petroleum Corp.	Call	8/04/17	USD	47.50	233	(21,320)
Baker Hughes, Inc.	Call	8/04/17	USD	55.00	165	(23,100)
Chevron Corp.	Call	8/04/17	USD	107.00	183	(20,039)
Devon Energy Corp.	Call	8/04/17	USD	31.00	49	(9,947)

See Notes to Financial Statements.

BlackRock Energy and Resources Trust (BGR)

Put/ Expiration Strike				.il.o			
Description	Call	Expiration Date	Strike Price		Contracts		Value
EOG Resources, Inc.	Call	8/04/17	USD	89.00	522	\$	(194,445)
Marathon Oil Corp.	Call	8/04/17	USD	12.00	913	Ф	(49,759)
Tesoro Corp.	Call	8/04/17	USD	94.50	113		(28,476)
Valero Energy Corp.	Call	8/04/17	USD	68.50	89		(12,327)
Anadarko Petroleum Corp.	Call	8/11/17	USD	46.50	310		(44,330)
Cabot Oil & Gas Corp.	Call	8/11/17	USD	26.00	225		(19,800)
ConocoPhillips	Call	8/11/17	USD	45.00	319		(30,305)
Halliburton Co.	Call	8/11/17	USD	43.00	244		
							(36,600)
Hess Corp.	Call	8/11/17	USD	43.50	227		(53,118)
Phillips 66	Call	8/11/17	USD	82.50	198		(43,560)
Schlumberger Ltd.	Call	8/11/17	USD	67.50	176		(21,648)
Exxon Mobil Corp.	Call	8/14/17	USD	83.00	254		(13,836)
Halliburton Co.	Call	8/16/17	USD	46.10	320		(16,597)
Anadarko Petroleum Corp.	Call	8/18/17	USD	50.00	153		(8,491)
Baker Hughes, Inc.	Call	8/18/17	USD	55.00	218		(40,330)
Canadian Natural Resources Ltd.	Call	8/18/17	CAD	38.00	367		(32,829)
ConocoPhillips	Call	8/18/17	USD	45.00	320		(33,920)
ConocoPhillips	Call	8/18/17	USD	47.00	290		(14,065)
Devon Energy Corp.	Call	8/18/17	USD	33.00	615		(77,490)
Enbridge, Inc.	Call	8/18/17	CAD	54.00	250		(5,783)
Exxon Mobil Corp.	Call	8/18/17	USD	85.00	150		(3,975)
Marathon Oil Corp.	Call	8/18/17	USD	13.00	332		(9,628)
Noble Energy, Inc.	Call	8/18/17	USD	30.00	425		(23,375)
Pioneer Natural Resources Co.	Call	8/18/17	USD	170.00	60		(18,750)
Schlumberger Ltd.	Call	8/18/17	USD	70.00	69		(4,243)
Tesoro Corp.	Call	8/18/17	USD	95.00	87		(24,795)
ConocoPhillips	Call	8/30/17	USD	47.60	347		(17,711)
Superior Energy Services, Inc.	Call	9/15/17	USD	10.00	220		(34,650)
Total						\$	(1,807,294)

OTC Options Written

	Put/		Expiration Strike		rike		
Description	Call	Counterparty	Date	Pı	rice	Contracts	Value
BP PLC	Call	Credit Suisse International	07/06/17	GBP	4.75	450,000	\$ (434)
Royal Dutch Shell PLC ADR, Class A	Call	Citibank N.A.	07/06/17	GBP	21.26	138,900	(1,592)
Encana Corp.	Call	Deutsche Bank AG	07/07/17	CAD	16.05	17,900	(1)
EQT Corp.	Call	Credit Suisse International	07/07/17	USD	60.07	20,300	(8,360)
Cimarex Energy Co.	Call	UBS AG	07/10/17	USD	119.70	4,300	
Superior Energy Services, Inc.	Call	UBS AG	07/10/17	USD	12.61	20,000	(518)
Oil Search Ltd.	Call	Deutsche Bank AG	07/18/17	AUD	7.19	100,000	(3,217)
BP PLC	Call	Credit Suisse International	07/19/17	GBP	4.69	180,800	(2,006)
Enbridge, Inc.	Call	Citibank N.A.	07/19/17	CAD	53.16	22,200	(3,376)
Eni SpA	Call	Credit Suisse International	07/19/17	EUR	14.06	87,000	(1,576)
Royal Dutch Shell PLC ADR, Class A	Call	Goldman Sachs International	07/26/17	GBP	20.95	40,000	(8,127)
BP PLC	Call	Credit Suisse International	07/27/17	GBP	4.73	363,000	(7,241)
TransCanada Corp.	Call	Morgan Stanley & Co. International PLC	07/31/17	CAD	63.99	46,500	(30,270)
Superior Energy Services, Inc.	Call	Royal Bank of Canada	08/02/17	USD	10.84	27,600	(19,572)
BP PLC	Call	Credit Suisse International	08/04/17	GBP	4.75	363,000	(9,618)
Eni SpA	Call	Goldman Sachs International	08/04/17	EUR	14.34	12,800	(425)
Oil Search Ltd.	Call	Deutsche Bank AG	08/04/17	AUD	7.08	215,000	(20,417)
Cimarex Energy Co.	Call	Goldman Sachs International	08/07/17	USD	98.61	15,500	(26,560)
Encana Corp.	Call	Citibank N.A.	08/08/17	CAD	11.49	39,000	(19,144)
Encana Corp.	Call	Morgan Stanley & Co. International PLC	08/08/17	CAD	13.81	62,000	(6,724)
BP PLC	Call	Goldman Sachs International	08/09/17	GBP	4.54	299,500	(26,643)
Eni SpA	Call	Morgan Stanley & Co. International PLC	08/09/17	EUR	13.80	87,000	(11,543)
Superior Energy Services, Inc.	Call	UBS AG	08/09/17	USD	10.80	39,600	(34,751)
TransCanada Corp.	Call	Citibank N.A.	08/15/17	CAD	63.48	43,000	(13,804)
Superior Energy Services, Inc.	Call	Goldman Sachs International	08/16/17	USD	10.90	27,500	(23,590)

Encana Corp.	Call	Citibank N.A.	08/22/17	CAD	12.04	32,500	(12,412)
Encana Corp.	Call	Royal Bank of Canada	08/22/17	CAD	11.33	42,000	(26,602)
Cimarex Energy Co.	Call	Goldman Sachs International	08/23/17	USD	98.61	15,500	(35,478)
Enbridge, Inc.	Call	Goldman Sachs International	08/31/17	CAD	54.10	25,000	(6,405)
Encana Corp.	Call	Royal Bank of Canada	09/06/17	CAD	11.89	47,600	(25,535)
Total							\$ (385,941)

See Notes to Financial Statements.

BlackRock Energy and Resources Trust (BGR)

Transactions in Options Written for the Period Ended June 30, 2017

	Ca	Calls		
		Premiums		
	Contracts	Received		
Outstanding options, beginning of period	3,570,352	\$ 4,804,608		
Options written	12,778,126	13,413,684		
Options exercised				
Options expired	(8,735,561)	(6,859,698)		
Options closed	(4,705,074)	(8,016,696)		
Outstanding options, end of period	2,907,843	\$ 3,341,898		

As of period end, the value of portfolio securities subject to covered call options written was \$140,124,445.

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

		Commodity		Equity	Foreign Currency Exchange	Interest Rate	Other	
Liabilities Derivative Financial Instrun	ients	Contracts	Contracts	Contracts	Contracts	Contracts	Contracts	Total
Options written	Options written, at value			\$ 2,193,235				\$ 2,193,235
For the six month ended June 30, 2017, the effect of derivative financial instruments in the Statements of Operations was as follows:								
Net Realized Gain (Loss) from:								
Options written				\$ 9,048,883				\$ 9,048,883
Net Change in Unrealized Appreciation o Options written	n:			\$ 2,496,409				\$ 2,496,409

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:

Average value of option contracts written \$ 2,447,757

For more information about the Trust s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments Offsetting as of Period End

The Trust s derivative assets and liabilities (by type) are as follows:

Derivative Financial Instruments

Assets Liabilities

Options \$ 2,193,235

Derivatives not subject to a Master Netting Agreement or similar agreement (MNA)

\$ (1,807,294)

Total derivative assets and liabilities subject to an MNA

385,941

The following table presents the Trust s derivative liabilities by counterparty net of amounts available for offset under a Master Netting Agreement (MNA) and net of the related collateral received by the Trust:

Counterparty	Derivative Liabilities Subject to an MNA by Counterparty		Derivatives Available for Offset	Non-cash Collateral Pledged ¹	Cash Collateral Pledged	Net Amount o Derivative Liabilities ²	
Citibank N.A.	\$	50,328		\$ (50,328)			
Credit Suisse International		29,235				\$	29,235
Deutsche Bank AG		23,635					23,635
Goldman Sachs International		127,228					127,228
Morgan Stanley & Co. International PLC		48,537		(48,537)			
Royal Bank of Canada		71,709					71,709
UBS AG		35,269					35,269
Total	\$	385,941		\$ (98,865)		\$	287,076

¹ Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.

See Notes to Financial Statements.

28 SEMI-ANNUAL REPORT

JUNE 30, 2017

² Net amount represents the net amount payable due to the counterparty in the event of default. Net Amount may be offset further by net options written receivable/payable on the Statements of Assets and Liabilities.

BlackRock Energy and Resources Trust (BGR)

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust s policy regarding valuation of investments and derivative financial instruments refer to the Notes to Financial Statements.

The following tables summarize the Trust s investments and derivative financial instruments categorized in the disclosure hierarchy:

Level 1 Level 2 Level 3	Total
Assets:	
Investments:	
Long-Term Investments:	
Energy Equipment & Services \$ 47,787,266	\$ 47,787,266
Oil, Gas & Consumable Fuels 311,548,508 \$ 58,659,723	370,208,231
Short-Term Securities 6,214,460	6,214,460
Total \$365,550,234 \$58,659,723	\$ 424,209,957
Derivative Financial Instruments ¹	
Liabilities:	
Equity contracts \$ (1,706,445) \$ (486,790)	\$ (2,193,235)
¹ Derivative financial instruments are options written, which are shown at value.	

During the six months ended June 30, 2017, there were no transfers between levels.

See Notes to Financial Statements.

Schedule of Investments June 30, 2017 (Unaudited)

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

(Percentages shown are based on Net Assets)

Common Stocks Airlines 1.9%	Shares	Value
Delta Air Lines, Inc. (a)(b) Southwest Airlines Co. (a)	232,835 14,810	\$ 12,512,553 920,293
Auto Components 2.4%		13,432,846
Goodyear Tire & Rubber Co. (a) Lear Corp. (a)	270,397 50,102	9,453,079 7,118,492
Banks 12.3%		16,571,571
Bank of America Corp. (a)(b) Citigroup, Inc. (a) JPMorgan Chase & Co. (a)(b) Regions Financial Corp. (a) SunTrust Banks, Inc. (a) U.S. Bancorp (a)	842,001 91,993 305,724 310,429 218,766 288,037	20,426,944 6,152,492 27,943,174 4,544,681 12,408,407 14,954,881
Biotechnology 4.1%		86,430,579
Biogen, Inc. (a)(c) Gilead Sciences, Inc. (a)	54,407 201,321	14,763,884 14,249,500
Conital Manhata 100		29,013,384
Capital Markets 1.9% Goldman Sachs Group, Inc. (a) Chemicals 2.4%	60,296	13,379,682
Dow Chemical Co. (a)	267,847	16,893,110
Communications Equipment 2.0% Cisco Systems, Inc. (a)	456,067	14,274,897
Construction & Engineering 0.4% EMCOR Group, Inc. (a) Consumer Finance 1.1%	38,519	2,518,372
SLM Corp. (a)(c) Containers & Packaging 1.9%	667,970	7,681,655
Avery Dennison Corp. (a) Packaging Corp. of America (a)	49,267 79,712	4,353,725 8,879,120
Diversified Telecommunication Services 0.2%		13,232,845
AT&T, Inc. (a) Electric Utilities 1.1%	37,700	1,422,421
FirstEnergy Corp. (a) Electronic Equipment, Instruments & Components 2.0%	273,587	7,977,797
CDW Corp. (a) Flex Ltd. (a)(c)	108,840 458,631	6,805,765 7,480,272
Food & Staples Retailing 4.1%		14,286,037
CVS Health Corp. (a)(b) Wal-Mart Stores, Inc. (a) Walgreens Boots Alliance, Inc. (a)	138,171 80,756 150,485	11,117,239 6,111,614 11,784,480
Health Care Equipment & Supplies 120		29,013,333
Health Care Equipment & Supplies 1.2% Baxter International, Inc. (a) Health Care Providers & Services 7.4%	140,986	8,535,293

Aetna, Inc. (a)	8,732	1,325,780
Anthem, Inc. (a)	18,397	3,461,028
Centene Corp. (a)(c)	92,304	7,373,243
Humana, Inc. (a)	64,918	15,620,569
Laboratory Corp. of America Holdings (a)(c)	37,064	5,713,045
McKesson Corp. (a)	18,519	3,047,116
UnitedHealth Group, Inc. (a)	83,455	15,474,226
		52,015,007
Common Stocks	Shares	Value
Hotels, Restaurants & Leisure 2.6%		
Carnival Corp. (a)	275,660	\$ 18,075,026
Household Durables 2.6%		
D.R. Horton, Inc.	322,419	11,146,025
Lennar Corp., Class A (a)	60,253	3,212,690
NVR, Inc. (c)	1,453	3,502,616
NVK, Inc. (c)	1,433	3,302,010
		17,861,331
Insurance 0.6%		
Hartford Financial Services Group, Inc. (a)	80,016	4,206,441
Internet Software & Services 4.4%		
Alphabet, Inc., Class A (a)(b)(c)	33,504	31,147,999
IT Services 2.7%		
Amdocs Ltd. (a)	99,436	6,409,645
	· · · · · · · · · · · · · · · · · · ·	12,392,099
Cognizant Technology Solutions Corp., Class A (a)	186,628	12,392,099
		18,801,744
Machinery 2.0%		10,001,744
Stanley Black & Decker, Inc. (a)	79,957	11,252,349
WABCO Holdings, Inc. (a)(c)	22,204	2,831,232
WADCO Holdings, file. (a)(c)	22,204	2,031,232
		14,083,581
Media 3.3%		, ,
Comcast Corp., Class A (a)(b)	589,266	22,934,233
Metals & Mining 1.0%	,	,, _ ,,
	157.001	((4(520
Rio Tinto PLC, ADR (a)	157,091	6,646,520
Multi-Utilities 0.5%		
Public Service Enterprise Group, Inc.	88,510	3,806,815
Oil, Gas & Consumable Fuels 6.3%		
Anadarko Petroleum Corp. (a)	35,386	1,604,401
* ''		
BP PLC ADR (a)	211,505	7,328,648
Chevron Corp. (a)	130,394	13,604,006
Marathon Oil Corp. (a)	131,595	1,559,401
Statoil ASA, ADR (a)	142,350	2,353,046
Suncor Energy, Inc. (a)	367,356	10,726,795
TOTAL SA ADR (a)	90,924	4,508,921
Valero Energy Corp. (a)	34,800	
valeto Energy Colp. (a)	34,600	2,347,608
		44,032,826
Pharmaceuticals 3.8%		,,
Merck & Co., Inc. (a)	101,505	6,505,455
Pfizer, Inc. (a)	591,440	19,866,470
		26 271 025
Professional Services 0.8%		26,371,925
	111 106	£ 205 211
Robert Half International, Inc. (a)	111,106	5,325,311
Road & Rail 2.0%		
Norfolk Southern Corp. (a)	115,132	14,011,564
Semiconductors & Semiconductor Equipment 2.8%		
Intel Corp. (a)(b)	266,433	8,989,449
Lam Research Corp. (a)	56,881	8,044,680
Qorvo, Inc. (a)(c)	40,771	2,581,620
		19,615,749
Software 7.6%		17,013,749
Activision Blizzard, Inc. (a)	199,362	11,477,270
Dell Technologies, Inc., Class V (a)(c)	92,419	5,647,725

Microsoft Corp. (a) Oracle Corp. (a)	400,742 167,147	27,623,146 8,380,751
Specialty Detail 400/		53,128,892
Specialty Retail 4.9%		
Home Depot, Inc. (a)(b)	102,046	15,653,856
Lowe s Cos., Inc. (a)(b)	187,711	14,553,234
Urban Outfitters, Inc. (a)(c)	226,753	4,204,001
		34,411,091

See Notes to Financial Statements.

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

Common Stocks	Shares		Value
Technology Hardware, Storage & Peripherals 5.2% Apple, Inc. (a)(b)	251,629	\$	36,239,609
Tobacco 1.7% Altria Group, Inc. (a)(b)	162,564		12,106,141
Total Long-Term Investments (Cost \$595,730,513) 101.2%			709,485,627
Short-Term Securities BlackRock Liquidity Funds, T-Fund, Institutional Class, 0.84% (d)(e)	815,956		815,956
Total Short-Term Securities (Cost \$815,956) 0.1%			815,956
Total Short-Term Securities 0.1% Total Investments Before TBA Sale Commitments and Options Written			815,956
(Cost \$596,546,469) 101.3%			710,301,583
Options Written (Premiums Received \$7,476,756) (1.1)%		(8	,011,076)
Common Stocks Total Investments, Net of Options Written			Value
(Cost \$589,069,713) 100.2% Liabilities in Excess of Other Assets (0.2)%			\$ 702,290,507 (1,138,914)
Net Assets 100.0%			\$ 701,151,593

Notes to Schedule of Investments

- (a) All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.
- (b) All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.
- (c) Non-income producing security.
- (d) Current yield as of period end.
- (e) During the six months ended June 30, 2017, investments in issuers considered to be affiliates of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

	Shares		Chanas	Value of			Change in Unrealized
	Snares Held at	Not	Shares Held at	Value at		Net Realized	
Affiliate	December 31, 2016	Net Activity	June 30, 2017	June 30, 2017	Incomo	Gain	Appreciation (Depreciation)
	December 31, 2010	Activity	June 30, 2017	2017	Income	Gaill	(Depreciation)
BlackRock Liquidity Funds,							
T-Fund, Institutional Class	24,715,046	(23,899,090)	815,956	\$ 815,956	\$ 51,867		

SL Liquidity Series, LLC, Money

Market Series. 695,518 (695,518) 1,191¹ \$ (54) **Total** \$ 815,956 \$ 53,058 \$ (54)

For Trust compliance purposes, the Trust s industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Derivative Financial	Instruments Outstanding as of Period End
Exchange-Traded Op	ptions Written

	Put/	Expiration	S	trike		
Description	Call	Date	I	Price	Contracts	Value
Lam Research Corp.	Call	7/05/17	USD	150.01	299	\$ (2,595)
JPMorgan Chase & Co.	Call	7/06/17	USD	87.50	188	(65,199)
Marathon Oil Corp.	Call	7/06/17	USD	15.50	14	
Alphabet, Inc., Class A	Call	7/07/17	USD	1,010.00	28	(280)
Anadarko Petroleum Corp.	Call	7/07/17	USD	53.50	52	(208)
Anthem, Inc.	Call	7/07/17	USD	182.50	37	(21,183)
Bank of America Corp.	Call	7/07/17	USD	24.00	606	(25,755)
Bank of America Corp.	Call	7/07/17	USD	24.25	375	(12,433)
BP PLC ADR	Call	7/07/17	USD	36.00	91	(182)

See Notes to Financial Statements.

¹ Represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

Exchange-Traded Options Written (continued)

	Put/	Expiration	Strike		
Description	Call	Date	Price	Contracts	Value
Chevron Corp.	Call	7/07/17	USD 107.00	130	\$ (585)
Cisco Systems, Inc.	Call	7/07/17	USD 32.00	308	(616)
Citigroup, Inc.	Call	7/07/17	USD 61.00	37	(22,478)
Citigroup, Inc.	Call	7/07/17	USD 61.50	24	(13,080)
D.R. Horton, Inc.	Call	7/07/17	USD 33.50	435	(54,158)
	Call			475	
Flex Ltd.		7/07/17	USD 17.50		(17,100)
Goldman Sachs Group, Inc.	Call	7/07/17	USD 225.00	148	(11,026)
Goodyear Tire & Rubber Co.	Call	7/07/17	USD 32.50	210	(52,500)
Humana, Inc.	Call	7/07/17	USD 235.00	63	(41,895)
Intel Corp.	Call	7/07/17	USD 36.50	221	(442)
Marathon Oil Corp.	Call	7/07/17	USD 14.00	69	(138)
Merck & Co., Inc.	Call	7/07/17	USD 64.50	147	(4,483)
Suncor Energy, Inc.	Call	7/07/17	USD 31.50	55	(1,925)
U.S. Bancorp	Call	7/07/17	USD 53.00	572	(4,004)
UnitedHealth Group, Inc.	Call	7/07/17	USD 177.50	38	(30,685)
Valero Energy Corp.	Call	7/07/17	USD 67.00	14	(1,232)
Walgreens Boots Alliance, Inc.	Call	7/07/17	USD 81.00	259	(1,813)
Lennar Corp., Class A	Call	7/10/17	USD 52.10	151	(25,079)
Bank of America Corp.	Call	7/11/17	USD 24.25	188	(7,804)
Chevron Corp.	Call	7/13/17	USD 107.50	130	(2,457)
Alphabet, Inc., Class A	Call	7/14/17	USD 997.50	28	(1,610)
1	Call	7/14/17	USD 76.00	467	
Altria Group, Inc.					(7,939)
Anadarko Petroleum Corp.	Call	7/14/17	USD 52.50	24	(96)
Bank of America Corp.	Call	7/14/17	USD 23.00	205	(28,085)
Bank of America Corp.	Call	7/14/17	USD 23.50	478	(43,976)
BP PLC ADR	Call	7/14/17	USD 36.00	92	(506)
Cisco Systems, Inc.	Call	7/14/17	USD 31.50	456	(8,664)
D.R. Horton, Inc.	Call	7/14/17	USD 34.00	160	(13,600)
Dow Chemical Co.	Call	7/14/17	USD 65.50	729	(6,925)
Flex Ltd.	Call	7/14/17	USD 16.50	105	(1,995)
Goldman Sachs Group, Inc.	Call	7/14/17	USD 220.00	153	(68,468)
Intel Corp.	Call	7/14/17	USD 36.50	250	(500)
Goodyear Tire & Rubber Co.	Call	7/14/17	USD 36.00	214	(4,280)
Merck & Co., Inc.	Call	7/14/17	USD 64.50	89	(4,761)
Norfolk Southern Corp.	Call	7/14/17	USD 121.00	304	(68,400)
Pfizer, Inc.	Call	7/14/17	USD 33.00	680	(49,980)
Suncor Energy, Inc.	Call	7/14/17	USD 32.00	55	(1,045)
UnitedHealth Group, Inc.	Call	7/14/17	USD 182.50	48	(19,800)
*	Call		USD 66.00	40	
Valero Energy Corp.		7/14/17			(7,760)
Walgreens Boots Alliance, Inc.	Call	7/14/17	USD 82.00	373	(5,968)
Delta Air Lines, Inc.	Call	7/18/17	USD 49.51	518	(254,884)
Qorvo, Inc.	Call	7/18/17	USD 75.55	75	(37)
Activision Blizzard, Inc.	Call	7/21/17	USD 60.00	256	(15,488)
Alphabet, Inc., Class A	Call	7/21/17	USD 945.00	27	(30,375)
Alphabet, Inc., Class A	Call	7/21/17	USD 950.00	14	(14,280)
Amdocs Ltd.	Call	7/21/17	USD 65.00	247	(17,290)
Anthem, Inc.	Call	7/21/17	USD 190.00	17	(3,995)
Apple, Inc.	Call	7/21/17	USD 149.00	333	(27,639)
Avery Dennison Corp.	Call	7/21/17	USD 85.00	185	(60,588)
Avery Dennison Corp.	Call	7/21/17	USD 90.00	61	(3,507)
Bank of America Corp.	Call	7/21/17	USD 23.00	665	(95,428)
Bank of America Corp.	Call	7/21/17	USD 25.00	187	(5,142)
Baxter International, Inc.	Call	7/21/17	USD 57.50	562	(186,865)
Biogen, Inc.	Call	7/21/17	USD 265.00	174	(167,910)
BP PLC ADR	Call	7/21/17	USD 36.00	174	(2,187)
BP PLC ADR	Call	7/21/17	USD 37.00	61 510	(244)
Carnival Corp.	Call	7/21/17	USD 62.50	510	(173,400)
CDW Corp.	Call	7/21/17	USD 65.00	350	(11,375)
Chevron Corp.	Call	7/21/17	USD 110.00	162	(1,620)
Cisco Systems, Inc.	Call	7/21/17	USD 32.00	307	(4,451)
Citigroup, Inc.	Call	7/21/17	USD 62.50	162	(76,140)

Comcast Corp., Class A	Call	7/21/17	USD	38.75	522	(44,370)
CVS Health Corp.	Call	7/21/17	USD	80.00	254	(39,370)
D.R. Horton, Inc.	Call	7/21/17	USD	34.00	305	(29,128)
Dell Technologies, Inc., Class V	Call	7/21/17	USD	65.00	285	(5,700)

See Notes to Financial Statements.

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

Exchange-Traded Options Written (continued)

	Put/	Expiration	Strike				
Description	Call	Date	P	rice	Contracts	Value	
Dell Technologies, Inc., Class V	Call	7/21/17	USD	70.00	45	\$ (450)	
Dow Chemical Co.	Call	7/21/17	USD	64.00	99	(5,742)	
EMCOR Group, Inc.	Call	7/21/17	USD	65.00	114	(21,660)	
FirstEnergy Corp.	Call	7/21/17	USD	29.00	225	(11,812)	
FirstEnergy Corp.	Call	7/21/17	USD	30.00	711	(10,665)	
Flex Ltd.	Call	7/21/17	USD	17.00	924	(9,702)	
Gilead Sciences, Inc.	Call	7/21/17	USD	67.50	462	(168,630)	
Goodyear Tire & Rubber Co.	Call	7/21/17	USD	36.00	300	(9,750)	
Home Depot, Inc.	Call	7/21/17	USD	160.00	172	(4,128)	
Humana, Inc.	Call	7/21/17	USD	235.00	98	(79,870)	
Laboratory Corp. of America Holdings	Call	7/21/17	USD	145.00	75	(73,875)	
Lam Research Corp.	Call	7/21/17	USD	160.00	125	(2,187)	
Lear Corp.	Call	7/21/17	USD	145.00	70	(11,900)	
Lennar Corp., Class A	Call	7/21/17	USD	55.00	175	(5,512)	
Lowe s Cos., Inc.	Call	7/21/17	USD	80.00	120	(5,820)	
Merck & Co., Inc.	Call	7/21/17	USD	65.00	56	(3,416)	
Microsoft Corp.	Call	7/21/17	USD	70.00	295	(32,745)	
Norfolk Southern Corp.	Call	7/21/17	USD	125.00	160	(15,200)	
Oracle Corp.	Call	7/21/17	USD	46.00	418	(175,560)	
Packaging Corp. of America	Call	7/21/17	USD	110.00	136	(39,440)	
Pfizer, Inc.	Call	7/21/17	USD	33.00	26	(2,067)	
Qorvo, Inc.	Call	7/21/17	USD	75.00	150	(1,500)	
Rio Tinto PLC ADR	Call	7/21/17	USD	42.50	340	(34,000)	
SLM Corp.	Call	7/21/17	USD	11.00	1,370	(92,475)	
Stanley Black & Decker, Inc.	Call	7/21/17	USD	140.00	399	(100,748)	
Statoil ASA ADR	Call	7/21/17	USD	17.70	392	(1,530)	
SunTrust Bank, Inc.	Call	7/21/17	USD	55.00	210	(51,135)	
U.S. Bancorp	Call	7/21/17	USD	52.50	896	(58,688)	
UnitedHealth Group, Inc.	Call	7/21/17	USD	180.00	63	(45,833)	
UnitedHealth Group, Inc.	Call	7/21/17	USD	185.00	49	(18,253)	
Valero Energy Corp.	Call	7/21/17	USD	65.00	59	(17,494)	
Valero Energy Corp.	Call	7/21/17	USD	67.50	15	(1,830)	
Walgreens Boots Alliance, Inc.	Call	7/21/17	USD	82.50	150	(3,150)	
Dell Technologies, Inc., Class V	Call	7/24/17	USD	62.01	134	(15,184)	
Activision Blizzard, Inc.	Call	7/28/17	USD	57.00	235	(49,233)	
Alphabet, Inc., Class A	Call	7/28/17	USD	962.50	28	(46,620)	
Bank of America Corp.	Call	7/28/17	USD	24.00	507	(41,067)	
BP PLC ADR	Call	7/28/17	USD	36.00	87	(1,566)	
Chevron Corp.	Call	7/28/17	USD	108.00	107	(6,366)	
Cisco Systems, Inc.	Call	7/28/17	USD	32.00	203	(4,466)	
Citigroup, Inc.	Call	7/28/17	USD	65.00	24	(6,540)	
Cognizant Technology Solutions Corp.	Call	7/28/17	USD	66.50	182	(23,660)	
Comcast Corp., Class A	Call	7/28/17	USD	40.00	776	(42,292)	
CVS Health Corp.	Call	7/28/17	USD	78.00	218	(66,272)	
D.R. Horton, Inc.	Call	7/28/17	USD	34.50	280	(27,440)	
Delta Air Lines, Inc.	Call	7/28/17	USD	52.00	128	(33,856)	
Dow Chemical Co.	Call	7/28/17	USD	65.00	300	(18,750)	
Flex Ltd.	Call	7/28/17	USD	17.00	105	(2,572)	
Goodyear Tire & Rubber Co.	Call	7/28/17	USD	34.00	365	(62,963)	
Hartford Financial Services Group, Inc.	Call	7/28/17	USD	53.00	400	(38,600)	
Home Depot, Inc.	Call	7/28/17	USD	157.50	172	(15,910)	
JPMorgan Chase & Co.	Call	7/28/17	USD	89.00	292	(89,498)	
JPMorgan Chase & Co.	Call	7/28/17	USD	91.50	385	(60,830)	
Marathon Oil Corp.	Call	7/28/17	USD	13.00	130	(1,820)	
Merck & Co., Inc.	Call	7/28/17	USD	66.50	34	(1,547)	
Microsoft Corp.	Call	7/28/17	USD	70.00	345	(43,815)	
Microsoft Corp.	Call	7/28/17	USD	70.50	700	(74,200)	
Norfolk Southern Corp.	Call	7/28/17	USD	120.00	50	(21,750)	
Pfizer, Inc.	Call	7/28/17	USD	32.50	411	(52,814)	
Pfizer, Inc.	Call	7/28/17	USD	34.50	146	(2,044)	
Suncor Energy, Inc.	Call	7/28/17	USD	30.50	1,297	(36,316)	
Suncor Energy, Inc.	Call	1120/11	USD	30.30	1,297	(30,310)	

U.S. Bancorp	Call	7/28/17	USD	52.00	56	(5,936)
UnitedHealth Group, Inc.	Call	7/28/17	USD	182.50	170	(96,475)
UnitedHealth Group, Inc.	Call	7/28/17	USD	185.00	49	(20,703)
Urban Outfitters, Inc.	Call	7/28/17	USD	19.00	262	(13,755)

See Notes to Financial Statements.

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

Exchange-Traded Options Written (continued)

Exchange-Traded Options Written (continued)	.		~			
Description	Put/	Expiration		trike	G	¥7.1
Description	Call	Date		Price	Contracts	Value \$ (5.800)
Valero Energy Corp.	Call	7/28/17	USD	65.50	20	(-,)
Wal-Mart Stores, Inc.	Call Call	7/28/17	USD USD	77.00 32.25	248 503	(16,244) (11,701)
Cisco Systems, Inc. Pfizer, Inc.	Call	7/31/17 7/31/17	USD	34.25	144	(2,431)
SunTrust Bank, Inc.	Call	7/31/17	USD	57.50	132	(19,141)
Public Service Enterprise Group, Inc.	Call	8/01/17	USD	44.40	132	(3,415)
Activision Blizzard, Inc.	Call	8/04/17	USD	59.00	235	(39,363)
Alphabet, Inc., Class A	Call	8/04/17	USD	965.00	14	(24,710)
Anadarko Petroleum Corp.	Call	8/04/17	USD	47.50	23	(2,104)
Apple, Inc.	Call	8/04/17	USD	150.00	219	(43,910)
Biogen, Inc.	Call	8/04/17	USD	280.00	98	(56,840)
BP PLC ADR	Call	8/04/17	USD	35.00	174	(11,310)
Carnival Corp.	Call	8/04/17	USD	66.50	358	(41,170)
Chevron Corp.	Call	8/04/17	USD	107.00	122	(13,359)
Cisco Systems, Inc.	Call	8/04/17	USD	32.00	252	(6,804)
Citigroup, Inc.	Call	8/04/17	USD	65.50	34	(8,347)
CVS Health Corp.	Call	8/04/17	USD	82.50	218	(16,677)
D.R. Horton, Inc.	Call	8/04/17	USD	34.50	316	(35,866)
Dow Chemical Co.	Call	8/04/17	USD	64.50	10	(845)
Flex Ltd.	Call	8/04/17	USD	17.00	104	(3,120)
Gilead Sciences, Inc.	Call	8/04/17	USD	72.50	544	(81,056)
Home Depot, Inc.	Call	8/04/17	USD	155.00	166	(36,188)
Intel Corp.	Call	8/04/17	USD	35.00	247	(10,003)
JPMorgan Chase & Co.	Call	8/04/17	USD	92.50	385	(48,895)
Lowe s Cos., Inc.	Call	8/04/17	USD	79.50	215	(20,210)
Marathon Oil Corp.	Call	8/04/17	USD	12.00	164	(8,938)
Merck & Co., Inc.	Call	8/04/17	USD	65.00	34	(3,536)
Microsoft Corp.	Call	8/04/17	USD	70.50	212	(25,758)
Norfolk Southern Corp.	Call	8/04/17	USD	119.00	111	(57,720)
Suncor Energy, Inc.	Call	8/04/17	USD	29.50 18.00	123 310	(9,102)
Urban Outfitters, Inc. Valero Energy Corp.	Call Call	8/04/17 8/04/17	USD USD	68.50	26	(34,875) (3,601)
Wal-Mart Stores, Inc.	Call	8/04/17	USD	77.00	155	(12,865)
Comcast Corp., Class A	Call	8/09/17	USD	39.90	131	(9,043)
Anadarko Petroleum Corp.	Call	8/11/17	USD	46.50	66	(9,438)
Apple, Inc.	Call	8/11/17	USD	146.00	373	(151,811)
Bank of America Corp.	Call	8/11/17	USD	25.00	1,175	(55,813)
Carnival Corp.	Call	8/11/17	USD	66.00	510	(79,050)
Cisco Systems, Inc.	Call	8/11/17	USD	32.00	251	(8,534)
Citigroup, Inc.	Call	8/11/17	USD	68.00	35	(4,025)
Cognizant Technology Solutions Corp., Class A	Call	8/11/17	USD	66.50	440	(94,600)
Dow Chemical Co.	Call	8/11/17	USD	64.50	151	(14,194)
JPMorgan Chase & Co.	Call	8/11/17	USD	91.50	186	(35,898)
Lowe s Cos., Inc.	Call	8/11/17	USD	77.50	298	(58,408)
Microsoft Corp.	Call	8/11/17	USD	70.41	140	(19,175)
Urban Outfitters, Inc.	Call	8/11/17	USD	19.50	280	(14,560)
Activision Blizzard, Inc.	Call	8/18/17	USD	60.00	270	(46,305)
Aetna, Inc.	Call	8/18/17	USD	155.00	43	(12,449)
Alphabet, Inc., Class A	Call	8/18/17	USD	1,000.00	28	(28,700)
Anadarko Petroleum Corp.	Call	8/18/17	USD	50.00	11	(610)
Anthem, Inc.	Call	8/18/17	USD	200.00	37	(5,920)
Apple, Inc.	Call	8/18/17	USD	150.00	333	(81,086)
Bank of America Corp.	Call	8/18/17	USD	24.00	507	(50,954)
BP PLC ADR	Call Call	8/18/17	USD	36.00	180	(6,030)
Centene Corp.		8/18/17	USD	80.00 65.00	461 5	(172,875)
Citigroup, Inc. Cognizant Technology Solutions Corp.	Call Call	8/18/17 8/18/17	USD USD	65.00 67.91	311	(1,477) (49,623)
D.R. Horton, Inc.	Call	8/18/17	USD	34.00	140	(21,210)
D.R. Horton, Inc.	Call	8/18/17	USD	35.00	140	(13,160)
Delta Air Lines, Inc.	Call	8/18/17	USD	55.00	518	(68,894)
EMCOR Group, Inc.	Call	8/18/17	USD	65.00	78	(20,280)
	Juii	3/10/1/	200	33.30	70	(20,200)

FirstEnergy Corp.	Call	8/18/17	USD	30.00	310	(10,850)
Flex Ltd.	Call	8/18/17	USD	17.00	105	(3,622)
Goodyear Tire & Rubber Co.	Call	8/18/17	USD	35.00	262	(35,370)
Humana, Inc.	Call	8/18/17	USD	240.00	50	(42,250)

See Notes to Financial Statements.

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

Exchange-Traded Options Written (continued)

Exchange-11 aueu Options Written (continueu)	Put/	Expiration	St.	rike			
Description	Call	Date		rice	Contracts	Value	
Intel Corp.	Call	8/18/17	USD	36.30	364	\$ (7,649)	
JPMorgan Chase & Co.	Call	8/18/17	USD	90.00	244	(70,272)	
Lear Corp.	Call	8/18/17	USD	145.00	63	(24,570)	
Lowe s Cos., Inc.	Call	8/18/17	USD	82.50	305	(15,555)	
Marathon Oil Corp.	Call	8/18/17	USD	13.00	127	(3,683)	
McKesson Corp.	Call	8/18/17	USD	165.00	92	(50,140)	
Merck & Co., Inc.	Call	8/18/17	USD	65.00	147	(18,743)	
Microsoft Corp.	Call	8/18/17	USD	72.50	311	(23,636)	
Regions Financial Corp.	Call	8/18/17	USD	14.60	456	(30,006)	
Rio Tinto PLC ADR	Call	8/18/17	USD	42.50	430 170	. , ,	
						(24,990)	
SLM Corp.	Call	8/18/17	USD	11.00	500	(42,750)	
SLM Corp.	Call	8/18/17	USD	12.00	250	(8,250)	
Southwest Airlines Co.	Call	8/18/17	USD	62.10	74	(18,796)	
Suncor Energy, Inc.	Call	8/18/17	USD	31.00	78	(2,730)	
SunTrust Bank, Inc.	Call	8/18/17	USD	56.82	131	(23,187)	
TOTAL SA ADR	Call	8/18/17	USD	51.25	454	(29,943)	
Urban Outfitters, Inc.	Call	8/18/17	USD	20.00	281	(18,265)	
WABCO Holdings, Inc	Call	8/18/17	USD	130.00	55	(17,710)	
Citigroup, Inc.	Call	8/25/17	USD	63.95	113	(44,840)	
Comcast Corp., Class A	Call	8/30/17	USD	41.22	497	(26,804)	
Pfizer, Inc.	Call	9/01/17	USD	34.17	325	(13,820)	
Altria Group, Inc.	Call	9/15/17	USD	76.42	345	(36,129)	
Citigroup, Inc.	Call	9/15/17	USD	67.50	25	(4,925)	
Comcast Corp., Class A	Call	9/15/17	USD	41.25	522	(31,581)	
Oracle Corp.	Call	9/15/17	USD	51.30	418	(44,387)	
Pfizer, Inc.	Call	9/15/17	USD	34.00	814	(46,398)	
Total	Cuii	,, -0, 1,	2.52	2	01.	\$ (6,800,610)	
						+ (=,=00,010)	

OTC Options Written

•	Put/		Expiration	St	rike		
Description	Call	Counterparty	Date	Pı	rice	Contracts	Value
Baxter International, Inc.	Call	Bank of America N.A.	07/06/17	USD	56.46	14,200	\$ (59,558)
Lear Corp.	Call	Goldman Sachs International	07/06/17	USD	146.63	11,700	(2,781)
SunTrust Bank, Inc.	Call	Goldman Sachs International	07/06/17	USD	57.22	41,500	(22,875)
CDW Corp.	Call	Société Générale	07/07/17	USD	59.65	19,400	(58,510)
Packaging Corp. of America	Call	Deutsche Bank AG	07/07/17	USD	99.50	6,200	(73,871)
Regions Financial Corp.	Call	UBS AG	07/07/17	USD	14.42	25,100	(9,672)
Amdocs Ltd.	Call	JPMorgan Chase Bank N.A.	07/10/17	USD	63.50	25,000	(32,360)
Laboratory Corp. of America Holdings	Call	Deutsche Bank AG	07/11/17	USD	139.81	11,000	(158,898)
Public Service Enterprise Group, Inc.	Call	Morgan Stanley & Co. International PLC	07/11/17	USD	43.54	31,000	(7,098)
Humana, Inc.	Call	Barclays Bank PLC	07/12/17	USD	228.00	11,300	(148,616)
Rio Tinto PLC ADR	Call	Barclays Bank PLC	07/13/17	USD	41.68	10,200	(12,473)
Robert Half International, Inc.	Call	Barclays Bank PLC	07/13/17	USD	47.77	40,000	(51,318)
Regions Financial Corp.	Call	Citibank N.A.	07/14/17	USD	14.43	42,300	(20,409)
SLM Corp.	Call	Morgan Stanley & Co. International PLC	07/14/17	USD	10.87	87,000	(62,089)
SunTrust Bank, Inc.	Call	Barclays Bank PLC	07/14/17	USD	56.55	20,800	(26,695)
WABCO Holdings, Inc	Call	Bank of America N.A.	07/14/17	USD	123.00	5,600	(32,822)
Robert Half International, Inc.	Call	Barclays Bank PLC	07/25/17	USD	48.38	15,500	(22,856)
Statoil ASA ADR	Call	JPMorgan Chase Bank N.A.	07/26/17	USD	17.29	31,900	(4,926)
BP PLC ADR	Call	UBS AG	07/31/17	USD	35.85	10,900	(1,670)
BP PLC ADR	Call	UBS AG	07/31/17	USD	36.53	8,800	(980)
Pfizer, Inc.	Call	Citibank N.A.	07/31/17	USD	33.32	41,200	(28,086)
Packaging Corp. of America	Call	Bank of America N.A.	08/02/17	USD	100.00	20,000	(239,709)
Regions Financial Corp.	Call	Barclays Bank PLC	08/02/17	USD	14.09	42,200	(36,607)
Flex Ltd.	Call	Citibank N.A.	08/10/17	USD	17.26	47,500	(12,712)
SLM Corp.	Call	Citibank N.A.	08/10/17	USD	10.80	62,900	(64,637)
Rio Tinto PLC ADR	Call	UBS AG	08/11/17	USD	41.83	17,300	(18,238)
Total							\$ (1,210,466)

See Notes to Financial Statements.

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

Transactions in Options Written for the Period Ended June 30, 2017

	Calls		
		Premiums	
	Contracts	Received	
Outstanding options, beginning of period	1,129,789	\$ 8,212,203	
Options written	3,109,166	31,004,653	
Options exercised	(10,682)	(5,957,395)	
Options expired	(1,069,231)	(76,895)	
Options closed	(2,403,303)	(25,705,810)	
Outstanding options, end of period	755,739	\$ 7,476,756	

As of period end, the value of portfolio securities subject to covered call options written was \$380,711,463.

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

		Commodity Codit	Equity	Foreign Currency Interest	Othon	
		Commodity Credit	Equity	Exchange Rate	Other	
Liabilities Derivative Financia	l Instruments	Contracts Contracts	Contracts	Contracts Contracts	Contracts	Total
Options written	Options written, at					
	value		\$ 8.011.076			\$ 8.011.076

Foreign

For the six months ended June 30, 2017, the effect of derivative financial instruments in the Statements of Operations was as follows:

Net Realized Gain (Loss) from: Futures contracts Options purchased ¹ Options written	Commodity Contracts	Credit Contracts	Equity Contracts \$ 529,712 (84) (11,633,153)	Currency Exchange Contracts	Interest Rate Contracts	Other Contracts	Total \$ 529,712 (84) (11,633,153)
Total			\$ (11,103,525)				\$ (11,103,525)
1 Options purchased are included in n	et realized gain (le	oss) from inve	estments.				
Net Change in Unrealized Appreciati	ion on:						
Futures contracts			\$ 128,627				\$ 128,627
Options written			1,555,959				1,555,959
Total			\$ 1,684,586				\$ 1,684,586

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Futures contracts:

Average notional value of contracts long \$6,193,031

Options:

Average market value of option contracts purchased \$681

Average value of option contracts written \$7,150,396

For more information about the Trust s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments Offsetting as of Period End

The Trust s derivative assets and liabilities (by type) are as follows:

Desirables Eigenstal Ladamanda	Assets	Liabilities
Derivative Financial Instruments: Options		\$ 8,011,076
Derivatives not subject to a Master Netting Agreement or similar agreement (MNA)		(6,800,610)
Total derivative assets and liabilities subject to an MNA		\$ 1,210,466

See Notes to Financial Statements.

¹ Actual amounts for the period are shown due to limited outstanding derivative financial instruments as of each quarter end.

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

The following table presents the Trust s derivative liabilities by counterparty net of amounts available for offset under a Master Netting Agreement (MNA) and net of the related collateral received by the Trust:

Counterparty	Derivative Liabilities Subject to an MNA by Counterparty		Derivatives Available for Offset	Non-cash Collateral Pledged ¹	Collateral Collateral		Amount of erivative abilities ²
Bank of America N.A.	\$	332,089				\$	332,089
Barclays Bank PLC		298,565			\$ (5,000)		293,565
Citibank N.A.		125,844		\$ (119,537)			6,307
Deutsche Bank AG		232,769			(70,000)		162,769
Goldman Sachs International		25,656					25,656
JPMorgan Chase Bank N.A.		37,286					37,286
Morgan Stanley & Co. International PLC		69,187		(69,187)			
Société Générale		58,510					58,510
UBS AG		30,560		(30,560)			
Total	\$	1,210,466		\$ (219,284)	\$ (75,000)	\$	916,182

¹ Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivatives financial instruments. For information about the Trust spolicy regarding valuation of investments and derivatives financial instruments refer to the Notes to Financial Statements.

The following tables summarize the Trust s investments and derivative financial instruments categorized in the disclosure hierarchy:

	Level 1	Level 2	Level 3	Total	
Assets:					
Investments:					
Long-Term Investments:					
Common Stocks ¹	\$ 709,485,627			\$ 709,485,627	
Short-Term Securities	815,956			815,956	
Total	\$ 710,301,583			\$ 710,301,583	
Derivative Financial Instruments ²					
Liabilities:					
Equity contracts	\$ (6,014,152)	\$ (1,996,924)		\$ (8,011,076)	
¹ See above Schedule of Investments for values in each industry.					

During the six months ended June 30, 2017, there were no transfers between levels.

See Notes to Financial Statements.

Net amount represents the net amount payable due to the counterparty in the event of default. Net Amount may be offset further by net options written receivable/payable on the Statements of Assets and Liabilities.

² Derivative financial instruments are options written, which are shown at value.

Schedule of Investments June 30, 2017 (Unaudited)

BlackRock Enhanced Equity Dividend Trust (BDJ)

(Percentages shown are based on Net Assets)

Common Stocks	Shares		Value
Aerospace & Defense 2.9% Lockheed Martin Corp. (a)	81,930	\$	22,744,587
Northrop Grumman Corp. (a)	108,800	φ	27,930,048
			50,674,635
Air Freight & Logistics 0.7% United Parcel Service, Inc., Class B (a)	109,170		12,073,110
Banks 18.0%	105,170		12,073,110
Bank of America Corp. (a)(b)	2,802,680		67,993,017
Citigroup, Inc. (a)	1,047,020		70,024,698
JPMorgan Chase & Co. (a)(b)	838,228		76,614,039
KeyCorp (a)	585,860		10,979,016
SunTrust Banks, Inc. (a)	337,240		19,128,253
U.S. Bancorp (a)	532,143		27,628,865
Wells Fargo & Co. (a)	869,791		48,195,119
			320,563,007
Beverages 1.7%			
Coca-Cola Co. (a)	283,760		12,726,636
Diageo PLC ADR	613,300		18,124,084
			30,850,720
Capital Markets 3.6%			
Goldman Sachs Group, Inc. (a)	107,120		23,769,928
Invesco Ltd. (a)	251,864		8,863,094
Morgan Stanley & Co. LLC (a)	718,670		32,023,935
			64,656,957
Chemicals 3.2%			
Dow Chemical Co. (a)	817,000		51,528,190
Praxair, Inc. (a)	41,900		5,553,845
			57,082,035
Communications Equipment 0.8%			
Motorola Solutions, Inc. (a)	171,600		14,884,584
Diversified Telecommunication Services 1.5%			
BCE, Inc. (a)	103,700		4,670,648
Verizon Communications, Inc. (a)	503,600		22,490,776
			27,161,424
Electric Utilities 3.0%	***		
Exelon Corp. (a)	300,100		10,824,607
FirstEnergy Corp. (a)	464,075		13,532,427
NextEra Energy, Inc. (a)	211,150		29,588,449
			53,945,483
Energy Equipment & Services 0.4%			
Halliburton Co. (a)	164,300		7,017,253
Food & Staples Retailing 0.8%	505 000		12 000 407
Kroger Co. (a) Food Products 0.30/	595,990		13,898,487
Food Products 0.3% Mondelez International, Inc., Class A (a)	132,225		5,710,798
Health Care Equipment & Supplies 1.0%	132,223		3,710,798
Becton Dickinson & Co. (a)	66,700		13,013,837
Smith & Nephew PLC	304,550		5,259,117
Similar Copiler LDC	304,550		5,257,117
			18,272,954
Health Care Providers & Services 7.5%			

0 0	' '	
Aetna, Inc. (a)	249,056	37,814,173
Anthem, Inc. (a)	221,710	41,710,302
Cardinal Health, Inc. (a)	49,060	3,822,755
McKesson Corp. (a)	95,880	15,776,095
Quest Diagnostics, Inc. (a)	128,330	14,265,163
UnitedHealth Group, Inc. (a)	104,500	19,376,390
		122.764.070
Hotels, Restaurants & Leisure 0.0%		132,764,878
Hilton Worldwide Holdings, Inc.	10,241	633,406
Common Stocks	Shares	Value
Household Products 1.0%		
Procter & Gamble Co. (a)	209,320	\$ 18,242,238
Industrial Conglomerates 6.0%		
3M Co. (a)	63,200	13,157,608
General Electric Co. (a)	1,498,000	40,460,980
Honeywell International, Inc. (a)	189,600	25,271,784
Koninklijke Philips NV	769,060	27,377,517
		106,267,889
Insurance 6.7%		
Allstate Corp. (a)	96,000	8,490,240
American International Group, Inc. (a)	571,320	35,718,926
Marsh & McLennan Cos., Inc. (a)	171,547	13,373,804
MetLife, Inc. (a)	478,500	26,288,790
Prudential Financial, Inc. (a)	217,900	23,563,706
Travelers Cos., Inc. (a)	95,700	12,108,921
		119,544,387
Machinery 0.3% Pentair PLC (a)	72,400	4,817,496
Media 2.5%	,	.,,,
Comcast Corp., Class A (a)	762,770	29,687,009
Publicis Groupe SA	188,010	14,012,949
		12 (00 050
NATIONAL AND		43,699,958
Multi-Utilities 2.3%	157 100	12.020.552
Dominion Resources, Inc. (a)	157,100	12,038,573
PG&E Corp. (a)	199,400	13,234,178
Public Service Enterprise Group, Inc. (a)	378,600	16,283,586
M kg D 4 3 A O		41,556,337
Multiline Retail 0.8%	202.847	14 (22 240
Dollar General Corp. (a) Oil, Gas & Consumable Fuels 10.7%	202,847	14,623,240
Anadarko Petroleum Corp. (a)	81,600	3,699,744
Chevron Corp. (a)	241,100	25,153,963
Enbridge, Inc. (a)	189,699	7,551,917
Exxon Mobil Corp. (a)	187,400	15,128,802
Hess Corp. (a)	411,110	18,035,396
Marathon Oil Corp. (a)	682,660	8,089,521
Marathon Petroleum Corp. (a)	279,400	14,621,002
Occidental Petroleum Corp. (a)	453,500	27,151,045
Royal Dutch Shell PLC ADR, Class A (a)	299,330	15,921,363
Suncor Energy, Inc. (a)	961,240	28,068,208
TOTAL SA ADR (a)	526,600	26,114,094
Paper & Forest Products 0.6%		189,535,055
International Paper Co. (a)	177,700	10,059,597
Personal Products 1.3% Unilever NV NV Shares (a)	426,000	22 504 762
Unilever NV NY Shares (a) Pharmaceuticals 8.1%	426,900	23,594,763
AstraZeneca PLC	482,236	32,301,864
Johnson & Johnson (a)	84,600	11,191,734
Merck & Co., Inc. (a)	607,500	38,934,675
Pfizer, Inc. (a)(b)	1,856,990	62,376,294
	,	- ,- · -, ·

D 0 1 10 1 446		144,804,567
Professional Services 1.4% Experian PLC Nielsen Holdings PLC (a)	723,400 260,150	14,846,218 10,057,399
D. LT. (A. A. C.		24,903,617
Real Estate Investment Trusts (REITs) 0.4% Weyerhaeuser Co. (a) Road & Rail 0.6%	220,200	7,376,700
Union Pacific Corp. (a)	96,000	10,455,360

See Notes to Financial Statements.

38 SEMI-ANNUAL REPORT JUNE 30, 2017

BlackRock Enhanced Equity Dividend Trust (BDJ)

Common Stocks	Shares		Value
Semiconductors & Semiconductor Equipment 4.0% QUALCOMM, Inc. (a)	189,300	\$	10,453,146
Samsung Electronics Co. Ltd. GDR (c)	32,600	Ψ	33,798,562
Taiwan Semiconductor Manufacturing Co. Ltd. ADR (a)	740,700		25,894,872
Software 5.4%			70,146,580
Constellation Software, Inc.	7,300		3,818,933
Microsoft Corp. (a)	522,330		36,004,207
Oracle Corp. (a)	1,111,700		55,740,638
Specialty Retail 1.3%			95,563,778
Gap, Inc. (a)	323,200		7,107,168
Home Depot, Inc. (a)	106,400		16,321,760
Tashnalagu Handurana Stanaga & Davinhanala (0.5%)			23,428,928
Technology Hardware, Storage & Peripherals 0.5% Lenovo Group Ltd. Tobacco 0.9%	13,220,000		8,343,562
Altria Group, Inc. (a)	105,290		7,840,946
Philip Morris International, Inc. (a)	69,800		8,198,010
Common Stocks	Shares		16,038,956 Value
Wireless Telecommunication Services 0.6% SK Telecom Co. Ltd. ADR (a)	400,700	\$	10,285,969
Total Long-Term Investments	, , , , ,		
(Cost \$1,356,693,370) 100.8%			1,793,478,708
Short-Term Securities BlackRock Liquidity Funds, T-Fund, Institutional Class, 0.84% (d)(e)	1,218,990		1,218,990
Total Short-Term Securities (Cost \$1,218,990) 0.1%			1,218,990
Total Investments Before Options Written (Cost \$1,357,912,360) 100.9%			1,794,697,698
Options Written (Premiums Received \$17,058,110) (1.1)%			(18,689,806)
Total Investments, Net of Options Written (Cost \$1,340,854,250) 99.8%			1,776,007,892
Other Assets Less Liabilities 0.2%			2,974,279
Net Assets 100.0%		\$	1,778,982,171

Notes to Schedule of Investments

- (a) All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.
- (b) All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

- (c) Non-income producing security.
- (d) Current yield as of period end.
- (e) During the period ended June 30, 2017, investments in issuers considered to be an affiliate of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

							Change
	Shares		Shares				in
	Held at		Held at	Value at			Unrealized
	December 31,	Net	June 30,	June 30,		Net Realized	Appreciation
Affiliate	2016	Activity	2017	2017	Income	Gain	(Depreciation)
BlackRock Liquidity Funds, T-Fund,							
Institutional Class	3,630,472	(2,411,482)	1,218,990	\$ 1,218,990	\$ 22,544		
SL Liquidity Series, LLC, Money							
Market Series					$1,508^{1}$		
Total				\$ 1,218,990	\$ 24,052		

Represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

For Trust compliance purposes, the Trust s industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

Put/	Expiration	St	rike		
Call	Date	P	rice	Contracts	Value
Call	7/06/17	USD	87.50	292	\$ (101,266)
Call	7/06/17	USD	15.50	188	
Call	7/07/17	USD	182.50	383	(219,268)
Call	7/07/17	USD	24.00	1,217	(51,723)
Call	7/07/17	USD	24.25	949	(31,464)
Call	7/07/17	USD	107.00	309	(1,390)
Call	7/07/17	USD	61.00	499	(303,143)
	Call Call Call Call Call Call Call Call	Call Date Call 7/06/17 Call 7/06/17 Call 7/07/17 Call 7/07/17 Call 7/07/17 Call 7/07/17 Call 7/07/17	Call Date P Call 7/06/17 USD Call 7/06/17 USD Call 7/07/17 USD	Call Date Price Call 7/06/17 USD 87.50 Call 7/06/17 USD 15.50 Call 7/07/17 USD 182.50 Call 7/07/17 USD 24.00 Call 7/07/17 USD 24.25 Call 7/07/17 USD 107.00	Call Date Price Contracts Call 7/06/17 USD 87.50 292 Call 7/06/17 USD 15.50 188 Call 7/07/17 USD 182.50 383 Call 7/07/17 USD 24.00 1,217 Call 7/07/17 USD 24.25 949 Call 7/07/17 USD 107.00 309

See Notes to Financial Statements.

SEMI-ANNUAL REPORT JUNE 30, 2017 39

Ermination

Ctuiles

BlackRock Enhanced Equity Dividend Trust (BDJ)

Exchange-Traded Options Written (continued)

Exchange-Traded Options Written (continued)	75.44	- · ·	α.			
December 1997	Put/	Expiration		rike	G	X7.1
Description Citizens Inc.	Call	Date		rice	Contracts	Value
Citigroup, Inc.	Call	7/07/17	USD	61.50 38.98	331 463	\$ (180,395)
Enbridge, Inc. Exxon Mobil Corp.	Call Call	7/07/17 7/07/17	USD USD	82.00	116	(48,351) (1,160)
General Electric Co.	Call	7/07/17	USD	28.50	114	(228)
General Electric Co.	Call	7/07/17	USD	29.00	1,704	(1,704)
Goldman Sachs Group, Inc.	Call	7/07/17	USD	225.00	279	(20,785)
KeyCorp	Call	7/07/17	USD	18.50	360	(13,680)
Lockheed Martin Corp.	Call	7/07/17	USD	282.50	96	(2,640)
Marathon Oil Corp.	Call	7/07/17	USD	14.00	608	(1,216)
Marathon Petroleum Corp.	Call	7/07/17	USD	53.00	566	(23,780)
Merck & Co., Inc.	Call	7/07/17	USD	64.50	457	(13,938)
MetLife, Inc.	Call	7/07/17	USD	52.00	513	(155,952)
Mondelez International, Inc., Class A	Call	7/07/17	USD	47.00	153	(1,377)
Morgan Stanley & Co. LLC	Call	7/07/17	USD	43.00	518	(85,988)
Northrop Grumman Corp.	Call	7/07/17	USD	257.50	181	(21,267)
Occidental Petroleum Corp.	Call	7/07/17	USD	61.50	120	(1,140)
Royal Dutch Shell PLC ADR, Class A	Call	7/07/17	USD	55.95	587	(274)
Suncor Energy, Inc.	Call	7/07/17	USD	31.50	253	(8,855)
U.S. Bancorp	Call	7/07/17	USD	53.00	355	(2,485)
Union Pacific Corp.	Call	7/07/17	USD	110.00	123	(4,858)
Union Pacific Corp.	Call	7/07/17	USD	111.00	124	(2,108)
UnitedHealth Group, Inc.	Call	7/07/17	USD	177.50	94	(75,905)
Verizon Communications, Inc.	Call	7/07/17	USD	45.50	122	(244)
Wells Fargo & Co.	Call	7/07/17	USD	53.50	1,453	(293,506)
Wells Fargo & Co.	Call	7/07/17	USD	55.00	449	(34,573)
Weyerhaeuser Co.	Call	7/07/17	USD	33.50	403	(12,090)
Becton Dickinson & Co.	Call	7/10/17	USD	187.00	239	(203,947)
Bank of America Corp.	Call	7/11/17	USD	24.25	476	(19,759)
Exelon Corp.	Call	7/12/17	USD	36.51	499	(11,165)
Chevron Corp.	Call	7/13/17	USD	107.50	308	(5,822)
Altria Group, Inc.	Call	7/14/17	USD	76.00	275	(4,675)
American International Group, Inc.	Call	7/14/17	USD	64.00	463	(7,871)
Anadarko Petroleum Corp.	Call	7/14/17	USD	52.50	99	(396)
Bank of America Corp.	Call	7/14/17	USD	23.00	667	(91,379)
Bank of America Corp.	Call Call	7/14/17	USD	23.50	1,282 743	(117,944)
Dow Chemical Co. Exxon Mobil Corp.	Call	7/14/17 7/14/17	USD USD	65.50 81.00	263	(7,058) (17,095)
General Electric Co.	Call	7/14/17	USD	28.00	1,030	(4,120)
General Electric Co.	Call	7/14/17	USD	28.50	82	(123)
Goldman Sachs Group, Inc.	Call	7/14/17	USD	220.00	94	(42,065)
Merck & Co., Inc.	Call	7/14/17	USD	64.50	855	(45,743)
Mondelez International, Inc., Class A	Call	7/14/17	USD	46.50	157	(706)
Morgan Stanley & Co. LLC	Call	7/14/17	USD	45.50	291	(9,748)
Pfizer, Inc.	Call	7/14/17	USD	33.00	1,190	(87,465)
Philip Morris International, Inc.	Call	7/14/17	USD	123.00	174	(1,566)
Suncor Energy, Inc.	Call	7/14/17	USD	32.00	253	(4,807)
Union Pacific Corp.	Call	7/14/17	USD	111.00	233	(11,650)
United Parcel Service, Class B	Call	7/14/17	USD	109.00	190	(41,895)
UnitedHealth Group, Inc.	Call	7/14/17	USD	182.50	144	(59,400)
Verizon Communications, Inc.	Call	7/14/17	USD	47.00	427	(640)
Wells Fargo & Co.	Call	7/14/17	USD	52.00	1,361	(500,168)
Weyerhaeuser Co.	Call	7/14/17	USD	34.00	53	(1,192)
Marsh & McLennan Cos., Inc.	Call	7/20/17	USD	78.50	394	(38,516)
Pentair PLC	Call	7/20/17	USD	67.00	294	(27,051)
3M Co.	Call	7/21/17	USD	200.00	60	(54,300)
3M Co.	Call	7/21/17	USD	206.40	193	(86,561)
Aetna, Inc.	Call	7/21/17	USD	140.00	340	(400,350)
Allstate Corp.	Call	7/21/17	USD	86.10	480	(145,302)
American International Group, Inc.	Call	7/21/17	USD	62.50	214	(18,511)
Anthem, Inc.	Call	7/21/17	USD	190.00	263	(61,805)
Bank of America Corp.	Call	7/21/17	USD	23.00	335	(48,073)

Bank of America Corp.	Call	7/21/17	USD	25.00	475	(13,062)
Chevron Corp.	Call	7/21/17	USD	110.00	335	(3,350)
Citigroup, Inc.	Call	7/21/17	USD	62.50	1,122	(527,340)
Comcast Corp., Class A	Call	7/21/17	USD	38.75	863	(73,355)

See Notes to Financial Statements.

40 SEMI-ANNUAL REPORT JUNE 30, 2017

BlackRock Enhanced Equity Dividend Trust (BDJ)

Exchange-Traded Options Written (continued)

Exchange-Traded Options Written (continued)			~			
Don't de	Put/	Expiration		rike ·	G	X 7.1
Description Description	Call	Date		rice	Contracts	Value
Dominion Resources, Inc. Dow Chemical Co.	Call	7/21/17	USD	80.00	1,211 317	\$ (12,110)
Enbridge, Inc.	Call Call	7/21/17 7/21/17	USD USD	64.00 40.00	485	(18,386) (29,100)
Existence Exelon Corp.	Call	7/21/17	USD	37.00	187	(2,805)
Exeron Corp. Exxon Mobil Corp.	Call	7/21/17	USD	80.00	243	(35,842)
Exxon Mobil Corp.	Call	7/21/17	USD	85.00	208	(1,144)
FirstEnergy Corp.	Call	7/21/17	USD	29.00	550	(28,875)
FirstEnergy Corp.	Call	7/21/17	USD	30.00	1,021	(15,315)
Gap, Inc.	Call	7/21/17	USD	24.00	880	(4,840)
Hess Corp.	Call	7/21/17	USD	52.50	459	(918)
Home Depot, Inc.	Call	7/21/17	USD	160.00	157	(3,768)
Honeywell International, Inc.	Call	7/21/17	USD	132.05	328	(98,012)
Invesco Ltd.	Call	7/21/17	USD	33.00	741	(179,693)
Invesco Ltd.	Call	7/21/17	USD	35.00	644	(48,300)
Johnson & Johnson	Call	7/21/17	USD	127.52	272	(150,970)
KeyCorp	Call	7/21/17	USD	18.00	255	(24,097)
Kroger Co.	Call	7/21/17	USD	24.00	740	(25,900)
Kroger Co.	Call	7/21/17	USD	31.00	109	(545)
Marathon Petroleum Corp.	Call	7/21/17	USD	52.50	311	(35,765)
McKesson Corp.	Call	7/21/17	USD	162.25	60	(25,238)
Merck & Co., Inc.	Call	7/21/17	USD	65.00	447	(27,267)
MetLife, Inc.	Call	7/21/17	USD	52.50	315	(86,625)
Microsoft Corp.	Call	7/21/17	USD	70.00	643	(71,373)
Mondelez International, Inc., Class A	Call	7/21/17	USD	46.00	175	(2,712)
Morgan Stanley & Co. LLC	Call	7/21/17	USD	43.00	498	(102,339)
Motorola Solutions, Inc.	Call	7/21/17	USD	85.00	429	(117,761)
NextEra Energy, Inc.	Call	7/21/17	USD	140.00	186	(37,200)
NextEra Energy, Inc.	Call	7/21/17	USD	145.00	243	(6,075)
Nielsen Holdings PLC	Call	7/21/17	USD	40.00	711	(24,885)
Northrop Grumman Corp.	Call	7/21/17	USD	256.30	179	(64,509)
Oracle Corp.	Call	7/21/17	USD	45.00	1,015	(527,800)
Oracle Corp.	Call	7/21/17	USD	46.00	262	(110,040)
Pfizer, Inc.	Call	7/21/17	USD	33.00	1,416	(112,572)
Pfizer, Inc.	Call	7/21/17	USD	34.00	814	(17,094)
PG&E Corp. Philip Magnic International Inc.	Call Call	7/21/17	USD	70.00	401	(4,010)
Philip Morris International, Inc. Praxair, Inc.	Call	7/21/17 7/21/17	USD USD	120.00 130.00	175 137	(16,187) (54,115)
Procter & Gamble Co.	Call	7/21/17	USD	87.50	578	(37,859)
Prudential Financial, Inc	Call	7/21/17	USD	110.00	1,255	(138,678)
Public Service Enterprise Group, Inc.	Call	7/21/17	USD	45.00	292	(2,190)
QUALCOMM, Inc.	Call	7/21/17	USD	60.00	300	(6,750)
Quest Diagnostics, Inc.	Call	7/21/17	USD	110.00	409	(74,643)
Royal Dutch Shell PLC ADR, Class A	Call	7/21/17	USD	55.95	587	(4,808)
SK Telecom Co. Ltd. ADR	Call	7/21/17	USD	25.00	923	(76,148)
Travelers Cos., Inc.	Call	7/21/17	USD	125.00	237	(66,360)
U.S. Bancorp	Call	7/21/17	USD	52.50	1,577	(103,294)
Unilever NV NY Shares	Call	7/21/17	USD	57.50	1,300	(32,500)
United Parcel Service, Class B	Call	7/21/17	USD	110.00	140	(25,690)
UnitedHealth Group, Inc.	Call	7/21/17	USD	185.00	142	(52,895)
Verizon Communications, Inc.	Call	7/21/17	USD	46.00	686	(6,517)
Wells Fargo & Co.	Call	7/21/17	USD	52.50	661	(211,520)
Weyerhaeuser Co.	Call	7/21/17	USD	34.00	520	(16,900)
Exxon Mobil Corp.	Call	7/25/17	USD	83.25	118	(2,825)
Exelon Corp.	Call	7/27/17	USD	37.01	312	(6,140)
Honeywell International, Inc.	Call	7/27/17	USD	135.12	310	(45,962)
SK Telecom Co. Ltd. ADR	Call	7/27/17	USD	25.01	556	(48,118)
American International Group, Inc.	Call	7/28/17	USD	64.00	638	(25,520)
Bank of America Corp.	Call	7/28/17	USD	24.00	1,278	(103,518)
Chevron Corp.	Call	7/28/17	USD	108.00	253	(15,053)
Citigroup, Inc.	Call	7/28/17	USD	65.00	337	(91,833)
Dow Chemical Co.	Call	7/28/17	USD	65.00	962	(60,125)

General Electric Co.	Call	7/28/17	USD	29.50	1,703	(5,109)
Halliburton Co.	Call	7/28/17	USD	44.00	821	(66,501)
Home Depot, Inc.	Call	7/28/17	USD	157.50	200	(18,500)
JPMorgan Chase & Co.	Call	7/28/17	USD	89.00	1,255	(384,658)

See Notes to Financial Statements.

SEMI-ANNUAL REPORT JUNE 30, 2017 41

BlackRock Enhanced Equity Dividend Trust (BDJ)

Exchange-Traded Options Written (continued)

Exchange-Traded Options Written (continued)			~			
Description	Put/	Expiration		rike	G	X 7.1
Description	Call	Date		rice	Contracts	Value
JPMorgan Chase & Co.	Call Call	7/28/17	USD	91.50 282.50	772 159	\$ (121,976)
Lockheed Martin Corp. Marathon Oil Corp.	Call	7/28/17 7/28/17	USD USD	13.00	563	(44,043) (7,882)
McKesson Corp.	Call	7/28/17	USD	167.50	62	(18,755)
Merck & Co., Inc.	Call	7/28/17	USD	66.50	414	(18,837)
MetLife, Inc.	Call	7/28/17	USD	52.50	648	(186,948)
Microsoft Corp.	Call	7/28/17	USD	70.00	245	(31,115)
Microsoft Corp.	Call	7/28/17	USD	70.50	496	(52,576)
Mondelez International, Inc., Class A	Call	7/28/17	USD	45.50	176	(5,984)
Morgan Stanley & Co. LLC	Call	7/28/17	USD	46.00	290	(16,095)
Pfizer, Inc.	Call	7/28/17	USD	32.50	339	(43,562)
Pfizer, Inc.	Call	7/28/17	USD	33.00	549	(47,763)
Pfizer, Inc.	Call	7/28/17	USD	33.50	607	(32,474)
Pfizer, Inc.	Call	7/28/17	USD	34.50	408	(5,712)
Procter & Gamble Co.	Call	7/28/17	USD	89.00	98	(2,793)
Public Service Enterprise Group, Inc.	Call	7/28/17	USD	45.01	856	(10,126)
QUALCOMM, Inc.	Call	7/28/17	USD	57.00	215	(22,145)
Suncor Energy, Inc.	Call	7/28/17	USD	30.50	1,293	(36,204)
U.S. Bancorp	Call	7/28/17	USD	52.00	168	(17,808)
United Parcel Service, Class B	Call	7/28/17	USD	112.00	251	(37,023)
UnitedHealth Group, Inc.	Call	7/28/17	USD	182.50	158	(89,665)
UnitedHealth Group, Inc.	Call	7/28/17	USD	185.00	141	(59,573)
Verizon Communications, Inc.	Call	7/28/17	USD	47.00	214	(1,926)
Wells Fargo & Co.	Call	7/28/17	USD	54.50	150	(26,400)
Pfizer, Inc.	Call	7/31/17	USD	34.25	406	(6,855)
PG&E Corp.	Call	7/31/17	USD	68.50	402	(18,190)
SunTrust Bank, Inc.	Call	7/31/17	USD	57.50	426	(61,774)
Taiwan Semiconductor Manufacturing Co. Ltd. ADR	Call	7/31/17	USD	36.00	1,151	(63,820)
Unilever NV NY Shares	Call	7/31/17	USD	56.50	405	(30,980)
Coca-Cola Co.	Call	8/01/17	USD	45.40	615	(26,760)
Public Service Enterprise Group, Inc.	Call	8/01/17	USD	44.40	305	(7,890)
Royal Dutch Shell PLC ADR, Class A	Call	8/01/17	USD	55.50	154	(3,448)
Royal Dutch Shell PLC ADR, Class A	Call	8/01/17	USD	53.25	168	(18,357)
Anadarko Petroleum Corp.	Call	8/04/17	USD	47.50	101	(9,241)
Bank of America Corp.	Call	8/04/17	USD	23.50	1,507	(181,594)
Cardinal Health, Inc.	Call	8/04/17	USD	80.50	122	(12,505)
Citigroup, Inc.	Call	8/04/17	USD	65.50	474	(116,367)
Dollar General Corp.	Call	8/04/17	USD	72.50	602	(118,895)
Dow Chemical Co.	Call	8/04/17	USD	64.50	945	(79,853)
Gap, Inc.	Call	8/04/17	USD	23.00	736	(25,024)
Hess Corp.	Call	8/04/17	USD	43.00	853	(207,279)
Home Depot, Inc.	Call Call	8/04/17	USD USD	155.00	334 277	(72,812)
Johnson & Johnson	Call	8/04/17 8/04/17	USD	134.00 92.50	771	(44,874)
JPMorgan Chase & Co. KeyCorp	Call	8/04/17	USD	18.50	1,916	(97,917) (138,910)
Lockheed Martin Corp.	Call	8/04/17	USD	282.50	1,910	(50,820)
Marathon Oil Corp.	Call	8/04/17	USD	12.00	1,400	(76,300)
Marathon Petroleum Corp.	Call	8/04/17	USD	51.50	1,400	(22,250)
Merck & Co., Inc.	Call	8/04/17	USD	65.00	408	(42,432)
Microsoft Corp.	Call	8/04/17	USD	70.50	478	(58,077)
Occidental Petroleum Corp.	Call	8/04/17	USD	62.50	344	(24,596)
Procter & Gamble Co.	Call	8/04/17	USD	90.00	271	(7,452)
QUALCOMM, Inc.	Call	8/04/17	USD	58.00	144	(12,240)
Suncor Energy, Inc.	Call	8/04/17	USD	29.50	830	(61,420)
Union Pacific Corp.	Call	8/04/17	USD	110.00	144	(35,352)
Verizon Communications, Inc.	Call	8/04/17	USD	45.00	855	(47,880)
Weyerhaeuser Co.	Call	8/04/17	USD	34.00	54	(2,970)
Aetna, Inc.	Call	8/08/17	USD	141.90	417	(406,856)
Exelon Corp.	Call	8/08/17	USD	37.01	313	(9,265)
Honeywell International, Inc.	Call	8/08/17	USD	135.12	310	(60,612)
Comcast Corp., Class A	Call	8/09/17	USD	39.90	1,550	(107,001)
. I. A					-,	(- · , ~ ~ -)

Taiwan Semiconductor Manufacturing Co. Ltd. ADR	Call	8/09/17	USD	35.78	1,045	(86,321)
American International Group, Inc.	Call	8/11/17	USD	63.00	684	(93,708)
Anadarko Petroleum Corp.	Call	8/11/17	USD	46.50	104	(14,872)
Bank of America Corp.	Call	8/11/17	USD	25.00	4,551	(216,173)

See Notes to Financial Statements.

42 SEMI-ANNUAL REPORT JUNE 30, 2017

BlackRock Enhanced Equity Dividend Trust (BDJ)

Exchange-Traded Options Written (continued)

	Put/	Expiration	St	rike		
Description	Call	Date	P	rice	Contracts	Value
Citigroup, Inc.	Call	8/11/17	USD	68.00	472	\$ (54,280)
Dollar General Corp.	Call	8/11/17	USD	72.50	12	(2,520)
Dow Chemical Co.	Call	8/11/17	USD	64.50	483	(45,402)
Goldman Sachs Group, Inc.	Call	8/11/17	USD	232.50	162	(41,958)
Hess Corp.	Call	8/11/17	USD	43.50	743	(173,862)
International Paper Co. JPMorgan Chase & Co.	Call Call	8/11/17 8/11/17	USD USD	56.00 91.50	267 286	(52,332) (55,198)
KeyCorp	Call	8/11/17	USD	19.00	175	(8,662)
MetLife, Inc.	Call	8/11/17	USD	56.00	404	(44,844)
Microsoft Corp.	Call	8/11/17	USD	70.41	371	(50,814)
United Parcel Service, Inc., Class B	Call	8/11/17	USD	111.00	128	(28,800)
Wells Fargo & Co.	Call	8/11/17	USD	56.00	274	(29,318)
Exxon Mobil Corp.	Call	8/14/17	USD	83.00	156	(8,498)
Coca-Cola Co.	Call	8/15/17	USD	45.40	615	(35,342)
Travelers Cos., Inc.	Call	8/15/17	USD	125.38	385	(136,283)
Praxair, Inc.	Call	8/16/17	USD	135.25	136	(29,834)
3M Co.	Call	8/18/17	USD	212.90	63	(14,656)
Aetna, Inc.	Call	8/18/17	USD	155.00	488	(141,276)
Anadarko Petroleum Corp.	Call	8/18/17	USD	50.00	104	(5,772)
Anthem, Inc.	Call	8/18/17	USD	200.00	129	(20,640)
Bank of America Corp.	Call	8/18/17	USD	24.00	1,276	(128,238)
BCE, Inc.	Call	8/18/17	USD	45.00	251	(21,962)
Cardinal Health, Inc.	Call Call	8/18/17	USD USD	82.50	122 229	(7,930)
Citigroup, Inc. Dollar General Corp.	Call	8/18/17 8/18/17	USD	65.00 75.00	400	(67,670) (53,000)
Dow Chemical Co.	Call	8/18/17	USD	65.00	473	(48,956)
Exelon Corp.	Call	8/18/17	USD	37.00	189	(8,505)
Exxon Mobil Corp.	Call	8/18/17	USD	85.00	136	(3,604)
FirstEnergy Corp.	Call	8/18/17	USD	29.00	448	(35,840)
FirstEnergy Corp.	Call	8/18/17	USD	30.00	154	(5,390)
General Electric Co.	Call	8/18/17	USD	28.40	2,395	(49,380)
International Paper Co.	Call	8/18/17	USD	56.15	888	(164,885)
JPMorgan Chase & Co.	Call	8/18/17	USD	90.00	815	(234,720)
Kroger Co.	Call	8/18/17	USD	24.00	696	(45,240)
Marathon Oil Corp.	Call	8/18/17	USD	13.00	326	(9,454)
Marathon Petroleum Corp.	Call	8/18/17	USD	53.55	420	(52,500)
Marsh & McLennan Cos., Inc.	Call	8/18/17	USD	79.80	240	(18,813)
McKesson Corp.	Call	8/18/17	USD	165.00	357	(194,565)
Merck & Co., Inc.	Call Call	8/18/17	USD	65.00	456 512	(58,140) (166,400)
MetLife, Inc. Microsoft Corp.	Call	8/18/17 8/18/17	USD USD	52.50 72.50	1,162	(88,312)
Morgan Stanley & Co. LLC	Call	8/18/17	USD	45.00	1,400	(175,000)
Nielsen Holdings PLC	Call	8/18/17	USD	40.00	589	(73,625)
Northrop Grumman Corp.	Call	8/18/17	USD	260.00	184	(85,560)
Occidental Petroleum Corp.	Call	8/18/17	USD	62.50	344	(32,508)
Oracle Corp.	Call	8/18/17	USD	50.00	2,405	(289,803)
Pentair PLC	Call	8/18/17	USD	70.00	68	(4,420)
Pfizer, Inc.	Call	8/18/17	USD	34.00	801	(35,244)
PG&E Corp.	Call	8/18/17	USD	70.00	194	(5,335)
Quest Diagnostics, Inc.	Call	8/18/17	USD	107.75	425	(211,198)
Suncor Energy, Inc.	Call	8/18/17	USD	31.00	765	(26,775)
SunTrust Bank, Inc.	Call	8/18/17	USD	56.82	425	(75,225)
Taiwan Semiconductor Manufacturing Co. Ltd. ADR	Call	8/18/17	USD	36.00	566	(45,280)
Taiwan Semiconductor Manufacturing Co. Ltd. ADR	Call	8/18/17	USD	37.00	941	(44,698)
TOTAL SA ADR	Call	8/18/17	USD	51.25	1,612	(106,316)
Unilever NV NY Shares	Call	8/18/17	USD	57.50	429	(22,522)
Verizon Communications, Inc.	Call	8/18/17	USD	47.00	214	(4,494)
Weyerhaeuser Co. Motorola Solutions, Inc.	Call	8/18/17	USD	35.00 85.85	18	(630)
Citigroup, Inc.	Call Call	8/22/17 8/25/17	USD USD	85.85 63.95	429 1,435	(158,388) (569,432)
Comcast Corp., Class A	Call	8/30/17	USD	41.22	707	(38,130)
Comount Corp., Class 11	Cuii	0130111	COD	71,44	707	(30,130)

Coca-Cola Co.	Call	9/01/17	USD	45.40	615	(42,276)
Pfizer, Inc.	Call	9/01/17	USD	34.17	1,602	(68,123)
Oracle Corp.	Call	9/07/17	USD	51.50	1,014	(98,275)
Altria Group, Inc.	Call	9/15/17	USD	76.42	251	(26,285)

See Notes to Financial Statements.

SEMI-ANNUAL REPORT JUNE 30, 2017 43

BlackRock Enhanced Equity Dividend Trust (BDJ)

Exchange-Traded Options Written (continued)

	r uv	Expiration	Su	IKC			
Description	Call	Date	Pr	ice	Contracts		Value
Citigroup, Inc.	Call	9/15/17	USD	67.50	336	\$	(66,192)
Comcast Corp., Class A	Call	9/15/17	USD	41.25	1,209		(73,145)
Morgan Stanley & Co. LLC	Call	9/15/17	USD	46.00	596		(71,222)
Oracle Corp.	Call	9/15/17	USD	51.30	862		(91,534)
Pfizer, Inc.	Call	9/15/17	USD	34.00	815		(46,455)
Total						\$ (17,116,741)

OTC Options Written

-]	Put/		Expiration	xpiration Strike				
Description	•	Call	Counterparty	Date	I	Price	Contracts		Value
NextEra Energy, Inc.		Call	Bank of America N.A.	07/06/17	USD	137.76	31,300	\$	(87,238)
SunTrust Bank, Inc.		Call	Goldman Sachs International	07/06/17	USD	57.22	83,500		(46,025)
Public Service Enterprise Grou	p, Inc.	Call	Morgan Stanley & Co. International PLC	07/11/17	USD	43.54	44,000		(10,075)
Publicis Groupe SA		Call	UBS AG	07/12/17	EUR	68.64	26,600		(4,808)
Samsung Electronics Co. Ltd.	GDR	Call	UBS AG	07/12/17	USD	1,049.51	3,300		(40,325)
KeyCorp		Call	Barclays Bank PLC	07/13/17	USD	18.39	22,300		(13,008)
Koninklijke Philips N.V.		Call	Credit Suisse International	07/18/17	EUR	32.12	113,200		(28,000)
NextEra Energy, Inc.		Call	Bank of America N.A.	07/18/17	USD	137.76	31,300		(112,547)
Publicis Groupe SA		Call	Deutsche Bank AG	07/18/17	EUR	68.98	26,500		(7,381)
Samsung Electronics Co. Ltd.	GDR	Call	UBS AG	07/18/17	USD	1,049.51	3,300		(54,180)
Smith & Nephew PLC		Call	Credit Suisse International	07/18/17	GBP	13.60	51,500		(3,646)
AstraZeneca PLC		Call	Morgan Stanley & Co. International PLC	07/19/17	GBP	53.39	7,700		(13,645)
Experian PLC		Call	Morgan Stanley & Co. International PLC	07/19/17	GBP	15.99	69,600		(13,480)
Samsung Electronics Co. Ltd.	GDR	Call	UBS AG	07/25/17	USD	1,049.51	3,300		(67,724)
AstraZeneca PLC		Call	Credit Suisse International	07/26/17	GBP	53.58	94,200		(200,327)
AstraZeneca PLC		Call	Morgan Stanley & Co. International PLC	07/26/17	GBP	54.54	66,900		(116,991)
Diageo PLC ADR		Call	Credit Suisse International	07/26/17	GBP	23.63	142,000		(14,230)
Koninklijke Philips N.V.		Call	HSBC Bank PLC	07/26/17	EUR	32.68	100,000		(20,027)
Kroger Co.		Call	Citibank N.A.	07/26/17	USD	30.48	54,000		(1,016)
Diageo PLC ADR		Call	Morgan Stanley & Co. International PLC	07/27/17	GBP	23.70	71,000		(6,617)
Lenovo Group Ltd.		Call	Morgan Stanley & Co. International PLC	07/27/17	HKD	5.21	3,300,000		(5,915)
SK Telecom Co. Ltd. ADR		Call	Citibank N.A.	07/27/17	USD	24.53	52,400		(38,304)
BCE, Inc.		Call	Citibank N.A.	07/31/17	USD	45.34	26,700		(13,749)
Pfizer, Inc.		Call	Citibank N.A.	07/31/17	USD	33.32	33,800		(23,041)
Diageo PLC ADR		Call	Morgan Stanley & Co. International PLC	08/04/17	GBP	23.82	71,000		(10,806)
Experian PLC		Call	Goldman Sachs International	08/04/17	GBP	16.42	118,000		(11,125)
Lenovo Group Ltd.		Call	Morgan Stanley & Co. International PLC	08/04/17	HKD	5.24	3,300,000		(5,209)
Publicis Groupe SA		Call	Morgan Stanley & Co. International PLC	08/08/17	EUR	68.35	19,000		(14,850)
Samsung Electronics Co. Ltd.	GDR	Call	HSBC Bank PLC	08/08/17	USD	1,029.28	3,700		(135,398)
Experian PLC		Call	Morgan Stanley & Co. International PLC	08/09/17	GBP	16.55	108,000		(8,935)
Koninklijke Philips N.V.		Call	Morgan Stanley & Co. International PLC	08/09/17	EUR	33.50	47,600		(12,538)
Publicis Groupe SA		Call	Morgan Stanley & Co. International PLC	08/10/17	EUR	66.17	21,900		(36,702)
Becton Dickinson & Co.		Call	JPMorgan Chase Bank N.A.	08/14/17	USD	193.10	19,400		(115,052)
Diageo PLC ADR		Call	Morgan Stanley & Co. International PLC	08/16/17	GBP	23.58	52,000		(8,488)
Experian PLC		Call	Morgan Stanley & Co. International PLC	08/16/17	GBP	16.64	108,000		(8,922)
Samsung Electronics Co. Ltd.	GDR	Call	Credit Suisse International	08/16/17	USD	1,022.79	3,600		(156,843)
U.S. Bancorp		Call	Morgan Stanley & Co. International PLC	08/21/17	USD	51.93	56,000		(94,699)
Smith & Nephew PLC		Call	Credit Suisse International	08/22/17	GBP	13.95	75,500		(11,199)
Total								\$ ((1,573,065)
									ĺ

Transactions in Options Written for the Period Ended June 30, 2017

Calls

		Premiums
	Contracts	Received
Outstanding options, beginning of period	2,828,869	\$ 20,925,252
Options written	22,166,287	72,604,907
Options exercised	(3,054,938)	(15,098,985)
Options expired	(451)	(40,348)
Options closed	(13,335,351)	(61,332,716)
Outstanding options, end of period	8,604,416	\$ 17,058,110

As of period end, the value of portfolio securities subject to covered call options written was \$884,128,147.

See Notes to Financial Statements.

44 SEMI-ANNUAL REPORT

JUNE 30, 2017

BlackRock Enhanced Equity Dividend Trust (BDJ)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

		Commodity	Credit	Equity	Foreign Currency Exchange		Other		
Liabilities Derivative Financial Instru	ments	Contracts	Contracts	Contracts	Contracts	Contracts	Contracts	Total	
Options written	Options written, at								
	value			\$ 18,689,806				\$ 18,689,806	

For the six months ended June 30, 2017, the effect of derivative financial instruments in the Statements of Operations was as follows:

Net Realized Gain (Loss) from: Futures Contract Options purchased ¹ Options written	Commodity Contracts	Credit Contracts	Equity Contracts \$ 1,196 (1,002) (14,543,346)	Foreign Currency Exchange Contracts	Interest Rate Contracts	Other Contracts	Total \$ 1,196 (1,002) (14,543,346)
Total			\$ (14,543,152)				\$ (14,543,152)
Options purchased are included in r	net realized gain (loss) from inve	stments.				
Net Change in Unrealized Appreciat Options written	ion on:		\$ 6,910,289				\$ 6,910,289

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:

Average market value of option contracts purchased

\$ 816¹ \$ 16,427,897

Average value of option contracts written

Actual amounts for the period are shown due to limited outstanding derivative financial instruments as of each quarter end.

For more information about the Trust s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments Offsetting as of Period End

The Trust s derivative assets and liabilities (by type) are as follows:

Derivative Financial Instruments: Options	Assets	Liabilities \$ 18,689,806
Derivatives not subject to a Master Netting Agreement or similar agreement (MNA)		(17,116,741)

Total derivative assets and liabilities subject to an MNA

\$ 1,573,065

The following table presents the Trust s derivative liabilities by counterparty net of amounts available for offset under a Master Netting Agreement (MNA) and net of the related collateral received by the Trust:

Counterparty	Subject	ve Liabilities to an MNA interparty	Derivatives Available for Offset	Non-cash Collateral Pledged ¹	Cash Collateral Pledged	D	Amount of erivative abilities ²
Bank of America N.A.	\$	199,785				\$	199,785
Barclays Bank PLC		13,008					13,008
Citibank N.A.		76,110		\$ (61,832)	\$ (14,278)		
Credit Suisse International		414,245		(414,245)			
Deutsche Bank AG		7,381					7,381
Goldman Sachs International		57,150					57,150
HSBC Bank PLC		155,425			(155,425)		
JPMorgan Chase Bank N.A.		115,052					115,052
Morgan Stanley & Co. International PLC		367,872		(367,872)			
UBS AG		167,037		(167,037)			
Total	\$	1,573,065		\$ (1.010.986)	\$ (169.703)	\$	392,376

¹ Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT JUNE 30, 2017 45

² Net amount represents the net amount payable due to the counterparty in the event of default. Net Amount may be offset further by net options written receivable/payable on the Statements of Assets and Liabilities.

BlackRock Enhanced Equity Dividend Trust (BDJ)

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivatives financial instruments. For information about the Trust s policy regarding valuation of investments and derivatives financial instruments refer to the Notes to Financial Statements.

The following tables summarize the Trust s investments and derivative financial instruments categorized in the disclosure hierarchy:

	Level 1	Level 2	Level 3 Total
Assets:			
Investments:			
Long-Term Investments:			
Common Stocks			
Aerospace & Defense	\$ 50,674,635		\$ 50,674,635
Air Freight & Logistics	12,073,110		12,073,110
Banks	320,563,007		320,563,007
Beverages	12,726,636	\$ 18,124,084	30,850,720
Capital Markets	64,656,957		64,656,957
Chemicals	57,082,035		57,082,035
Communications Equipment	14,884,584		14,884,584
Diversified Telecommunication Services	27,161,424		27,161,424
Electric Utilities	53,945,483		53,945,483
Energy Equipment & Services	7,017,253		7,017,253
Food & Staples Retailing	13,898,487		13,898,487
Food Products	5,710,798		5,710,798
Health Care Equipment & Supplies	13,013,837	5,259,117	18,272,954
Health Care Providers & Services	132,764,878		132,764,878
Hotels, Restaurants & Leisure	633,406		633,406
Household Products	18,242,238		18,242,238
Industrial Conglomerates	78,890,372	27,377,517	106,267,889
Insurance	119,544,387		119,544,387
Machinery	4,817,496		4,817,496
Media	29,687,009	14,012,949	43,699,958
Multi-Utilities	41,556,337		41,556,337
Multiline Retail	14,623,240		14,623,240
Oil, Gas & Consumable Fuels	189,535,055		189,535,055
Paper & Forest Products	10,059,597		10,059,597
Personal Products	23,594,763		23,594,763
Pharmaceuticals	112,502,703	32,301,864	144,804,567
Professional Services	10,057,399	14,846,218	24,903,617
Real Estate Investment Trusts (REITs)	7,376,700		7,376,700
Road & Rail	10,455,360		10,455,360
Semiconductors & Semiconductor Equipment	36,348,018	33,798,562	70,146,580
Software	95,563,778		95,563,778
Specialty Retail	23,428,928		23,428,928
Technology Hardware, Storage & Peripherals		8,343,562	8,343,562
Tobacco	16,038,956		16,038,956
Wireless Telecommunication Services	10,285,969		10,285,969
Short-Terms Securities	1,218,990		1,218,990
Total	\$ 1,640,633,825	\$ 154,063,873	\$ 1,794,697,698
Derivative Financial Instruments ¹			
Liabilities:	h (10.000 :==)		40.505.555
Equity contracts	\$ (12,962,457)	\$ (5,727,349)	\$ (18,689,806)
1 Derivative financial instruments are options written, which are shown at value.			

During the six months ended June 30, 2017, there were no transfers between levels.

See Notes to Financial Statements.

46 SEMI-ANNUAL REPORT

JUNE 30, 2017

Schedule of Investments June 30, 2017 (Unaudited)

BlackRock Enhanced Global Dividend Trust (BOE)

(Percentages shown are based on Net Assets)

Common Stocks Australia 2.1%	Shares	Value
Ansell Ltd.	581,649	\$ 10,607,044
Ensogo, Ltd. (a) Sonic Healthcare Ltd.	418,198 573,678	3 10,681,187
Belgium 1.5%		21,288,234
Anheuser-Busch InBev SA	93,835	10,363,931
bpost SA	208,197	5,028,450
Canada 5.7%		15,392,381
Rogers Communications, Inc., Class B TELUS Corp.	600,492 820,119	28,362,226 28,313,331
China 0.8%		56,675,557
ANTA Sports Products Ltd. Denmark 1.1%	2,405,000	7,945,247
Novo Nordisk A/S, Class B Finland 1.9%	254,434	10,932,337
Kone OYJ, Class B France 2.5%	378,629	19,262,773
Sanofi SA Germany 2.5%	264,646	25,358,355
Deutsche Post AG, Registered Shares Hong Kong 1.1%	675,301	25,349,614
Sands China Ltd. Japan 1.3%	2,282,000	10,445,936
Japan Tobacco, Inc. Netherlands 1.2%	358,400	12,597,070
Heineken NV Sweden 1.4%	126,700	12,319,624
Svenska Handelsbanken AB, Class A Switzerland 9.9%	937,035	13,420,329
Givaudan SA, Registered Shares	7,300	14,627,732
Nestle SA, Registered Shares	302,545	26,387,264
Novartis AG, Registered Shares	382,027	31,909,419
Roche Holding AG SGS SA, Registered Shares	54,260 5,070	13,864,236 12,293,152
303 3A, Registered Shales	3,070	
Taiwan 2.6%		99,081,803
Far EasTone Telecommunications Co. Ltd.	3,304,000	8,415,224
Taiwan Semiconductor Manufacturing Co. Ltd.	2,590,000	17,695,432
United Kingdom 16.8%		26,110,656
AstraZeneca PLC	525,120	35,174,385
British American Tobacco PLC	553,688	37,729,893
Diageo PLC	498,054	14,718,363
GlaxoSmithKline PLC	872,498	18,573,082
Imperial Brands PLC	746,764 9,630,811	33,557,423
Lloyds Banking Group PLC Unilever PLC	357,490	8,299,604 19,346,596
		167,399,346
United States 42.9% 3M Co.	88,255	18,373,834

AbbVie, Inc. (b) Altria Group, Inc. (c) Cisco Systems, Inc. (b)	200,328 535,210 829,702	14,525,783 39,857,089 25,969,673
Citizens Financial Group, Inc. Coca-Cola Co. (b)(c) Genuine Parts Co.	297,440 525,688 287,055	10,612,659 23,577,107 26,627,222
H&R Block, Inc. (b) Common Stocks United States (continued)	722,343 Shares	22,327,622 Value
International Paper Co. (b) Johnson & Johnson (b) M&T Bank Corp. Microsoft Corp. (b) PepsiCo, Inc.	430,158 246,336 96,920 249,977 128,351	\$ 24,351,244 32,587,789 15,696,194 17,230,915 14,823,257
Pfizer, Inc. (b)(c) Philip Morris International, Inc. (c) Procter & Gamble Co. (b) Reynolds American, Inc. Strategic Growth Bancorp, (Acquired 3/10/14, cost \$5,461,692) (a)(d)(e)	863,614 239,400 170,124 163,592 120,312	29,008,794 28,117,530 14,826,307 10,640,024 4,206,107
U.S. Bancorp United Parcel Service, Inc., Class B (b) United Technologies Corp. (b) Wells Fargo & Co.(b)	296,914 103,122 92,228 291,584	15,415,775 11,404,262 11,261,961 16,156,669
Total Common Stocks 95.3%		427,597,817 951,177,079
Preferred Stocks India 0.1%		
Jasper Infotech Private Ltd., Series F, (Acquired 5/7/14, cost \$1,888,464), 0.00% (a)(d)(e) Jasper Infotech Private Ltd., Series G, (Acquired 10/29/14, cost \$741,913), 0.00% (a)(d)(e)	266 88	923,307 373,394
United States 1.8% Palantir Technologies, Inc., Series I (Acquired 2/7/14, cost \$3,118,944), 0.00% (a)(d)(e) Uber Technologies, Inc., Series D (Acquired 6/06/14, cost \$3,845,800), 0.00% (a)(d)(e)	508,800 247,908	1,296,701 4,075,488 13,357,283
Total Preferred Stocks 1.9% Total Long-Term Investments		17,432,771 18,729,472
(Cost \$949,493,685) 97.2%		969,906,551
Short-Term Securities BlackRock Liquidity Funds, T-Fund, Institutional Class, 0.84% (f)(g) Total Short-Term Securities	31,045,510	31,045,510
(Cost \$31,045,510) 3.1% Total Investments Before Options Written (Cost \$980,539,195) 100.3%		31,045,510 1,000,952,061
Options Written (Premiums Received \$6,038,342) (0.5)% Total Investments, Net of Options Written (Cost \$974,500,853) 99.8% Other Assets Less Liabilities 0.2%		(4,970,133) 995,981,928 1,703,625
Net Assets 100.0%		\$ 997,685,553

See Notes to Financial Statements.

BlackRock Enhanced Global Dividend Trust (BOE)

Notes to Schedule of Investments

- (a) Non-income producing security.
- (b) All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.
- (c) All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.
- (d) Restricted security as to resale, excluding 144A securities. As of period end, the Trust held restricted securities with a current value of \$22,935,579 and an original cost of \$15,056,813, which was 1.9% of its net assets.
- (e) Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.
- (f) During the six months ended June 30, 2017, investments in issuers considered to be affiliates of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

						Change
						in
	Shares		Shares	Value at		Unrealized
	Held at	Net	Held at	June 30,		Net Realized Appreciation
Affiliate	December 31, 2016	Activity	June 30, 2017	2017	Income	Gain (Depreciation)
BlackRock T-Fund, Institutional						
Class	11,863,116	19,182,394	31,045,510	\$ 31,045,510	\$ 68,091	
SL Liquidity Series, LLC, Money						
Market Series					32,5611	
Total					\$ 100,652	

Represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

(g) Current yield as of period end.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written Put/ Expiration Strike Description Call Date Price Contracts Value 7/21/17 USD 32.00 Cisco Systems, Inc. 1,106 Call (16,037)H&R Block, Inc. 7/21/17 Call USD 32.00 722 (23,465)International Paper Co. Call 7/21/17 USD 57.50 574 (32,431)Microsoft Corp. Call 7/21/17 USD 72.50 333 (12,487)Pfizer, Inc. USD 33.00 754 (59,943)Call 7/21/17 195 (4,095)Pfizer, Inc. Call 7/21/17 USD 34.00

United Parcel Service, Inc., Class B	Call	7/21/17	USD	110.00	206	(37,801)
AbbVie, Inc.	Call	7/28/17	USD	70.50	400	(96,600)
Cisco Systems, Inc.	Call	7/28/17	USD	32.00	1,106	(24,332)
International Paper Co.	Call	7/28/17	USD	57.00	574	(65,723)
Johnson & Johnson	Call	7/28/17	USD	134.00	329	(48,363)
Pfizer, Inc.	Call	7/28/17	USD	33.50	145	(7,757)
Pfizer, Inc.	Call	7/28/17	USD	34.50	97	(1,358)
Procter & Gamble Co.	Call	7/28/17	USD	89.00	340	(9,690)
United Technologies Corp.	Call	7/28/17	USD	122.00	184	(38,364)
Wells Fargo & Co.	Call	7/28/17	USD	53.50	950	(238,925)
Pfizer, Inc.	Call	7/31/17	USD	34.25	98	(1,655)
Coca-Cola Co.	Call	8/01/17	USD	45.40	700	(30,459)
Microsoft Corp.	Call	8/11/17	USD	70.25	333	(47,852)
Coca-Cola Co.	Call	8/15/17	USD	45.40	700	(40,226)
Johnson & Johnson	Call	8/17/17	USD	134.00	329	(65,357)
AbbVie, Inc.	Call	8/18/17	USD	70.51	400	(107,246)
Cisco Systems, Inc.	Call	8/18/17	USD	32.00	1,106	(61,383)
H&R Block, Inc.	Call	8/18/17	USD	32.00	361	(25,270)
International Paper Co.	Call	8/18/17	USD	57.50	574	(72,037)
Microsoft Corp.	Call	8/18/17	USD	70.25	333	(47,481)
Pfizer, Inc.	Call	8/18/17	USD	34.00	192	(8,448)
Procter & Gamble Co.	Call	8/18/17	USD	90.00	340	(14,110)
United Parcel Service, Inc., Class B	Call	8/18/17	USD	110.00	206	(59,740)
United Technologies Corp.	Call	8/18/17	USD	122.10	184	(42,794)
Wells Fargo & Co.	Call	8/18/17	USD	57.50	126	(7,623)
Coca-Cola Co.	Call	9/01/17	USD	45.40	700	(48,119)
Pfizer, Inc.	Call	9/01/17	USD	34.17	403	(17,137)
Johnson & Johnson	Call	9/05/17	USD	134.00	329	(65,535)
Pfizer, Inc.	Call	9/15/17	USD	34.00	1,571	(89,547)
Total						\$ (1,569,390)

See Notes to Financial Statements.

48 SEMI-ANNUAL REPORT JUNE 30, 2017

Expiration

Schedule of Investments (continued)

Put/

BlackRock Enhanced Global Dividend Trust (BOE)

Strike

OTC Options	Written
-------------	---------

	Put		Expiration		trike		
Description	Call	Counterparty	Date	I	Price	Contracts	Value
GlaxoSmithKline PLC	Call	Morgan Stanley & Co. International PLC	07/06/17	GBP	16.23	236,400	\$ (67,559)
AstraZeneca PLC	Call	Deutsche Bank AG	07/18/17	GBP	54.34	150,000	(204,218)
GlaxoSmithKline PLC	Call	Deutsche Bank AG	07/18/17	GBP	17.42	135,000	(845)
Unilever PLC	Call	Goldman Sachs International	07/18/17	GBP	44.68	35,000	(3,282)
AstraZeneca PLC	Call	Morgan Stanley & Co. International PLC	07/19/17	GB{	53.39	90,100	(159,665)
bpost SA	Call	Morgan Stanley & Co. International PLC	07/26/17	EUR	22.40	41,500	(2,830)
British American Tobacco PLC	Call	Goldman Sachs International	07/26/17	GBP	55.53	110,500	(25,886)
Heineken NV	Call	Deutsche Bank AG	07/26/17	EUR	88.34	25,000	(9,758)
Imperial Brands PLC	Call	Credit Suisse International	07/26/17	GBP	36.79	100,000	(5,552)
Kone OYJ, Class B	Call	Credit Suisse International	07/26/17	EUR	47.39	80,500	(24,346)
Llyods Banking Group PLC	Call	Credit Suisse International	07/26/17	GBP	0.71	1,925,000	(474)
Nestle SA, Registered Shares	Call		07/26/17	CHF	82.37	60,000	(134,318)
Novartis AG, Registered Shares	Call	Credit Suisse International	07/26/17	CHF	79.66	152,000	(282,209)
Novo Nordisk A/S, Class B	Call	Goldman Sachs International	07/26/17	DKK	297.67	50,500	(13,963)
Sanofi SA	Call	Goldman Sachs International	07/26/17	EUR	87.10	52,800	(40,822)
SGS SA, Registered Shares	Call		07/26/17	CHF	2,353.79	1,000	(30,047)
Svenska Handelsbanken AB, Class A	Call	Morgan Stanley & Co. International PLC	07/26/17	SEK	125.87	187,000	(10,955)
Taiwan Semiconductor Manufacturing Co. Ltd.	Call	Deutsche Bank AG	07/26/17	USD	211.55	1,159,000	(71,661)
Unilever PLC	Call	HSBC Bank PLC	07/26/17	GBP	43.92	128,000	(43,670)
Diageo PLC	Call	Morgan Stanley & Co. International PLC	07/27/17	GBP	23.70	100,000	(9,320)
Deutsche Post AG, Registered Shares	Call	Morgan Stanley & Co. International PLC	07/27/17	EUR	33.99	138,000	(33,638)
Rogers Communications, Inc., Class B	Call	Deutsche Bank AG	07/27/17	CAD	64.09	80,000	(13,042)
3M Co.	Call	Deutsche Bank AG	08/01/17	USD	209.98	17,700	(54,692)
Japan Tobacco, Inc.	Call	Goldman Sachs International	08/01/17	JPY	4,163.13	71,700	
•							(12,261)
M&T Bank Corp.	Call	UBS AG	08/01/17	USD	166.52	19,400	(43,219)
U.S. Bancorp	Call	Bank of America N.A.	08/01/17	USD	53.57	59,400	(26,650)
Altria Group, Inc.	Call	UBS AG	08/02/17	USD	76.11	71,400	(46,697)
Anheuser-Busch InBev SA	Call	Morgan Stanley & Co. International PLC	08/02/17	EUR	103.44	33,300	(15,326)
Sands China Ltd.	Call	JPMorgan Chase Bank N.A.	08/02/17	HKD	38.19	456,400	(14,211)
Reynolds American, Inc.	Call	Morgan Stanley & Co. International PLC	08/03/17	USD	65.62	32,700	(19,442)
ANTA Sports Products Ltd.	Call	Citibank N.A.	08/04/17	HKD	23.77	481,000	(139,740)
bpost SA	Call		08/04/17	EUR	22.40	41,500	(2,852)
British American Tobacco PLC	Call	Goldman Sachs International	08/04/17	GBP	55.80	110,500	(34,576)
Diageo PLC	Call	Morgan Stanley & Co. International PLC	08/04/17	GBP	23.82	100,000	(15,220)
_	Call			EUR	34.15		
Deutsche Post AG, Registered Shares		Morgan Stanley & Co. International PLC	08/04/17			138,000	(49,334)
Givaudan SA, Registered Shares	Call	Bank of America N.A.	08/04/17	CHF	2,009.00	1,500	(15,312)
Heineken NV	Call	Credit Suisse International	08/04/17	EUR	88.77	25,000	(13,701)
Kone OYJ, Class B	Call	Credit Suisse International	08/04/17	EUR	47.62	80,500	(18,336)
Llyods Banking Group PLC	Call	Goldman Sachs International	08/04/17	GBP	0.71	1,925,000	(11,626)
Nestle SA, Registered Shares	Call	Morgan Stanley & Co. International PLC	08/04/17	CHF	82.37	60,000	(146,646)
Novo Nordisk A/S, Class B	Call	Deutsche Bank AG	08/04/17	DKK	298.39	50,500	(26,997)
PepsiCo, Inc.	Call	UBS AG	08/04/17	USD	117.16	25,700	(32,133)
Sanofi SA	Call	Goldman Sachs International	08/04/17	EUR	87.53	52,800	(51,333)
SGS SA, Registered Shares	Call	Morgan Stanley & Co. International PLC	08/04/17	CHF	2,365.38	1,000	(24,897)
Svenska Handelsbanken AB, Class A	Call	•	08/04/17	SEK	126.49	187,000	(9,800)
Citizens Financial Group, Inc.	Call	Barclays Bank PLC	08/07/17	USD	37.57	59,500	(39,039)
Ansell Ltd.	Call	Deutsche Bank AG	08/08/17	AUD	24.21	116,400	(51,244)
TELUS CORP.	Call	Citibank N.A.	08/08/17	CAD	45.23	109,300	(36,532)
Genuine Parts Co.	Call	Goldman Sachs International	08/09/17	USD	95.54	39,700	(43,008)
Philip Morris International, Inc.	Call	JPMorgan Chase Bank N.A.	08/09/17	USD	119.60	48,000	(71,226)
Sonic Healthcare Ltd.	Call	Deutsche Bank AG	08/09/17	AUD	24.67	114,800	(29,251)
3M Co.	Call	Deutsche Bank AG	08/11/17	USD	209.98	17,700	(64,980)
Far Eastone Telecommunications Co. Ltd.	Call	Goldman Sachs International	08/11/17	USD	79.23	661,000	(7,053)
Altria Group, Inc.	Call	UBS AG	08/16/17	USD	76.11	71,400	(63,065)
Anheuser-Busch InBev SA	Call	Goldman Sachs International	08/16/17	EUR	103.08	4,300	(3,461)
Rogers Communications, Inc., Class B	Call	Deutsche Bank AG	08/16/17	CAD	64.09	80,000	(26,582)
Genuine Parts Co.	Call	Goldman Sachs International	08/17/17	USD	95.54	39,700	(50,456)
M&T Bank Corp.	Call	UBS AG	08/17/17	USD	166.52	19,400	(59,216)

TELUS CORP.	Call	Citibank N.A.	08/17/17	CAD	45.23	109,300	(42,596)
Roche Holding AG	Call	Credit Suisse International	08/18/17	CHF	258.91	10,800	(12,064)
U.S. Bancorp	Call	Bank of America N.A.	08/21/17	USD	53.57	59,400	(42,419)
Japan Tobacco, Inc.	Call	Goldman Sachs International	08/22/17	JPY	4,163.13	71,700	(24,121)
ANTA Sports Products Ltd.	Call	JPMorgan Chase Bank N.A.	08/23/17	HKD	23.77	481,000	(149,905)
Reynolds American, Inc.	Call	Morgan Stanley & Co. International PLC	08/23/17	USD	65.62	32,700	(27,047)
Sands China Ltd.	Call	JPMorgan Chase Bank N.A.	08/23/17	HKD	38.19	456,400	(25,388)

See Notes to Financial Statements.

SEMI-ANNUAL REPORT JUNE 30, 2017 49

BlackRock Enhanced Global Dividend Trust (BOE)

OTC Options Written (continued)

	Put/		Expiration	Stı	rike		
Description	Call	Counterparty	Date	Pr	rice	Contracts	Value
PepsiCo, Inc.	Call	UBS AG	08/24/17	USD	117.16	25,700	\$ (45,532)
Ansell Ltd.	Call	JPMorgan Chase Bank N.A.	08/25/17	AUD	24.21	116,400	(50,741)
Philip Morris International, Inc.	Call	JPMorgan Chase Bank N.A.	08/25/17	USD	119.60	48,000	(93,223)
TELUS CORP.	Call	Citibank N.A.	08/28/17	CAD	45.23	109,300	(49,353)
Altria Group, Inc.	Call	UBS AG	08/29/17	USD	76.11	71,400	(76,356)
Genuine Parts Co.	Call	Goldman Sachs International	08/29/17	USD	95.54	39,700	(60,624)
Sonic Healthcare Ltd.	Call	JPMorgan Chase Bank N.A.	08/29/17	AUD	24.67	114,800	(37,845)
Citizens Financial Group, Inc.	Call	Barclays Bank PLC	08/30/17	USD	37.57	59,500	(59,421)
Rogers Communications, Inc., Class B	Call	Deutsche Bank AG	08/31/17	CAD	64.09	80,000	(35,874)
Far Eastone Telecommunications Co. Ltd.	Call	Goldman Sachs International	09/01/17	USD	79.23	USD 661,000	(10,060)
Total							\$ (3,400,743)

Transactions in Options Written for the Period Ended June 30, 2017

	Calls			Puts
	Premiums			Premiums
	Contracts	Received	Contracts	Received
Outstanding options, beginning of period	12,951,795	\$ 11,575,998	505	\$ 32,198
Options written	65,215,133	41,244,037	114	44,148
Options exercised	(456,475)	(2,621,253)		
Options expired	(26,411,505)	(12,826,720)	(505)	(32,198)
Options closed	(38,274,348)	(31,333,720)	(114)	(44,148)
Outstanding options, end of period	13,024,600	\$ 6,038,342		

As of period end, the value of portfolio securities subject to covered call options written was \$364,029,799.

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

Liabilities Derivative Financial Instruments		Commodity Credit Contracts Contracts	Equity Contracts	Foreign Currency Interest Exchange Rate Other Contracts Contracts Contracts	Total
Options written	Options written, at				
	value		\$ 4,970,133		\$ 4,970,133

For the six months ended June 30, 2017, the effect of derivative financial instruments in the Statements of Operations was as follows:

Net Realized Gain (Loss)	Commodity	Credit	Equity	Foreign Currency Exchange	Interest Rate	Other	
from:	Contracts	Contracts	Contracts	Contracts	Contracts	Contracts	Total
Futures contracts			\$ 39,453				\$ 39,453
Options purchased ¹			36,539				36,539
Options written			(12,010,415)				(12,010,415)

Total \$ (11,934,423) \$ (11,934,423)

Net Change in Unrealized Appreciation (Depreciation) on:

Options written \$ 670,609 \$ 670,609

¹ Options purchased are included in net realized gain (loss) from investments.

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Financial futures contracts::

Average notional value of contracts long \$100,175,6251

Options:

Average value of option contracts purchased \$ 569,0271

Average value of option contracts written

\$ 8,378,440

Actual amounts for the period are shown due to limited outstanding derivative financial instruments as of each quarter end.

For more information about the Trust s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

See Notes to Financial Statements.

50 SEMI-ANNUAL REPORT JUNE 30, 2017

BlackRock Enhanced Global Dividend Trust (BOE)

Derivative Financial Instruments Offsetting as of Period End

The Trust s derivative assets and liabilities (by type) are as follows:

Derivative Financial Instruments	Assets	Liabilities
Options		\$ 4,970,133
Derivatives not subject to a Master Netting Agreement or similar agreement (MNA)		(1,569,390)
Total derivative assets and liabilities subject to an MNA		\$ 3,400,743

The following table presents the Trust s derivative liabilities by counterparty net of amounts available for offset under an Master Netting Agreement (MNA) and net of the related collateral pledged by the Trust:

Counterparty Bank of America N.A.	Su	tive Liabilities bject to an MNA ounterparty	ct to an Available NA for		Cash Collateral Pledged \$ (84,381)	Liabilities ²		
Barclays Bank PLC	Ą	98.460		\$ (98,460)	\$ (04,301)			
Citibank N.A.		268,221		φ (20,400)	(20,000)	\$	248,221	
Credit Suisse International		356,682		(356,682)	(==,===)	_		
Deutsche Bank AG		589,144		(589,144)				
Goldman Sachs International		392,532		(392,532)				
HSBC Bank PLC		43,670					43,670	
JPMorgan Chase Bank N.A.		442,539		(314,150)			128,389	
Morgan Stanley & Co. International PLC		758,896		(758,896)				
UBS AG		366,218		(366,218)				
Total	\$	3,400,743		\$ (2,876,082)	\$ (104,381)	\$	420,280	

¹ Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust spolicy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

 $The following tables summarize the Trust \ s \ investments \ and \ derivative \ financial \ instruments \ categorized \ in the \ disclosure \ hierarchy:$

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				
Common Stocks:				
Australia		\$ 21,288,231	\$ 3 \$	21,288,234
Belgium		15,392,381		15,392,381
Canada	\$ 56,675,557			56,675,557
China		7,945,247		7,945,247
Denmark		10,932,337		10,932,337

² Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Finland		19,262,773		19,262,773
France		25,358,355		25,358,355
Germany		25,349,614		25,349,614
Hong Kong		10,445,936		10,445,936
Japan		12,597,070		12,597,070
Netherlands		12,319,624		12,319,624
Sweden		13,420,329		13,420,329
Switzerland		99,081,803		99,081,803
Taiwan		26,110,656		26,110,656
United Kingdom		167,399,346		167,399,346
United States	423,391,710		4,206,107	427,597,817
Preferred Stocks			18,729,472	18,729,472
Short-Term Securities	31,045,510			31,045,510
Total	\$ 511,112,777	\$ 466,903,702	\$ 22,935,582	\$ 1,000,952,061

Derivative Financial Instruments¹

Liabilities:

Equity contracts (1,055,530) (3,914,603) (4,970,133)

See Notes to Financial Statements.

SEMI-ANNUAL REPORT JUNE 30, 2017 51

¹ Derivative financial instruments are options written, which are shown at value.

BlackRock Enhanced Global Dividend Trust (BOE)

\$ 16,689,746

\$ (16,689,746)

Transfers between Level 1 and Level 2 were as follow:

Common Stocks

	Transfers into	Transfers out	Transfers into	Transfers out
	Level 1	of Level 11	Level 21	of Level 2
Assets:				
Long-Term Investments:				

¹ External pricing service used to reflect any significant market movements between the time the Trust valued such foreign securities and the earlier closing of foreign markets.

A reconciliation of Level 3 investments is presented when the Trust had a significant amount of Level 3 investments at the beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

	Common	Preferred	
Acceta	Stocks	Stocks	Total
Assets: Opening Balance, as of December 31, 2016 Transfers into Level 3	\$ 4,421,995	\$ 24,994,450	\$ 29,416,445
Transfers out of Level 3 Accrued discounts/premiums			
Net realized gain (loss) Net change in unrealized appreciation (depreciation) ^{1,2}	(215,885)	(6,264,978)	(6,480,863)
Purchases Sales			
Closing Balance, as of June 30, 2017	\$ 4,206,110	\$ 18,729,472	\$ 22,935,582
Net change in unrealized appreciation (depreciation) on investments still held at June 30, 2017 ²	\$ (215,885)	\$ (6,264,978)	\$ (6,480,863)

¹ Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations.

Assets:	Value	Valuation Approach	Unobservable Inputs	Range of unobservable Inputs Utilized	Weighted Average of Unobservable Inputs
Common Stocks	\$ 4,206,107	Market	Tangible Book Value Multiple ¹	1.75x	
Common Stocks	\$ 4,200,107	Market	Illiquidity Discount ²	1.46%	
Preferred Stocks ³	18,729,472	Market	Revenue Growth Rate ¹	131.00%	
	-77		Revenue Multiple ¹	8.25x 10.75x	8.83x
			Time to Exit ²	1 year	
			Volatility ¹	29.00%	
Total	\$ 22,935,579				

¹ Increase in unobservable input may result in a significant increase to value, while a decrease in the unobservable input may result in a significant decrease to value.

Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on derivative financial instruments still held at June 30, 2017 is generally due to derivative financial instruments no longer held or categorized as Level 3 at period end. The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Global Valuation Methodologies Committee (the Global Valuation Committee) to determine the value of certain of the Trust's Level 3 investments as of period end.

- ² Decrease in unobservable input may result in a significant increase to value, while an increase in the unobservable input may result in a significant decrease to value.
- 3 For the six months ended June 30, 2017, the valuation technique for investments classified as preferred stocks with a total value of \$1,296,701 changed to an Option Pricing Model (OPM). The investments were previously valued utilizing Probability-Weighted Expected Return Model (PWERM). The change was due to consideration of liquidation preferences and exit strategy.

See Notes to Financial Statements.

52 SEMI-ANNUAL REPORT

JUNE 30, 2017

Schedule of Investments June 30, 2017 (Unaudited)

BlackRock Enhanced International Dividend Trust (BGY)

(Percentages shown are based on Net Assets)

Common Stocks Australia 2.6%	Shares	Value
Ansell Ltd. Sonic Healthcare Ltd.	523,055 515,888	\$ 9,538,514 9,605,207
Belgium 1.9%		19,143,721
Anheuser-Busch InBev SA bpost SA	84,953 188,771	9,382,928 4,559,266
Canada 7.1%		13,942,194
Canadian Pacific Railway Ltd. Rogers Communications, Inc., Class B TELUS Corp.	8,600 541,912 740,272	1,383,706 25,595,396 25,556,738
China 3.9%		52,535,840
Alibaba Group Holding Ltd. ADR (a)(b)	77,678	10,944,830
ANTA Sports Products Ltd. Tencent Holdings Ltd.	2,169,600 290,400	7,167,571 10,418,082
Denmark 1.3%		28,530,483
Novo Nordisk A/S, Class B Finland 2.5%	230,350	9,897,513
Kone OYJ, Class B France 5.3%	365,441	18,591,833
AXA SA	10,400	284,787
BNP Paribas SA Dassault Aviation SA	79,064 5,063	5,692,031 7,075,547
Sanofi SA	239,046	22,905,365
Societe Generale SA	54,570	2,942,722
Germany 5.1%		38,900,452
Continental AG	1,400	302,862
Deutsche Post AG, Registered Shares	624,361	23,437,416
Innogy SE (c) KION Group AG	22,900 30,360	901,262 2,322,312
SAP SE	96,900	10,142,652
Wacker Chemie AG	4,100	446,235
Hong Kong 2.3%		37,552,739
AIA Group Ltd.	998,400	7,304,653
Melco Resorts & Entertainment Ltd. ADR (a)	19,163	430,210
Sands China Ltd.	2,052,000	9,393,103
India 1.4%		17,127,966
Federal Bank, Ltd. HDFC Bank Ltd.	1,063,500 338,302	1,854,172 8,703,369
Ireland 0.9%		10,557,541
Ryanair Holdings PLC ADR (a)(b) Italy 0.3%	64,436	6,933,958
Azimut Holding SpA	23,400	470,757

3 3		
Buzzi Unicem SpA	68,931	1,718,793
		2,189,550
Japan 3.7%		_,,
FANUC Corp.	22,900	4,432,198
Japan Tobacco, Inc.	323,600	11,373,917
Nintendo Co. Ltd.	21,300	7,131,056
SMC Corp.	12,800	3,912,860
Sumitomo Mitsui Financial Group, Inc.	22,900	894,118
		27,744,149
Common Stocks	Shares	Value
Netherlands 5.1%		
Aalberts Industries NV	114,252	\$ 4,546,343
ASML Holding NV	64,680	8,431,209
Heineken NV	114,502	11,133,556
Koninklijke Philips NV	186,400	6,635,593
Royal Dutch Shell PLC, Class B	261,584	7,022,588
N 0.00		37,769,289
Norway 0.0% Statoil ASA	17 000	201 007
Portugal 1.0%	17,000	281,896
Galp Energia SGPS SA	486,604	7,373,879
South Africa 1.4%	460,004	1,313,019
Naspers Ltd., Class N	53,619	10,559,335
South Korea 2.0%		.,,.
LG Chem Ltd.	7,645	1,945,449
Samsung Electronics Co. Ltd.	6,000	12,496,922
		14,442,371
Sweden 2.8%		
Hexagon AB, Class B	188,266	8,944,451
Svenska Handelsbanken AB, Class A	846,390	12,122,100
		21,066,551
Switzerland 12.3%		
Givaudan SA, Registered Shares	6,583	13,191,009
Nestle SA, Registered Shares	280,396	24,455,480
Novartis AG, Registered Shares	345,282	28,840,234
Roche Holding AG	48,966	12,511,540
SGS SA, Registered Shares	4,584	11,114,755
UBS Group AG, Registered Shares (b)	37,100	630,918
		90,743,936
Taiwan 3.2%		
Far EasTone Telecommunications Co. Ltd.	2,971,000	7,567,080
Taiwan Semiconductor Manufacturing Co. Ltd.	2,342,000	16,001,043
		23,568,123
United Kingdom 21.6%		
AstraZeneca PLC	436,880	29,263,759
BAE Systems PLC	563,600	4,652,673
British American Tobacco PLC	506,741	34,530,790
CNH Industrial NV	55,267	626,769
Diageo PLC ADR	449,115	13,272,131
GlaxoSmithKline PLC	788,359	16,781,994
Imperial Brands PLC	686,880	30,866,408
Lloyds Banking Group PLC	8,673,254	7,474,404
Metro Bank PLC (b)	53,870	2,517,893
Rio Tinto PLC	58,502	2,477,665
Unilever PLC	322,806	17,469,571
		159,934,057
United States 4.6%	7 0 004	17.712.75
3M Co. (d)	79,801	16,613,770
Microsoft Corp. (a)	226,034	15,580,524

 Pfizer, Inc. (a)(d)
 16,200
 544,158

 Shire PLC ADR (a)
 8,700
 1,437,849

34,176,301

Total Common Stocks 92.3% 683,563,677

Investment Companies 2.9%

United States 2.9%

WisdomTree Japan Hedged Equity Fund (a)(d) 420,310 21,856,120

See Notes to Financial Statements.

SEMI-ANNUAL REPORT JUNE 30, 2017 53

BlackRock Enhanced International Dividend Trust (BGY)

Preferred Stocks	Shares	Value
China 0.5% Xiaoju Kuaizhi, Inc., Series A-17 (Acquired 7/28/15, cost \$2,106,332), 0.00% (b)(e)(f) India 0.3%	76,800	\$ 3,911,424
Jasper Infotech Private Ltd., Series F, (Acquired 5/7/14, cost \$2,825,580), 0.00% (b)(e)(f) Jasper Infotech Private Ltd., Series G, (Acquired 10/29/14, cost \$1,112,870), 0.00% (b)(e)(f)	398 132	1,381,490 560,091
Total Preferred Stocks 0.8% Total Long-Term Investments (Cost \$633,209,527) 96.0% Short-Term Securities BlackRock Liquidity Funds, T-Fund, Institutional Class, 0.84% (g)(h) Total Short-Term Securities (Cost \$30,845,879) 4.2% Total Investments Before Options Written (Cost \$664,055,406) 100.2%	Shares 30,845,879	\$ 1,941,581 5,853,005 711,272,802 Value 30,845,879 30,845,879 742,118,681
Options Written (Premiums Received \$4,751,142) (0.5)% Total Investments, Net of Options Written (Cost \$659,304,264) 99.7% Other Assets Less Liabilities 0.3%		(3,858,188) 738,260,493 2,130,911
Net Assets 100.0%		\$ 740,391,404

Notes to Schedule of Investments

- (a) All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.
- (b) Non-income producing security.
- (c) Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.
- (d) All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.
- (e) Restricted security as to resale, excluding 144A securities. As of period end, the Trust held restricted securities with a current value of \$5,853,005 and an original cost of \$6,044,782, which was 0.8% of its net assets.
- (f) Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.
- (g) During the six months ended June 30, 2017, investments in issuers considered to be affiliates of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliate Income

	Shares Held at December 31, 2016	Net Activity	Shares Held at June 30, 2017	Value at June 30, 2017		Net Realized Gain	Change in Unrealized Appreciation (Depreciation)
BlackRock Liquidity Funds, T-Fund, Institutional Class SL Liquidity Series, LLC,	22,641,400	8,204,479	30,845,879	\$ 30,845,879	\$ 77,705		•
Money Market Series Total				\$ 30,845,879	501 ¹ \$ 78,206		

¹ Represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

(h) Current yield as of period end.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

	Put/	Expiration	Strike			
Description	Call	Date	Pı	rice	Contracts	Value
Alibaba Group Holding Ltd. ADR	Call	7/07/17	USD	124.00	73	\$ (125,013)
WisdomTree Japan Hedged Equity Fund	Call	7/14/17	USD	52.00	410	(19,885)
Alibaba Group Holding Ltd. ADR	Call	7/21/17	USD	120.00	52	(109,980)
Canadian Pacific Railway Ltd.	Call	7/21/17	CAD	215.00	34	(3,474)
Microsoft Corp.	Call	7/21/17	USD	72.50	301	(11,287)
Pfizer, Inc.	Call	7/21/17	USD	34.00	17	(357)
Ryanair Holdings PLC ADR	Call	7/21/17	USD	110.00	400	(51,000)
WisdomTree Japan Hedged Equity Fund	Call	7/21/17	USD	52.00	410	(24,600)
Pfizer, Inc.	Call	7/28/17	USD	33.50	13	(695)
Pfizer, Inc.	Call	7/28/17	USD	34.50	8	(112)
Shire PLC ADR	Call	7/28/17	USD	182.50	34	(2,975)
WisdomTree Japan Hedged Equity Fund	Call	7/28/17	USD	52.00	410	(30,955)
Pfizer, Inc.	Call	7/31/17	USD	34.25	9	(152)

See Notes to Financial Statements.

54 SEMI-ANNUAL REPORT JUNE 30, 2017

BlackRock Enhanced International Dividend Trust (BGY)

Exchange-Traded Options Written (continued)

	Put/	Expiration	St	rike		
Description	Call	Date	P	rice	Contracts	Value
Microsoft Corp.	Call	8/11/17	USD	70.25	301	\$ (43,254)
Alibaba Group Holding Ltd. ADR	Call	8/18/17	USD	140.00	185	(139,213)
Melco Resorts & Entertainment Ltd. ADR	Call	8/18/17	USD	26.00	76	(1,710)
Microsoft Corp.	Call	8/18/17	USD	70.25	301	(42,918)
Pfizer, Inc.	Call	8/18/17	USD	34.00	17	(748)
WisdomTree Japan Hedged Equity Fund	Call	8/18/17	USD	52.00	900	(94,050)
Total						\$ (702,378)

OTC Options Written

OTC Options Written				~			
	Put/		Expiration		trike		
Description	Call	Counterparty	Date		Price	Contracts	Value
Innogy SE	Call	Deutsche Bank AG	07/07/17		34.11	22,900	\$ (16,651)
Hexagon AB, Class B	Call	Bank of America N.A.	07/12/17	SEK	388.85	14,600	(25,185)
Roche Holding AG	Call	Credit Suisse International	07/12/17		269.27	11,000	(22)
AstraZeneca PLC	Call	Deutsche Bank AG	07/18/17	GBP	54.34	92,000	(125,254)
Diageo PLC ADR	Call	Goldman Sachs International	07/18/17	GBP	24.10	38,000	(613)
GlaxoSmithKline PLC	Call	Deutsche Bank AG	07/18/17	GBP	17.42	60,000	(375)
Novartis AG, Registered Shares	Call	Credit Suisse International	07/18/17		80.95	33,000	(30,446)
Unilever PLC	Call	Goldman Sachs International	07/18/17	GBP	44.68	14,000	(1,313)
Metro Bank PLC	Call	Credit Suisse International	07/19/17	GBP	38.40	10,400	(1,482)
Aalberts Industries NV	Call	Goldman Sachs International	07/26/17		36.35	25,500	(2,941)
AIA Group Ltd.	Call	Morgan Stanley & Co. International PLC	07/26/17	HKD	55.86	620,000	(135,947)
AstraZeneca PLC	Call	Goldman Sachs International	07/26/17	GBP	55.00	30,000	(47,329)
bpost SA	Call	Morgan Stanley & Co. International PLC	07/26/17	EUR	22.40	37,500	(2,557)
British American Tobacco PLC	Call	Goldman Sachs International	07/26/17	GBP	55.53	97,500	(22,841)
Diageo PLC ADR	Call	Credit Suisse International	07/26/17	GBP	23.63	195,800	(19,621)
GlaxoSmithKline PLC	Call	Credit Suisse International	07/26/17	GBP	17.38	146,000	(3,591)
Heineken NV	Call	Deutsche Bank AG	07/26/17	EUR	88.34	22,500	(8,782)
Imperial Brands PLC	Call	Credit Suisse International	07/26/17	GBP	36.79	40,000	(2,221)
Kone OYJ, Class B	Call	Credit Suisse International	07/26/17	EUR	47.39	73,000	(22,078)
Koninklijke Philips N.V.	Call	HSBC Bank PLC	07/26/17		32.68	74,500	(14,920)
Llyods Banking Group PLC	Call	Credit Suisse International	07/26/17	GBP	0.71	1,735,000	(427)
Naspers Ltd., Class N	Call	Credit Suisse International	07/26/17		2,648.44	24,500	(93,327)
Nestle SA, Registered Shares	Call	Morgan Stanley & Co. International PLC	07/26/17		82.37	54,500	(122,005)
Novartis AG, Registered Shares	Call	Credit Suisse International	07/26/17		79.66	55,800	(103,600)
Novo Nordisk A/S, Class B	Call	Goldman Sachs International	07/26/17		297.67	46,000	(12,719)
Sanofi SA	Call	Goldman Sachs International	07/26/17		87.10	38,800	(29,998)
SGS SA, Registered Shares	Call	Morgan Stanley & Co. International PLC	07/26/17		2,353.79	900	(27,043)
Svenska Handelsbanken AB, Class A	Call	Morgan Stanley & Co. International PLC	07/26/17	SEK	125.87	169,000	(9,901)
Taiwan Semiconductor Manufacturing Co. Ltd.	Call	Deutsche Bank AG	07/26/17		211.55	1,328,000	(82,110)
Unilever PLC	Call	HSBC Bank PLC	07/26/17	GBP	43.92	93,000	(31,729)
Dassault Aviation SA	Call	Goldman Sachs International	07/27/17		1,339.66	1,000	(486)
Deutsche Post AG, Registered Shares	Call	Morgan Stanley & Co. International PLC	07/27/17		33.99	124,500	(30,347)
Rogers Communications, Inc., Class B	Call	Deutsche Bank AG	07/27/17		64.09	72,000	(11,738)
Royal Dutch Shell PLC, Class B	Call	Credit Suisse International	07/27/17		22.37	65,000	(1,637)
Unilever PLC	Call	Goldman Sachs International	07/27/17		43.65	22,000	(8,284)
3M Co.	Call	Deutsche Bank AG	08/01/17		209.98	16,000	(49,439)
Imperial Brands PLC	Call	Bank of America N.A.	08/01/17		37.40	50,000	(4,178)
•	Call	Goldman Sachs International	08/01/17		4,163.13	64,700	(11,064)
Japan Tobacco, Inc. Anheuser-Busch InBev SA	Call		08/01/17		103.44	,	` ' '
		2 ,				6,200	(2,853)
Sands China Ltd.	Call	JPMorgan Chase Bank N.A.	08/02/17		38.19	410,400	(12,779)
ANTA Sports Products Ltd.	Call	Citibank N.A.	08/04/17		23.77	434,000	(126,086)
AstraZeneca PLC	Call	Deutsche Bank AG	08/04/17		54.32	52,000	(86,614)
BNP Paribas SA	Call	Goldman Sachs International	08/04/17		65.46	43,400	(46,556)
bpost SA	Call	e ,	08/04/17		22.40	37,500	(2,577)
British American Tobacco PLC	Call	Goldman Sachs International	08/04/17		55.80	97,500	(30,508)
Buzzi Unicem SpA	Call	Goldman Sachs International	08/04/17		24.10	27,500	(3,187)
Dassault Aviation SA	Call	Credit Suisse International	08/04/17	EUR	1,335.87	1,000	(1,344)

Deutsche Post AG, Registered Shares	Call	Morgan Stanley & Co. International PLC	08/04/17	EUR	34.15	124,500	(44,508)
Givaudan SA, Registered Shares	Call	Bank of America N.A.	08/04/17	CHF	2,009.00	1,300	(13,270)
Heineken NV	Call	Credit Suisse International	08/04/17	EUR	88.77	22,500	(12,331)
Kone OYJ, Class B	Call	Credit Suisse International	08/04/17	EUR	47.62	73,000	(16,628)
Llyods Banking Group PLC	Call	Goldman Sachs International	08/04/17	GBP	0.71	1,735,000	(10,478)

See Notes to Financial Statements.

BlackRock Enhanced International Dividend Trust (BGY)

OTC Options Written (continued)
-----------------------	------------

	e 3,203)
Nestle SA, Registered Shares Call Morgan Stanley & Co. International PLC 08/04/17 CHF 82.37 54,500 \$ (13)	
	3.203)
$N'_{11} + 1 = 0 = 1 + 1$ $C_{-1} + 1 = 0 = 0 = 0 = 0 = 0 = 0 = 0 = 0 = 0 =$	' '
	5,453)
Novartis AG, Registered Shares Call Morgan Stanley & Co. International PLC 08/04/17 CHF 80.38 49,300 (7),187)
Novo Nordisk A/S, Class B Call Deutsche Bank AG 08/04/17 DKK 298.39 46,000 (2	1,591)
Royal Dutch Shell PLC, Class B Call Goldman Sachs International 08/04/17 GBP 22.37 65,000 (3,391)
Sanofi SA Call Goldman Sachs International 08/04/17 EUR 87.53 38.800 (3	7,722)
SGS SA, Registered Shares Call Morgan Stanley & Co. International PLC 08/04/17 CHF 2,365.38 900 (2	2,407)
Svenska Handelsbanken AB, Class A Call Morgan Stanley & Co. International PLC 08/04/17 SEK 126.49 169,000 (3,857)
),276)
	5,049)
	2,741)
E · · · · · · · · · · · · · · · · · · ·),082)
· · · · · · · · · · · · · · · · · · ·	5,956)
	5,683)
	0,671)
),870)
	2,989)
	,488)
	5,195)
	5,296)
	0,024)
3M Co. Call Deutsche Bank AG 08/11/17 USD 209.98 16,000 (5	3,739)
Far EasTone Telecommunications Co. Ltd. Call Goldman Sachs International 08/11/17 USD 79.23 594,000 (5,338)
Anheuser-Busch InBev SA Call Goldman Sachs International 08/16/17 EUR 103.08 27,800 (2	2,373)
CNH Industrial NV Call Credit Suisse International 08/16/17 EUR 10.47 22,200 (3,638)
Galp Energia SGPS SA Call Bank of America N.A. 08/16/17 EUR 13.44 50,000 (1	5,567)
GlaxoSmithKline PLC Call Goldman Sachs International 08/16/17 GBP 17.39 109,300 (5,557)
Kion Group AG Call Goldman Sachs International 08/16/17 EUR 70.14 12,000 (1	2,457)
Rio Tinto PLC Call Credit Suisse International 08/16/17 GBP 32.48 23.500 (3	,970)
	3,924)
	3,110)
	3,465)
	1,915)
· · · · · · · · · · · · · · · · · · ·	3,765)
	3,586)
	7,990)
	,766)
	5,258)
	2,830)
	5,597)
	1,566)
	1,021)
	2,286)
·	,041)
Total \$ (3,15	5,810)

Transactions in Options Written for the Period Ended June 30, 2017

	Calls				
		Premiums			
	Contracts	(000)	Received		
Outstanding options, beginning of period	26,890,966		\$ 7,043,095		
Options written	115,196,708	537,000	28,950,499		
Options exercised	(45,368,196)		(270,455)		
Options expired	(41,710)		(11,883,854)		
Options closed	(83,732,417)	(537,000)	(19,088,143)		

Outstanding options, end of period 12,945,351

\$ 4,751,142

As of period end, the value of portfolio securities subject to covered call options written was \$269,002,467.

See Notes to Financial Statements.

56 SEMI-ANNUAL REPORT

JUNE 30, 2017

BlackRock Enhanced International Dividend Trust (BGY)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

					Foreign			
					Currency	Interest		
		Commodity	Credit	Equity	Exchange	Rate	Other	
Liabilities Deriv	ative Financial Instruments	Contracts	Contracts	Contracts	Contracts	Contracts	Contracts	Total
Options written	Options written, at							
	value			\$ 3,858,188				\$ 3,858,188

For the six months ended June 30, 2017, the effect of derivative financial instruments in the Statements of Operations was as follows:

Net Realized Gain (Loss) from: Forward foreign currency exchange Commodity Contracts	Credit Contracts	Equity Contracts	Foreign Currency Exchange Contracts	Interest Rate Contracts	Other Contracts	Total
contracts Futures contracts		\$ 344.941	\$ (2)			\$ (2) 344,941
Options purchased ¹		(21,287)				(21,287)
Options written		(11,548,380)				(11,548,380)
Total		\$ (11,224,726)	\$ (2)			\$ (11,224,728)
Net Change in Unrealized Appreciation (Depreciation) on: Options written Options purchased are included in net realized gain (loss) from	n investments.	\$ 2,512,044				\$ 2,512,044

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Financial futures contracts:

Average notional value of contracts long \$28,250,695\frac{1}{2}{2} Forward foreign currency exchange contracts:

Average amounts sold in USD \$4,828\frac{1}{2}\$ Options:

Average value of option contracts purchased \$464,884\frac{1}{2}\$ Average value of option contracts written \$6,612,031

For more information about the Trust s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments Offsetting as of Period End

The Trust s derivative assets and liabilities (by type) are as follows:

Derivative Financial Instruments Assets Liabilities

¹ Actual amounts for the period are shown due to limited outstanding derivative financial instruments as of each quarter end.

Options \$3,858,188

Derivatives not subject to a Master Netting Agreement or similar agreement (MNA)

(702,378)

Total derivative assets and liabilities subject to an MNA

\$ 3,155,810

The following table presents the Trust $\,$ s derivative liabilities by counterparty net of amounts available for offset under an Master Netting Agreement ($\,$ MNA $\,$) and net of the related collateral pledged by the Trust:

	Derivative Liabilities					
	Subject to an	Derivatives	Non-cash	Cash	Net Amount of	
	MNA	Available Collateral		Collateral	Derivative	
Counterparty	by Counterparty	for Offset	Pledged ¹	Pledged	Liabilities ²	
Bank of America N.A.	\$ 144,051			\$ (90,000)	\$ 54,051	
Citibank N.A.	242,106			(242,000)	106	
Credit Suisse International	437,976		\$ (437,976)			
Deutsche Bank AG	592,848		(592,848)			
Goldman Sachs International	617,737		(617,737)			
HSBC Bank PLC	46,649				46,649	
JPMorgan Chase Bank N.A.	280,761			(260,000)	20,761	

See Notes to Financial Statements.

BlackRock Enhanced International Dividend Trust (BGY)

Counterparty	Su	tive Liabilities bject to an MNA counterparty	Derivatives Available for Offset	Non-cash Collateral Pledged ¹	Cash Collateral Pledged	Net Amount of Derivative Liabilities ²
Morgan Stanley & Co. International PLC UBS AG	\$	718,767 74,915		\$ (718,767) (17,551)	\$ (57,364)	
Total	\$	3,155,810		\$ (2,384,879)	\$ (649,364)	\$ 121,567

¹ Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust s policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust s investments and derivative financial instruments categorized in the disclosure hierarchy:

Assets: Investments: Common Stocks: Australia \$ 19,143,721 \$ 19,143,721 Belgium 13,942,194 13,942,194 13,942,194 13,942,194 13,942,194 Colspan="3">Colspan="3"
Common Stocks: Australia \$ 19,143,721 \$ 19,143,721 Belgium 13,942,194 13,942,194 Canada \$ 52,535,840 52,535,840 China 10,944,830 17,585,653 28,530,483 Denmark 9,897,513 9,897,513 Finland 18,591,833 18,591,833 France 38,900,452 38,900,452
Australia \$ 19,143,721 \$ 19,143,721 Belgium 13,942,194 13,942,194 Canada \$ 52,535,840 52,535,840 China 10,944,830 17,585,653 28,530,483 Denmark 9,897,513 9,897,513 Finland 18,591,833 18,591,833 France 38,900,452 38,900,452
Belgium 13,942,194 13,942,194 Canada \$ 52,535,840 52,535,840 China 10,944,830 17,585,653 28,530,483 Denmark 9,897,513 9,897,513 Finland 18,591,833 18,591,833 France 38,900,452 38,900,452
Canada \$ 52,535,840 52,535,840 China 10,944,830 17,585,653 28,530,483 Denmark 9,897,513 9,897,513 Finland 18,591,833 18,591,833 France 38,900,452 38,900,452
China 10,944,830 17,585,653 28,530,483 Denmark 9,897,513 9,897,513 Finland 18,591,833 18,591,833 France 38,900,452 38,900,452
Denmark 9,897,513 9,897,513 Finland 18,591,833 18,591,833 France 38,900,452 38,900,452
Finland 18,591,833 18,591,833 France 38,900,452 38,900,452
France 38,900,452 38,900,452
Germany 37.552,739 37.552,739
Hong Kong 430,210 16,697,756 17,127,966
India 10,557,541 10,557,541
Ireland 6,933,958 6,933,958
Italy 2,189,550 2,189,550
Japan 27,744,149 27,744,149
Netherlands 37,769,289 37,769,289
Norway 281,896 281,896
Portugal 7,373,879 7,373,879
South Africa 10,559,335 10,559,335
South Korea 14,442,371 14,442,371
Sweden 21,066,551 21,066,551
Switzerland 90,743,936 90,743,936
Taiwan 23,568,123 23,568,123
United Kingdom 159,934,057 159,934,057
United States 34,176,301 34,176,301
Investment Companies 21,856,120 21,856,120
Preferred Stocks \$ 5,853,005
Short-Term Securities 30,845,879 30,845,879
Total \$157,723,138 \$578,542,538 \$5,853,005 \$742,118,681
Derivative Financial Instruments ¹ Liabilities:
Equity contracts (616,054) (3,242,134) (3,858,188)
Derivative financial instruments are options written, which are shown at value.

² Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

	Transfers into	Tı	ransfers out of	T	ransfers into	Transfers out of
	Level 1		Level 1 ¹		Level 2 ¹	Level 2
Assets:						
Long-Term Investments:						
Common Stocks		\$	(18,063,836)	\$	18,063,836	
External pricing service used to reflect any significant market moven	nents between the tin	ne the	Trust valued such	h for	eign securities a	and the earlier

closing of foreign markets.

See Notes to Financial Statements.

BlackRock Enhanced International Dividend Trust (BGY)

A reconciliation of Level 3 investments is presented when the Trust had a significant amount of Level 3 investments at the beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

	Preferred	
	Stocks	Total
Assets:		
Opening Balance, as of December 31, 2016	\$ 15,855,374	\$ 15,855,374
Transfers into Level 3		
Transfers out of Level 3		
Accrued discounts/premiums		
Net realized gain (loss)		
Net change in unrealized appreciation (depreciation) ^{1,2}	(10,002,369)	(10,002,369)
Purchases		
Sales		
Closing Balance, as of June 30, 2017	\$ 5,853,005	\$ 5,853,005
Net change in unrealized appreciation (depreciation) on investments still held at June 30, 2017 ²	\$ (10,002,369)	\$ (10,002,369)

¹ Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations.

See Notes to Financial Statements.

² Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on derivative financial instruments still held at June 30, 2017 is generally due to derivative financial instruments no longer held or categorized as Level 3 at period end.

Schedule of Investments June 30, 2017 (Unaudited)

BlackRock Health Sciences Trust (BME)

(Percentages shown are based on Net Assets)

Common Stocks	Shares	Value
Biotechnology 23.5% AbbVie, Inc. (a)	39,586	\$ 2,870,381
Acceleron Pharma, Inc. (a)(b)	46,400	
Acerta Pharma BV, Series B, (Acquired 2/01/16, cost \$986,402) (c)(d)	17,146,440	1,410,096 1,462,591
Agios Pharmaceuticals, Inc. (a)(b) Alder Biopharmaceuticals, Inc. (b)	9,600 5,829	493,920 66,742
1		
Always Planta systicals Inc. (a)(b)	17,800	1,031,866
Alnylam Pharmaceuticals, Inc. (a)(b)	19,000	1,515,440
Amgen, Inc. (a)	61,422	10,578,711
Aquinox Pharmaceuticals, Inc. (a)(b)	17,531	246,661
Audentes Therapeutics, Inc. (b)	10,083	192,888
Avexis, Inc. (a)(b)	17,252	1,417,424
Biogen, Inc. (a)(b)	24,048	6,525,665
Biohaven Pharmaceutical Holding Co. Ltd. (b)	13,650	341,250
BioMarin Pharmaceutical, Inc. (a)(b)	18,200	1,652,924
Bioverativ, Inc. (a)(b)	11,674	702,425
Celgene Corp. (a)(b)	97,986	12,725,442
Galapagos NV ADR (a)(b)	4,200	321,384
Genomic Health, Inc. (a)(b)	16,500	537,075
Gilead Sciences, Inc. (a)	67,200	4,756,416
Global Blood Therapeutics, Inc. (a)(b)	16,088	440,007
Halozyme Therapeutics, Inc. (a)(b)	49,200	630,744
Incyte Corp. (a)(b)	14,500	1,825,695
Iovance Biotherapeutics, Inc. (b)	62,723	461,014
Karyopharm Therapeutics, Inc. (a)(b)	6,500	58,825
Myovant Sciences, Ltd. (b)	29,453	344,600
Otonomy, Inc. (b)	9,400	177,190
Ovid therapeutics, Inc. (b)	4,600	48,254
Prothena Corp. PLC (b)	2,244	121,445
PTC Therapeutics, Inc. (a)(b)	15,700	287,781
Regeneron Pharmaceuticals, Inc. (a)(b)	9,358	4,596,088
REGENXBIO, Inc. (b)	36,250	715,938
Sage Therapeutics, Inc. (a)(b)	15,752	1,254,489
Sarepta Therapeutics, Inc. (a)(b)	37,450	1,262,440
Seattle Genetics, Inc. (a)(b)	22,767	1,177,965
Spark Therapeutics, Inc. (a)(b)	4,600	274,804
Syndax Pharmaceuticals, Inc. (b)	52,584	734,598
TESARO, Inc. (a)(b)	18,431	2,577,760
Tocagen, Inc. (b)	11,583	139,343
Ultragenyx Pharmaceutical, Inc. (a)(b)	15,100	937,861
Vertex Pharmaceuticals, Inc. (a)(b)	60,905	7,848,827
votex i harmaceateaus, no. (a)(b)	00,203	7,010,027
Diversified Consumer Services 0.5%		74,764,969
Service Corp. International	43,300	1,448,385
Health Care Equipment & Supplies 24.8%	43,300	1,770,303
Abbott Laboratories (a)	110,500	5,371,405
Baxter International, Inc. (a)	138,900	8,409,006
Becton Dickinson & Co. (a)	22,233	4,337,881
Boston Scientific Corp. (a)(b)	368,184	
• * * * * *		10,206,060
C.R. Bard, Inc.	23,653	7,476,950
Edwards Lifesciences Corp. (a)(b)	14,300	1,690,832
Hologic, Inc. (a)(b)	84,500	3,834,610
Intuitive Surgical, Inc. (a)(b)	5,700	5,331,609
iRhythm Technologies, Inc. (a)(b)	7,183	305,206
Masimo Corp. (a)(b)	21,500	1,960,370
Medtronic PLC (a)	194,100	17,226,375
ResMed, Inc.	20,000	1,557,400
Stryker Corp. (a)	68,300	9,478,674
Varian Medical Systems, Inc. (a)(b)	15,100	1,558,169

		78,744,547
Health Care Providers & Services 28.6%		
Aetna, Inc. (a)	44,311	6,727,739
Amedisys, Inc. (b)	58,660	3,684,434
AmerisourceBergen Corp. (a)	15,300	1,446,309
Anthem, Inc. Common Stocks	50,300 Shares	9,462,939 Value
Health Care Providers & Services (continued)	Shares	value
Cardinal Health, Inc. (a)	36,830	\$ 2,869,794
Centene Corp. (b)	35,300	2,819,764
Cigna Corp. (a)	46,100	7,716,679
DaVita, Inc. (a)(b)	64,994	4,209,011
HCA Holdings, Inc. (a)(b)	35,894	3,129,957
HealthEquity, Inc. (b)	12,500	622,875
Humana, Inc. (a)	39,200	9,432,304
McKesson Corp. (a)	16,100	2,649,094
Quest Diagnostics, Inc. (a)	57,300	6,369,468
Teladoc, Inc. (a)(b)	20,900	725,230
UnitedHealth Group, Inc. (a)	136,402	25,291,659
Universal Health Services, Inc., Class B (a)	19,500	2,380,560
WellCare Health Plans, Inc. (a)(b)	6,300	1,131,228
		90,669,044
Life Sciences Tools & Services 2.1%		
Agilent Technologies, Inc.	38,500	2,283,435
Thermo Fisher Scientific, Inc. (a)	23,100	4,030,257
Wuxi Biologics Cayman, Inc. (b)(e)	134,500	505,616
		6,819,308
Pharmaceuticals 20.6%		2,022,000
Allergan PLC (a)	37,185	9,039,302
AstraZeneca PLC	38,776	2,597,353
Bristol-Myers Squibb Co. (a)	97,162	5,413,867
Chugai Pharmaceutical Co. Ltd.	8,100	303,474
Dermira, Inc. (a)(b)	22,100	643,994
Eli Lilly & Co. (a)	92,100	7,579,830
GlaxoSmithKline PLC	75,300	1,602,930
Intra-Cellular Therapies, Inc. (b)	13,701	170,166
Jazz Pharmaceuticals PLC (a)(b)	11,400	1,772,700
Johnson & Johnson (a)	63,770	8,436,133
Mallinckrodt PLC (a)(b)	16,200	725,922
Merck & Co., Inc. (a)	91,000	5,832,190
Merck KGaA	28,400	3,436,362
Mylan NV (a)(b)	66,400	2,577,648
Novartis AG ADR	9,900	826,353
Pacira Pharmaceuticals, Inc. (a)(b)	7,800	372,060
Pfizer, Inc. (a)	118,398	3,976,989
Roche Holding AG	14,500	3,704,965
Sanofi SA	15,400	1,475,626
Sanofi SA ADR (a) Therefore Pionharms Inc. (a)(b)	37,000	1,772,670
Theravance Biopharma, Inc. (a)(b)	4,700 47,600	187,248 2,969,288
Zoetis, Inc. (a)	47,000	2,909,200
		65,417,070
Total Common Stocks 100.1%		317,863,323
Preferred Stock		
Biotechnology 0.1%		
Ovid Therapeutics Inc., (Acquired 8/7/15, Cost \$503,166), 0.00% (b)(c)(d)	37,565	380,484
Total Preferred Stocks 0.1%		380,484
Diahta		
Rights Biotechnology 0.1%		
Dyax Corp., CVR (b)(d)	61,727	141,355
2 jun 2014, 0 i ii (0)(a)	01,727	171,333

Total Long-Term Investments (Cost \$210,031,572) 100.3%

318,385,162

See Notes to Financial Statements.

60 SEMI-ANNUAL REPORT

JUNE 30, 2017

BlackRock Health Sciences Trust (BME)

Short-Term Securities	Shares		Value
BlackRock Liquidity Funds, T-Fund, Institutional Class, 0.84% (f)(g)	2,281,623	\$	2,281,623
Total Short-Term Securities			
(Cost \$2,281,623) 0.7%			2,281,623
Total Investments Before Options Written			
(Cost \$212,313,195) 101.0%			320,666,785
(COST #212,010,170) 10110.70			220,000,702
Ontions Written			
Options Written			
(Premiums Received \$2,322,880) (1.1)%			(3,438,994)
Total Investments, Net of Options Written			
(Cost \$209,990,315) 99.9%			317,227,791
Other Assets Less Liabilities 0.1%			308,005
Net Assets 100.0%		\$	317,535,796
		Ψ	,,

Notes to Schedule of Investments

- (a) All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.
- (b) Non-income producing security.
- (c) Restricted security as to resale, excluding 144A securities. As of period end, the Trust held restricted securities with a current value of \$1,843,075 and an original cost of \$1,489,568, which was 0.6% of its net assets.
- (d) Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.
- (e) Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.
- (f) During the six months ended June 30, 2017, investments in issuers considered to be affiliates of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Shares

	Held at	Net	Shares Held at June 30,	Value at June 30,		Net Realiz	Change in Unrealized edAppreciation
Affiliate	December 31, 2016	Activity	2017	2017	Income	Gain	(Depreciation)
BlackRock Liquidity Funds, T-Fund, Institution	al						
Class	8,611,967	(6,330,344)	2,281,623	\$ 2,281,623	\$ 16,585		
SL Liquidity Series, LLC, Money Market Series	126,889	(126,889)			1,5841		
Total					\$ 18,169		

¹ Represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

(g) Current yield as of period end.

For Trust compliance purposes, the Trust sindustry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine industry sub-classifications for reporting ease.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

	Put/	Expiration	Strike			
Description	Call	Date	P	rice	Contracts	Value
Abbott Laboratories	Call	7/07/17	USD	44.00	113	\$ (51,133)
Allergan PLC	Call	7/07/17	USD	225.00	63	(115,290)
Baxter International, Inc.	Call	7/07/17	USD	59.50	134	(16,415)
Bristol-Myers Squibb Co.	Call	7/07/17	USD	55.50	165	(12,292)
Celgene Corp.	Call	7/07/17	USD	118.00	226	(257,640)
Eli Lilly & Co.	Call	7/07/17	USD	82.00	112	(9,800)
Humana, Inc.	Call	7/07/17	USD	235.00	22	(14,630)
Medtronic PLC	Call	7/07/17	USD	86.00	309	(86,366)
Merck & Co., Inc.	Call	7/07/17	USD	64.50	45	(1,372)
UnitedHealth Group, Inc.	Call	7/07/17	USD	177.50	70	(56,525)
Becton Dickinson & Co.	Call	7/10/17	USD	187.00	75	(64,000)
Dermira, Inc.	Call	7/12/17	USD	29.01	77	(7,831)
Amgen, Inc.	Call	7/14/17	USD	157.50	87	(129,195)
Celgene Corp.	Call	7/14/17	USD	117.00	39	(52,065)

See Notes to Financial Statements.

BlackRock Health Sciences Trust (BME)

Exchange-Traded Options Written (continued)

Exchange-Traded Options Written (continued)	75.44	· ·	α.			
Description	Put/ Call	Expiration Date		rike rice	Contracts	Value
Cigna Corp.	Call	7/14/17	USD	170.00	101	\$ (12,120)
Eli Lilly & Co.	Call	7/14/17	USD	82.50	113	(9,605)
Merck & Co., Inc.	Call	7/14/17	USD	64.50	55	(2,942)
Thermo Fisher Scientific, Inc.	Call	7/14/17	USD	172.40	38	(14,518)
UnitedHealth Group, Inc.	Call	7/14/17	USD	182.50	40	(16,500)
Acceleron Pharma, Inc.	Call	7/21/17	USD	30.00	162	(38,475)
Aetna, Inc.	Call	7/21/17	USD	140.00	30	(35,325)
Alkermes PLC	Call	7/21/17	USD	60.00	49	(5,512)
Alnylam Pharmaceuticals, Inc.	Call	7/21/17	USD	80.00	17	(5,780)
Amgen, Inc.	Call	7/21/17	USD	165.00	75	(61,500)
Avexis, Inc.	Call	7/21/17	USD	85.00	60	(15,450)
Biogen, Inc.	Call	7/21/17	USD	265.00	24	(23,160)
BioMarin Pharmaceutical, Inc.	Call	7/21/17	USD	95.00	61	(10,370)
Bioverativ Inc.	Call	7/21/17	USD	55.00	40	(23,000)
Boston Scientific Corp.	Call	7/21/17	USD	27.00	287	(27,409)
Celgene Corp.	Call	7/21/17	USD	120.00	38	(39,900)
DaVita, Inc.	Call	7/21/17	USD	67.50	227	(8,512)
Edwards Lifesciences Corp.	Call	7/21/17	USD	115.00	50	(22,500)
Eli Lilly & Co.	Call	7/21/17	USD	80.00	87	(24,621)
Galapagos NV ADR	Call	7/21/17	USD	90.00	14	(7,000)
Gilead Sciences, Inc. Global Blood Therapeutics, Inc.	Call Call	7/21/17 7/21/17	USD USD	67.50 30.00	177 56	(64,605) (5,180)
Hologic, Inc.	Call	7/21/17	USD	45.00	295	(30,238)
Humana, Inc.	Call	7/21/17	USD	235.00	53	(43,195)
Incyte Corp.	Call	7/21/17	USD	125.00	50	(26,000)
Intuitive Surgical, Inc.	Call	7/21/17	USD	865.00	19	(144,115)
Jazz Pharmaceuticals PLC	Call	7/21/17	USD	155.00	13	(5,590)
Johnson & Johnson	Call	7/21/17	USD	127.52	108	(59,944)
Karyopharm Therapeutics, Inc.	Call	7/21/17	USD	10.00	22	(550)
Medtronic PLC	Call	7/21/17	USD	87.50	132	(22,308)
Pacira Pharmaceuticals, Inc.	Call	7/21/17	USD	45.00	27	(10,665)
Pfizer, Inc.	Call	7/21/17	USD	33.00	56	(4,452)
PTC Therapeutics, Inc.	Call	7/21/17	USD	17.00	54	(10,530)
Quest Diagnostics, Inc.	Call	7/21/17	USD	110.00	97	(17,703)
Sage Therapeutics, Inc.	Call	7/21/17	USD	90.00	55	(8,525)
Sanofi SA ADR	Call	7/21/17	USD	50.00	108	(3,240)
Spark Therapeutics, Inc.	Call	7/21/17	USD	60.00	20	(6,250)
Stryker Corp.	Call	7/21/17	USD	140.00	122	(17,385)
Teladoc, Inc.	Call	7/21/17	USD	35.00	73	(9,490)
Theravance Biopharma, Inc.	Call	7/21/17	USD	40.00	16	(2,960)
Thermo Fisher Scientific, Inc.	Call	7/21/17	USD	175.00	42	(10,710)
Ultragenyx Pharmaceutical, Inc. UnitedHealth Group, Inc.	Call Call	7/21/17 7/21/17	USD USD	65.00 180.00	52 113	(11,310)
UnitedHealth Group, Inc.	Call	7/21/17	USD	185.00	41	(82,208) (15,273)
Universal Health Services, Inc., Class B	Call	7/21/17	USD	120.00	70	(26,600)
Vertex Pharmaceuticals, Inc.	Call	7/21/17	USD	125.00	63	(44,730)
WellCare Health Plans, Inc.	Call	7/21/17	USD	175.00	25	(16,000)
Zoetis, Inc.	Call	7/21/17	USD	60.35	62	(14,811)
Genomic Health, Inc.	Call	7/25/17	USD	33.01	57	(5,707)
Abbott Laboratories	Call	7/28/17	USD	48.00	121	(15,670)
AmerisourceBergen Corp.	Call	7/28/17	USD	98.00	33	(2,887)
Baxter International, Inc.	Call	7/28/17	USD	60.01	133	(16,601)
Boston Scientific Corp.	Call	7/28/17	USD	28.00	321	(19,581)
HCA Holdings, Inc	Call	7/28/17	USD	86.00	81	(22,680)
Jazz Pharmaceuticals PLC	Call	7/28/17	USD	155.00	26	(11,960)
Mallinckrodt PLC	Call	7/28/17	USD	46.00	56	(9,100)
McKesson Corp.	Call	7/28/17	USD	167.50	53	(16,033)
Merck & Co., Inc.	Call	7/28/17	USD	66.50	59	(2,684)
Regeneron Pharmaceuticals, Inc.	Call	7/28/17	USD	525.00	16	(10,240)
UnitedHealth Group, Inc.	Call	7/28/17	USD	182.50	172	(97,610)
UnitedHealth Group, Inc.	Call	7/28/17	USD	185.00	41	(17,323)

Vertex Pharmaceuticals, Inc.	Call	7/28/17	USD	129.00	129	(79,980)
Zoetis, Inc.	Call	7/31/17	USD	63.00	100	(7,258)
AbbVie, Inc.	Call	8/04/17	USD	73.00	66	(7,161)
Amgen, Inc.	Call	8/04/17	USD	177.50	52	(12,090)

See Notes to Financial Statements.

BlackRock Health Sciences Trust (BME)

Description Call Nate Price Contracts Value Biogen, Inc. Call 8/04/17 USD 280.00 57 \$ (33,060) Boston Scientific Corp. Call 8/04/17 USD 2.00 83 (5,851) Bristol-Myers Squibb Co. Call 8/04/17 USD 8.70 175 (24,238) Cardinal Health, Inc. Call 8/04/17 USD 8.70 64 (6,560) Gliead Sciences, Inc. Call 8/04/17 USD 72.50 58 (8,642) Johnson & Johnson Call 8/04/17 USD 8.50 1115 (18,630) Medtronic PLC Call 8/04/17 USD 8.50 114 (11,856) Mylan NV Call 8/04/17 USD 9.50 114 (11,876) Alleran Inc. Call 8/04/17 USD 9.50 123 (22,2620) Actan, Inc. Call 8/04/17 USD 9.50 132 <td< th=""></td<>
Bosson Scientific Corp. Call 8/04/17 USD 28.00 83 (5,851) Bristol-Myers Squibb Co. Call 8/04/17 USD 57.00 175 (24,238) Cardinal Health, Inc. Call 8/04/17 USD 80.50 64 (6,560) Gilead Sciences, Inc. Call 8/04/17 USD 72.50 58 (8,642) Johnson & Johnson Call 8/04/17 USD 134.00 115 (18,630) Metrosic PLC Call 8/04/17 USD 89.50 245 (25,722) Merck & Co., Inc. Call 8/04/17 USD 65.00 114 (11,856) Mylan NV Call 8/04/17 USD 65.00 114 (11,470) Allergan PLC Call 8/11/17 USD 95.00 232 22,2620 Abbvic, Inc. Call 8/11/17 USD 94.00 152 (14,896) Abbvic, Inc. Call 8/11/17 USD 70.00
Bristol-Myers Squibb Co. Call 8/04/17 USD 57.00 175 (24,238) Cardinal Health, Inc. Call 8/04/17 USD 87.50 64 (6,560) Gilead Sciences, Inc. Call 8/04/17 USD 17.50 58 8(6,642) Johnson & Johnson Call 8/04/17 USD 134,00 115 (18,630) Methronic PLC Call 8/04/17 USD 85.00 245 (25,725) Mylan NV Call 8/04/17 USD 39.50 232 (22,620) Aten, Inc. Call 8/11/17 USD 39.50 232 (22,620) Allergan PLC Call 8/11/17 USD 39.50 232 (22,620) AmerisourceBergen Corp. Call 8/11/17 USD 39.50 232 (22,620) Abbott Laboratories Call 8/11/17 USD 97.00 20 (3,750) Abbot Laboratories Call 8/18/17 USD 99.00
Cardinal Health, Înc. Call 8/04/17 USD 80.50 64 (6,560) Gilead Sciences, Inc. Call 8/04/17 USD 72.50 58 8(,642) Johnson & Johnson Call 8/04/17 USD 134.00 115 (18,630) Medtronic PLC Call 8/04/17 USD 89.50 245 (25,725) Merck & Co., Inc. Call 8/04/17 USD 95.00 114 (11,856) Mylan NV Call 8/04/17 USD 95.00 114 (101,470) Allergan PLC Call 8/08/17 USD 95.00 232 (22,620) Albort Laboratories Call 8/11/17 USD 95.00 232 (23,626) Abbvie, Inc. Call 8/11/17 USD 95.00 23 (23,750) Abbvie, Inc. Call 8/18/17 USD 90.00 152 (14,896) Abbvie, Inc. Call 8/18/17 USD 70.00 78<
Gilead Sciences, Inc. Call 8/04/17 USD 72.50 58 (8,642) Johnson Call 8/04/17 USD 134.00 115 (18,630) Medrronic PLC Call 8/04/17 USD 189.00 245 (25,725) Merck & Co., Inc. Call 8/04/17 USD 65.00 114 (11,856) Mylan NV Call 8/04/17 USD 39.50 232 (22,620) Actma, Inc. Call 8/11/17 USD 39.50 32 (22,620) Allergan PLC Call 8/11/17 USD 97.00 20 (3,750) AmerisourceBergen Corp. Call 8/11/17 USD 97.00 20 (3,750) Abbot Laboratories Call 8/18/17 USD 97.00 20 (3,750) Abbrie, Inc. Call 8/18/17 USD 90.00 33 (3,712) Alkermes PLC Call 8/18/17 USD 96.00 33 <td< td=""></td<>
Dohnson & Johnson Call 8/04/17 USD 134.00 115 (18,630) Medronic PLC Call 8/04/17 USD 89.50 245 (25,725) C25,725 Merck & Co., Inc. Call 8/04/17 USD 65.00 114 (11,856) Mylan NV Call 8/04/17 USD 39.50 232 (22,620) Actna, Inc. Call 8/08/17 USD 39.50 232 (22,620) Actna, Inc. Call 8/11/17 USD 252.50 67 (19,363) AmerisourceBergen Corp. Call 8/11/17 USD 97.00 20 (3,750) Abbott Laboratories Call 8/18/17 USD 97.00 70.00 78 (23,946) AbbVie, Inc. Call 8/18/17 USD 60.00 33 (3,712) Albermaceuticals, Inc. Call 8/18/17 USD 60.00 33 (3,712) Alphan Pharmaceuticals, Inc. Call 8/18/17 USD 60.00 33 (3,712) Alphan Pharmaceuticals, Inc. Call 8/18/17 USD 60.00 13 (1,592) Alphan Pharmaceuticals, Inc. Call 8/18/17 USD 60.00 177 (35,046) Approximate Corp. Call 8/18/17 USD 15.00 61 (5,490) Approximate Corp. Call 8/18/17 USD 27.00 514 (69,647) Call 8/18/17 USD 28.00 83 (6,391) Cardinal Health, Inc. Call 8/18/17 USD 28.00 83 (6,391) Cardinal Health, Inc. Call 8/18/17 USD 28.00 83 (6,391) Cardinal Health, Inc. Call 8/18/17 USD 175.00 60 (13,200) Call 8/18/17 USD 175.00 Call Call 8/18/1
Medtronic PLC Call 8/04/17 USD 89.50 245 (25,725) Merck & Co., Inc. Call 8/04/17 USD 65.00 114 (11,856) Merck & Co., Inc. Call 8/04/17 USD 39.50 232 (22,620) Aetna, Inc. Call 8/08/17 USD 141.90 104 (101,470) Allergan PLC Call 8/11/17 USD 252.50 67 (19,363) AmerisourceBergen Corp. Call 8/11/17 USD 97.00 20 (3,750) Abbott Laboratories Call 8/18/17 USD 49.00 152 (14,896) Abbot Laboratories Call 8/18/17 USD 70.00 78 (23,946) Abbot Laboratories Call 8/18/17 USD 70.00 78 (23,946) Abb Vie, Inc. Call 8/18/17 USD 60.00 33 (3,712) Alkermes PLC Call 8/18/17 USD 60.00
Merck & Co., Inc. Call 8/04/17 USD 65.00 114 (11,856) Mylan NV Call 8/04/17 USD 39,50 232 (22,620) Aetna, Inc. Call 8/08/17 USD 141,90 104 (101,470) Allergan PLC Call 8/11/17 USD 252.50 67 (19,363) AmerisourceBergen Corp. Call 8/11/17 USD 97.00 20 (3,750) Abbott Laboratories Call 8/18/17 USD 99.00 152 (14,896) Agios Pharmaceuticals, Inc. Call 8/18/17 USD 90.00 33 (3,712) Alisemes PLC Call 8/18/17 USD 60.00 33 (3,712) Alisemes PLC Call 8/18/17 USD 60.00 33 (3,712) Alisemes PLC Call 8/18/17 USD 65.00 13 (1,592) Allorylam Pharmaceuticals, Inc. Call 8/18/17 USD 65.00
Mylan NV Call 8/04/17 USD 39.50 232 (22,620) Actna, Inc. Call 8/08/17 USD 141.90 104 (101,470) Allergan PLC Call 8/11/17 USD 252.50 67 (19,363) AmerisourceBergen Corp. Call 8/11/17 USD 97.00 20 (3,750) Abbott Laboratories Call 8/18/17 USD 79.00 78 (23,946) Abbvie, Inc. Call 8/18/17 USD 70.00 78 (23,946) Abbvie, Inc. Call 8/18/17 USD 60.00 33 (3,712) Alkermes PLC Call 8/18/17 USD 60.00 33 (3,712) Alkermes PLC Call 8/18/17 USD 60.00 33 (3,712) Alkermes PLC Call 8/18/17 USD 60.00 13 (1,592) Allyam Pharmaceuticals, Inc. Call 8/18/17 USD 60.00 177
Actina, Inc. Call 8/08/17 USD 141.90 104 (101,470) Allergan PLC Call 8/11/17 USD 252.50 67 (19,363) AmerisourceBergen Corp. Call 8/11/17 USD 97.00 20 (3,750) Abbott Laboratories Call 8/18/17 USD 49.00 152 (14,896) AbbVie, Inc. Call 8/18/17 USD 70.00 78 (23,946) Agios Pharmaceuticals, Inc. Call 8/18/17 USD 60.00 33 (3,712) Alleylam Pharmaceuticals, Inc. Call 8/18/17 USD 60.00 13 (1,592) Allylam Pharmaceuticals, Inc. Call 8/18/17 USD 60.00 13 (1,592) Alujunox Pharmaceuticals, Inc. Call 8/18/17 USD 60.00 177 (35,046) Baxter International, Inc. Call 8/18/17 USD 20.00 177 (35,046) Boston Scientific Corp. Call <
Allergan PLC Call 8/11/17 USD 252.50 67 (19,363) AmerisourceBergen Corp. Call 8/11/17 USD 97.00 20 (3,750) Abbott Laboratories Call 8/18/17 USD 49.00 152 (14,896) AbbVie, Inc. Call 8/18/17 USD 60.00 33 (23,946) Agios Pharmaceuticals, Inc. Call 8/18/17 USD 60.00 33 (3,712) Alkermes PLC Call 8/18/17 USD 65.00 13 (1,592) Alleylam Pharmaceuticals, Inc. Call 8/18/17 USD 60.00 49 (59,045) Apuinox Pharmaceuticals, Inc. Call 8/18/17 USD 70.00 49 (59,045) Apuinox Pharmaceuticals, Inc. Call 8/18/17 USD 70.00 49 (59,045) Baxter International, Inc. Call 8/18/17 USD 15.00 61 (5,490) Boston Scientific Corp. Call 8/1
AmerisourceBergen Corp. Call 8/11/17 USD 97.00 20 (3,750) Abbott Laboratories Call 8/18/17 USD 49.00 152 (14,896) AbbVie, Inc. Call 8/18/17 USD 70.00 78 (23,946) Agios Pharmaceuticals, Inc. Call 8/18/17 USD 65.00 13 (1,592) Alkermes PLC Call 8/18/17 USD 65.00 13 (1,592) Alnylam Pharmaceuticals, Inc. Call 8/18/17 USD 70.00 49 (59,045) Aquinox Pharmaceuticals, Inc. Call 8/18/17 USD 70.00 49 (59,045) Aquinox Pharmaceuticals, Inc. Call 8/18/17 USD 60.00 177 (35,046) Baxter International, Inc. Call 8/18/17 USD 60.00 177 (35,046) Boston Scientific Corp. Call 8/18/17 USD 27.00 514 (69,047) Boston Scientific Corp. Call
Abbott Laboratories Call 8/18/17 USD 49.00 152 (14,896) AbbVie, Inc. Call 8/18/17 USD 70.00 78 (23,946) Agios Pharmaceuticals, Inc. Call 8/18/17 USD 60.00 33 (3,712) Alkermes PLC Call 8/18/17 USD 65.00 13 (1,592) Alpylam Pharmaceuticals, Inc. Call 8/18/17 USD 70.00 49 (59,045) Aquinox Pharmaceuticals, Inc. Call 8/18/17 USD 70.00 49 (59,045) Aquinox Pharmaceuticals, Inc. Call 8/18/17 USD 70.00 49 (59,045) Aquinox Pharmaceuticals, Inc. Call 8/18/17 USD 60.00 177 (35,046) Baxter International, Inc. Call 8/18/17 USD 22.00 514 (69,647) Boston Scientific Corp. Call 8/18/17 USD 22.00 83 (6,391) Cardinal Health, Inc. Call
AbbVie, Inc. Call 8/18/17 USD 70.00 78 (23,946) Agios Pharmaceuticals, Inc. Call 8/18/17 USD 60.00 33 (3,712) Alkernes PLC Call 8/18/17 USD 65.00 13 (1,592) Alnylam Pharmaceuticals, Inc. Call 8/18/17 USD 70.00 49 (59,045) Aquinox Pharmaceuticals, Inc. Call 8/18/17 USD 70.00 49 (59,045) Baxter International, Inc. Call 8/18/17 USD 60.00 177 (35,046) Boston Scientific Corp. Call 8/18/17 USD 27.00 514 (69,647) Boston Scientific Corp. Call 8/18/17 USD 28.00 83 (6,391) Cardinal Health, Inc. Call 8/18/17 USD 28.00 83 (6,391) Celgene Corp. Call 8/18/17 USD 135.00 39 (9,789) Cigna Corp. Call 8/18/17
Agios Pharmaceuticals, Inc. Call 8/18/17 USD 60.00 33 (3,712) Alkermes PLC Call 8/18/17 USD 65.00 13 (1,592) Alnylam Pharmaceuticals, Inc. Call 8/18/17 USD 70.00 49 (59,045) Aquinox Pharmaceuticals, Inc. Call 8/18/17 USD 15.00 61 (5,490) Baxter International, Inc. Call 8/18/17 USD 60.00 177 (35,046) Boston Scientific Corp. Call 8/18/17 USD 27.00 514 (69,647) Boston Scientific Corp. Call 8/18/17 USD 28.00 83 (6,391) Cardinal Health, Inc. Call 8/18/17 USD 28.00 83 (6,391) Calgene Corp. Call 8/18/17 USD 135.00 39 (9,789) Cigna Corp. Call 8/18/17 USD 15.00 60 (13,200) Halozyme Therapeutics, Inc. Call 8/18/
Alkermes PLC Call 8/18/17 USD 65.00 13 (1,592) Alnylam Pharmaceuticals, Inc. Call 8/18/17 USD 70.00 49 (59,045) Aquinox Pharmaceuticals, Inc. Call 8/18/17 USD 15.00 61 (5490) Baxter International, Inc. Call 8/18/17 USD 60.00 177 (35,046) Boston Scientific Corp. Call 8/18/17 USD 27.00 514 (69,647) Boston Scientific Corp. Call 8/18/17 USD 28.00 83 (6,391) Cardinal Health, Inc. Call 8/18/17 USD 82.50 64 (4,160) Celgene Corp. Call 8/18/17 USD 135.00 39 (9,789) Cigna Corp. Call 8/18/17 USD 155.00 60 (13,200) Halozyme Therapeutics, Inc. Call 8/18/17 USD 14.00 172 (6,880) HCA Holdings, Inc Call 8/18/17
Alnylam Pharmaceuticals, Inc. Call 8/18/17 USD 70.00 49 (59,045) Aquinox Pharmaceuticals, Inc. Call 8/18/17 USD 15.00 61 (5,490) Baxter International, Inc. Call 8/18/17 USD 60.00 177 (35,046) Boston Scientific Corp. Call 8/18/17 USD 27.00 514 (69,647) Boston Scientific Corp. Call 8/18/17 USD 28.00 83 (6,391) Cardinal Health, Inc. Call 8/18/17 USD 28.00 83 (6,391) Cardinal Health, Inc. Call 8/18/17 USD 28.00 83 (6,391) Cardinal Health, Inc. Call 8/18/17 USD 28.00 83 (6,391) Cardinal Health, Inc. Call 8/18/17 USD 135.00 39 (9,789) Cigna Corp. Call 8/18/17 USD 145.00 172 (6,880) HCA Holdings, Inc Call 8/1
Aquinox Pharmaceuticals, Inc. Call 8/18/17 USD 15.00 61 (5,490) Baxter International, Inc. Call 8/18/17 USD 60.00 177 (35,046) Boston Scientific Corp. Call 8/18/17 USD 27.00 514 (69,647) Boston Scientific Corp. Call 8/18/17 USD 28.00 83 (6,391) Cardinal Health, Inc. Call 8/18/17 USD 28.00 83 (6,391) Cardinal Health, Inc. Call 8/18/17 USD 135.00 39 (9,789) Celgene Corp. Call 8/18/17 USD 135.00 39 (9,789) Gigna Corp. Call 8/18/17 USD 175.00 60 (13,200) Halozyme Therapeutics, Inc. Call 8/18/17 USD 14.00 172 (6,880) HCA Holdings, Inc Call 8/18/17 USD 87.50 44 (11,770) Humana, Inc. Call 8/18/17
Baxter International, Inc. Call 8/18/17 USD 60.00 177 (35,046) Boston Scientific Corp. Call 8/18/17 USD 27.00 514 (69,647) Boston Scientific Corp. Call 8/18/17 USD 28.00 83 (6,391) Cardinal Health, Inc. Call 8/18/17 USD 82.50 64 (4,160) Celgene Corp. Call 8/18/17 USD 135.00 39 (9,789) Cigna Corp. Call 8/18/17 USD 175.00 60 (13,200) Halozyme Therapeutics, Inc. Call 8/18/17 USD 14.00 172 (6,880) HCA Holdings, Inc Call 8/18/17 USD 87.50 44 (11,770) Humana, Inc. Call 8/18/17 USD 240.00 19 (16,055) iRhythm Technologies, Inc. Call 8/18/17 USD 40.00 25 (10,250) MacKesson Corp. Call 8/18/17 US
Boston Scientific Corp. Call 8/18/17 USD 27.00 514 (69,647) Boston Scientific Corp. Call 8/18/17 USD 28.00 83 (6,391) Cardinal Health, Inc. Call 8/18/17 USD 82.50 64 (4,160) Celgene Corp. Call 8/18/17 USD 135.00 39 (9,789) Cigna Corp. Call 8/18/17 USD 175.00 60 (13,200) Halozyme Therapeutics, Inc. Call 8/18/17 USD 14.00 172 (6,880) HCA Holdings, Inc Call 8/18/17 USD 87.50 44 (11,770) Humana, Inc. Call 8/18/17 USD 240.00 19 (16,055) iRhythm Technologies, Inc. Call 8/18/17 USD 40.00 25 (10,250) MacKesson Corp. Call 8/18/17 USD 100.00 11 (1,787) Merck & Co., Inc. Call 8/18/17 USD
Boston Scientific Corp. Call 8/18/17 USD 28.00 83 (6,391) Cardinal Health, Inc. Call 8/18/17 USD 82.50 64 (4,160) Celgene Corp. Call 8/18/17 USD 135.00 39 (9,789) Cigna Corp. Call 8/18/17 USD 175.00 60 (13,200) Halozyme Therapeutics, Inc. Call 8/18/17 USD 14.00 172 (6,880) HCA Holdings, Inc Call 8/18/17 USD 87.50 44 (11,770) Humana, Inc. Call 8/18/17 USD 240.00 19 (16,055) iRhythm Technologies, Inc. Call 8/18/17 USD 40.00 25 (10,250) Masimo Corp. Call 8/18/17 USD 100.00 11 (1,787) McKesson Corp. Call 8/18/17 USD 165.00 3 (1,635) Merck & Co., Inc. Call 8/18/17 USD 65.00
Cardinal Health, Inc. Call 8/18/17 USD 82.50 64 (4,160) Celgene Corp. Call 8/18/17 USD 135.00 39 (9,789) Cigna Corp. Call 8/18/17 USD 175.00 60 (13,200) Halozyme Therapeutics, Inc. Call 8/18/17 USD 14.00 172 (6,880) HCA Holdings, Inc Call 8/18/17 USD 87.50 44 (11,770) Humana, Inc. Call 8/18/17 USD 240.00 19 (16,055) iRhythm Technologies, Inc. Call 8/18/17 USD 40.00 25 (10,250) Masimo Corp. Call 8/18/17 USD 100.00 11 (1,787) McKesson Corp. Call 8/18/17 USD 165.00 3 (1,635) Merck & Co., Inc. Call 8/18/17 USD 107.75 103 (51,184) Regeneron Pharmaceuticals, Inc. Call 8/18/17 USD
Celgene Corp. Call 8/18/17 USD 135.00 39 (9,789) Cigna Corp. Call 8/18/17 USD 175.00 60 (13,200) Halozyme Therapeutics, Inc. Call 8/18/17 USD 14.00 172 (6,880) HCA Holdings, Inc Call 8/18/17 USD 87.50 44 (11,770) Humana, Inc. Call 8/18/17 USD 240.00 19 (16,055) iRhythm Technologies, Inc. Call 8/18/17 USD 40.00 25 (10,250) Masimo Corp. Call 8/18/17 USD 100.00 11 (1,787) McKesson Corp. Call 8/18/17 USD 165.00 3 (1,635) Merck & Co., Inc. Call 8/18/17 USD 65.00 45 (5,737) Quest Diagnostics, Inc. Call 8/18/17 USD 107.75 103 (51,184) Regeneron Pharmaceuticals, Inc. Call 8/18/17 USD
Cigna Corp. Call 8/18/17 USD 175.00 60 (13,200) Halozyme Therapeutics, Inc. Call 8/18/17 USD 14.00 172 (6,880) HCA Holdings, Inc Call 8/18/17 USD 87.50 44 (11,770) Humana, Inc. Call 8/18/17 USD 240.00 19 (16,055) iRhythm Technologies, Inc. Call 8/18/17 USD 40.00 25 (10,250) Masimo Corp. Call 8/18/17 USD 100.00 11 (1,787) McKesson Corp. Call 8/18/17 USD 165.00 3 (1,635) Merck & Co., Inc. Call 8/18/17 USD 65.00 45 (5,737) Quest Diagnostics, Inc. Call 8/18/17 USD 107.75 103 (51,184) Regeneron Pharmaceuticals, Inc. Call 8/18/17 USD 515.00 16 (25,760) Sarepta Therapeutics, Inc. Call 8/18/17 <td< td=""></td<>
Halozyme Therapeutics, Inc. Call 8/18/17 USD 14.00 172 (6,880) HCA Holdings, Inc Call 8/18/17 USD 87.50 44 (11,770) Humana, Inc. Call 8/18/17 USD 240.00 19 (16,055) iRhythm Technologies, Inc. Call 8/18/17 USD 40.00 25 (10,250) Masimo Corp. Call 8/18/17 USD 100.00 11 (1,787) McKesson Corp. Call 8/18/17 USD 165.00 3 (1,635) Merck & Co., Inc. Call 8/18/17 USD 65.00 45 (5,737) Quest Diagnostics, Inc. Call 8/18/17 USD 107.75 103 (51,184) Regeneron Pharmaceuticals, Inc. Call 8/18/17 USD 515.00 16 (25,760) Sarepta Therapeutics, Inc. Call 8/18/17 USD 36.00 131 (29,672)
HCA Holdings, Inc Call 8/18/17 USD 87.50 44 (11,770) Humana, Inc. Call 8/18/17 USD 240.00 19 (16,055) iRhythm Technologies, Inc. Call 8/18/17 USD 40.00 25 (10,250) Masimo Corp. Call 8/18/17 USD 100.00 11 (1,787) McKesson Corp. Call 8/18/17 USD 165.00 3 (1,635) Merck & Co., Inc. Call 8/18/17 USD 65.00 45 (5,737) Quest Diagnostics, Inc. Call 8/18/17 USD 107.75 103 (51,184) Regeneron Pharmaceuticals, Inc. Call 8/18/17 USD 515.00 16 (25,760) Sarepta Therapeutics, Inc. Call 8/18/17 USD 36.00 131 (29,672)
Humana, Inc. Call 8/18/17 USD 240.00 19 (16,055) iRhythm Technologies, Inc. Call 8/18/17 USD 40.00 25 (10,250) Masimo Corp. Call 8/18/17 USD 100.00 11 (1,787) McKesson Corp. Call 8/18/17 USD 165.00 3 (1,635) Merck & Co., Inc. Call 8/18/17 USD 65.00 45 (5,737) Quest Diagnostics, Inc. Call 8/18/17 USD 107.75 103 (51,184) Regeneron Pharmaceuticals, Inc. Call 8/18/17 USD 515.00 16 (25,760) Sarepta Therapeutics, Inc. Call 8/18/17 USD 36.00 131 (29,672)
iRhythm Technologies, Inc. Call 8/18/17 USD 40.00 25 (10,250) Masimo Corp. Call 8/18/17 USD 100.00 11 (1,787) McKesson Corp. Call 8/18/17 USD 165.00 3 (1,635) Merck & Co., Inc. Call 8/18/17 USD 65.00 45 (5,737) Quest Diagnostics, Inc. Call 8/18/17 USD 107.75 103 (51,184) Regeneron Pharmaceuticals, Inc. Call 8/18/17 USD 515.00 16 (25,760) Sarepta Therapeutics, Inc. Call 8/18/17 USD 36.00 131 (29,672)
Masimo Corp. Call 8/18/17 USD 100.00 11 (1,787) McKesson Corp. Call 8/18/17 USD 165.00 3 (1,635) Merck & Co., Inc. Call 8/18/17 USD 65.00 45 (5,737) Quest Diagnostics, Inc. Call 8/18/17 USD 107.75 103 (51,184) Regeneron Pharmaceuticals, Inc. Call 8/18/17 USD 515.00 16 (25,760) Sarepta Therapeutics, Inc. Call 8/18/17 USD 36.00 131 (29,672)
McKesson Corp. Call 8/18/17 USD 165.00 3 (1,635) Merck & Co., Inc. Call 8/18/17 USD 65.00 45 (5,737) Quest Diagnostics, Inc. Call 8/18/17 USD 107.75 103 (51,184) Regeneron Pharmaceuticals, Inc. Call 8/18/17 USD 515.00 16 (25,760) Sarepta Therapeutics, Inc. Call 8/18/17 USD 36.00 131 (29,672)
Merck & Co., Inc. Call 8/18/17 USD 65.00 45 (5,737) Quest Diagnostics, Inc. Call 8/18/17 USD 107.75 103 (51,184) Regeneron Pharmaceuticals, Inc. Call 8/18/17 USD 515.00 16 (25,760) Sarepta Therapeutics, Inc. Call 8/18/17 USD 36.00 131 (29,672)
Quest Diagnostics, Inc. Call 8/18/17 USD 107.75 103 (51,184) Regeneron Pharmaceuticals, Inc. Call 8/18/17 USD 515.00 16 (25,760) Sarepta Therapeutics, Inc. Call 8/18/17 USD 36.00 131 (29,672)
Regeneron Pharmaceuticals, Inc. Call 8/18/17 USD 515.00 16 (25,760) Sarepta Therapeutics, Inc. Call 8/18/17 USD 36.00 131 (29,672)
Sarepta Therapeutics, Inc. Call 8/18/17 USD 36.00 131 (29,672)
TESARO, Inc. Call 8/18/17 USD 155.00 64 (38.400)
Varian Medical System, Inc. Call 8/18/17 USD 105.00 28 (6,930)
Vertex Pharmaceuticals, Inc. Call 8/18/17 USD 135.00 21 (12,495)
Pfizer, Inc. Call 9/01/17 USD 34.17 362 (15,394)
Total \$ (3,110,513)

OTC Options Written

o i o options written						
	Put/		Expiration	Strike		
Description	Call	Counterparty	Date	Price	Contracts	Value
Baxter International, Inc.	Call	Bank of America N.A.	07/06/17	USD 56.46	4,200	\$ (17,616)
Humana, Inc.	Call	Barclays Bank PLC	07/12/17	USD228.00	4,300	(56,553)
Stryker Corp.	Call	Barclays Bank PLC	07/12/17	USD137.75	11,700	(29,800)
Agilent Technologies, Inc.	Call	Barclays Bank PLC	07/13/17	USD 56.00	13,000	(45,833)
Sanofi SA ADR	Call	Morgan Stanley & Co. International PLC	07/14/17	EUR 90.04	5,300	(197)
AstraZeneca PLC	Call	Morgan Stanley & Co. International PLC	07/19/17	GBP 53.39	13,200	(23,391)
Masimo Corp.	Call	Credit Suisse International	07/20/17	USD 87.00	6,400	(35,162)
Service Corp. International	Call	Barclays Bank PLC	07/24/17	USD 32.15	14,700	(24,828)
Amedisys, Inc.	Call	Deutsche Bank AG	07/31/17	USD 63.52	20,000	(29,934)
HealthEquity, Inc.	Call	Citibank N.A.	07/31/17	USD 51.72	5,000	(5,768)
Novartis AG ADR	Call	Citibank N.A.	07/31/17	USD 81.34	3,400	(10,841)
Syndax Pharmaceuticals, Inc.	Call	Morgan Stanley & Co. International PLC	08/03/17	USD 15.90	18,400	(16,683)
GlaxoSmithKline PLC	Call	Goldman Sachs International	08/16/17	GBP 17.39	26,300	(1,337)
Merck & Co., Inc.	Call	Goldman Sachs International	08/16/17	EUR111.09	9,600	(14,188)
Roche Holding AG	Call	Credit Suisse International	08/18/17	CHF258.91	2,500	(2,793)

REGENXBIO, Inc. Call Citibank N.A. 08/28/17 USD 22.80 12,600 (13,557)

Total (328,481)

See Notes to Financial Statements.

BlackRock Health Sciences Trust (BME)

Transactions in Options Written for the Period Ended June 30, 2017

	C	Calls
		Premiums
	Contracts	Received
Outstanding options, beginning of period	190,155	\$ 2,428,175
Options written	761,116	10,262,111
Options exercised	(339)	(34,224)
Options expired	(126,496)	(2,135,113)
Options closed	(643,493)	(8,198,069)
Outstanding options, end of period	180,943	\$ 2,322,880

As of period end, the value of portfolio securities subject to covered call options written was \$97,564,375.

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

				Foreign	
				Currency Interest	
		Commodity Credit	Equity	Exchange Rate Other	
Liabilities Derivative Finar	icial Instruments	Contracts Contracts	Contracts	Contracts Contracts Contract	s Total
Options written	Options written, at				
	value		\$ 3,438,994		\$ 3,438,994

For the six months ended June 30, 2017, the effect of derivative financial instruments in the Statements of Operations was as follows:

Net Realized Gain (Loss) from: Options purchased ¹ Options written	Commodity Contracts	Credit Contracts	Equity Contracts \$ (280) (4,475,585)	Foreign Currency Exchange Contracts	Interest Rate Contracts	Other Contracts	Total \$ (280) (4,475,585)	
Total			\$ (4,475,865)				\$ (4,475,865)	
¹ Options purchased are included in net realized gain (loss) from investments.								
Net Change in Unrealized Apprecia Options written	ation (Depreciation	n) on:	\$ (1,617,344)				\$ (1,617,344)	

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:

Average value of option contracts purchased

\$ 2281

Average value of option contracts written

\$ 2,792,921

¹ Actual amounts for the period are shown due to limited outstanding derivative financial instruments as of each quarter end. For more information about the Trust s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments Offsetting as of Period End

The Trust s derivative assets and liabilities (by type) are as follows:

Derivative Financial Instruments Options	Assets	Liabilities \$ 3,438,994
Derivatives not subject to a Master Netting Agreement or similar agreement (MNA)		(3,110,513)
Total derivative assets and liabilities subject to an MNA		\$ 328,481

See Notes to Financial Statements.

BlackRock Health Sciences Trust (BME)

The following table presents the Trust $\,$ s derivative liabilities by counterparty net of amounts available for offset under an Master Netting Agreement ($\,$ MNA $\,$) and net of the related collateral pledged by the Trust:

Counterparty	Derivative Liabilities Subject to an MNA by Counterparty		Derivatives Available for Offset	Non-cash Collateral Pledged	Cash Collateral Pledged	Net Amount of Derivative Liabilities ¹	
Bank of America N.A.	\$	17,616		_		\$	17,616
Barclays Bank PLC		157,014					157,014
Citibank N.A.		30,166					30,166
Credit Suisse International		37,955					37,955
Deutsche Bank AG		29,934					29,934
Goldman Sachs International		15,525					15,525
Morgan Stanley & Co. International PLC		40,271					40,271
Total	\$	328,481				\$	328,481

¹ Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust spolicy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust s investments and derivative financial instruments categorized in the disclosure hierarchy:

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				
Long-Term Investments:				
Common Stocks:				
Biotechnology	\$ 73,302,378		\$ 1,462,591	\$ 74,764,969
Diversified Consumer Services	1,448,385			1,448,385
Health Care Equipment & Supplies	78,744,547			78,744,547
Health Care Providers & Services	90,669,044			90,669,044
Life Sciences Tools & Services	6,819,308			6,819,308
Pharmaceuticals	52,296,360	\$ 13,120,710		65,417,070
Preferred Stock			380,484	380,484
Rights			141,355	141,355
Short-Term Securities	2,281,623			2,281,623
Total	\$ 305,561,645	\$ 13,120,710	\$ 1,984,430	\$ 320,666,785
Derivative Financial Instruments ¹				
Liabilities:	¢ (2.751.705)	¢ ((07.100)		e (2.429.004)
Equity contracts	\$ (2.751.795)	\$ (687,199)		\$ (3.438.994)

¹ Derivative financial instruments are options written, which are shown at value.

During the six months ended June 30, 2017, there were no transfers between Level 1 and Level 2.

A reconciliation of Level 3 investments is presented when the Trust had a significant amount of Level 3 investments at the beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

	Common	Preferred		
Assets: Opening Balance, as of December 31, 2016 Transfers into Level 3 Transfers out of Level 3	Stocks \$ 1,452,303	Stocks \$ 503,166	Rights \$ 68,517	Total \$ 2,023,986
Accrued discounts/premiums Net realized gain (loss) Net change in unrealized appreciation (depreciation) ^{1,2} Purchases Sales	10,288	(122,682)	72,838	(39,556)
Closing Balance, as of June 30, 2017	\$ 1,462,591	\$ 380,484	\$ 141,355	\$ 1,984,430
Net change in unrealized appreciation (depreciation) on investments still held at June 30, 2017 ²	\$ 10,288	\$ (122,682)	\$ 72,838	\$ (39,556)

¹ Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations.

See Notes to Financial Statements.

² Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on derivative financial instruments still held at June 30, 2017 is generally due to derivative financial instruments no longer held or categorized as Level 3 at period end.

Consolidated Schedule of Investments June 30, 2017 (Unaudited)

BlackRock Resources & Commodities Strategy Trust (BCX)

(Percentages shown are based on Net Assets)

Common Stocks Chemicals 13.5%	Shares		Value
Agrium, Inc.	234,401	\$	21,243,955
CF Industries Holdings, Inc. (a)	850,336	Ψ	23,775,395
Monsanto Co. (b)	364,970		43,197,849
Mosaic Co. (a)	219,733		5,016,504
Potash Corp. of Saskatchewan, Inc. (a)	1,149,440		18,735,872
Yara International ASA	266,000		10,002,199
	200,000		10,002,177
			121,971,774
Containers & Packaging 2.8%			
Packaging Corp. of America (a)	227,819		25,376,758
Energy Equipment & Services 4.4%			
Baker Hughes, Inc. (a)	213,777		11,652,984
Halliburton Co. (a)(b)	347,800		14,854,538
Precision Drilling Corp. (c)	1,749,350		5,975,957
Superior Energy Services, Inc. (a)(b)(c)	654,550		6,826,956
Food Products 4.6%			39,310,435
Food Products 4.6% AGT Food & Ingredients, Inc.	46,482		834,439
BRF SA ADR	997,160		11,756,516
Bunge Ltd. (a)	85,461		6,375,391
Elders, Ltd. (c)	1,246,695		5,126,422
Glanbia PLC	407,065		7,961,912
Origin Enterprises PLC	1,342,955		9,790,600
Origin Emerprises (Le	1,542,755		2,720,000
W. II. 100			41,845,280
Machinery 1.2%	90.750		11 002 215
Deere & Co. (a)	89,759		11,093,315
Metals & Mining 33.2% Barrick Gold Corp. (a)	398,909		6,346,642
BHP Billiton PLC	1,950,000		29,875,362
Boliden AB	328,757		8,986,547
Detour Gold Corp. (c)	422,269		4,942,970
First Quantum Minerals Ltd.	1,804,555		15,265,244
Fortescue Metals Group Ltd.	1,944,962		7,785,862
Franco-Nevada Corp.	72,000		5,195,126
Fresnillo PLC	691,401		13,402,621
Glencore PLC (c)	11,085,484		41,539,811
Lundin Mining Corp.	2,417,438		13,738,833
Neo Lithium Corp. (c)(d)	3,000,000		2,660,395
Nevsun Resources, Ltd.	3,527,285		8,513,573
Newcrest Mining Ltd.	1,665,137		25,842,510
Newmont Mining Corp. (a)	333,240		20,0.2,010
6 - F. (-)	,		